Judd Wendell Moul | Scholars@Duke

Judd Wendell Moul
James H. Semans, M.D. Professor of Urologic Surgery, in the School of Medicine

Dr Judd Moul joined the Duke faculty in mid 2004 after a career in the US Army Medical Corps mainly at Walter Reed Army Medical Center. He is a retired colonel and a noted researcher and clinician in the area of prostate cancer and is a urologic oncologist. He served as the division chief of Duke Division of Urology from 2004 to 2011 and was named the James H Semans MD Professor of surgery in 2009 becoming Duke's first named endowed chair for urology. He was awarded the Gold Cystoscope Award from the American Urologic Association as well as Castle Connelly Physician of the year for Clinical Medicine in 2009. He has performed more than 1300 radical prostatectomies since joining the Duke faculty and is committed to outcomes research on this series and in other areas of prostate cancer. He served as the Editor for Prostate Cancer and Prostatic Dissease, a Nature Medicine journal, for more than a decade and is a popular speaker and lecturer having been visiting professor and keynote speaker throughout the US and the World. He is very committed to training residents and mentoring students and trainees.

Office Hours

Clinic days: 2nd and 4th Mondays, all Tuesdays , Thursday mornings generally from 8am to 5pm
OR Days: 1st, 3rd, 5th Mondays and all Wednesdays

Current Appointments & Affiliations

James H. Semans, M.D. Professor of Urologic Surgery, in the School of Medicine, Surgery, Urology, Surgery 2009
Professor of Surgery, Surgery, Urology, Surgery 2005
Chief of the Division of Urology in the Department of Surgery, Surgery, Urology, Surgery 2004
Professor in Anesthesiology, Anesthesiology, Clinical Science Departments 2012
Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2004

Contact Information

1573 White Zone, Duke South, Durham, NC 27710
Box 3707 Med Ctr, Durham, NC 27710
judd.moul@duke.edu (919) 684-5057

Background
Education, Training, & Certifications
- Fellowship, Urologic Oncology, Duke University 1988 - 1989
- Residency, Urology, Walter Reed Army Medical Center 1983 - 1987
- Residency, Surgery, Walter Reed Army Medical Center 1982 - 1983
- M.D., Thomas Jefferson University 1982
- B.S., Pennsylvania State University 1979
Duke Appointment History
- Instructor, Temporary of Urology in the Department of Surgery, Surgery, Urology, Surgery 2004
Recognition
Awards & Honors
Expertise
Global Scholarship
- Teaching
Research
Selected Grants
- Phase III Randomized Efficacy and Safety Study awarded by Medivation, Inc. 2016 - 2023
- A Prospective Observational Cohort Study of Patients with Castration Resistant Prostate Cancer awarded by Astellas Pharma Global Development, Inc 2015 - 2020
- Exercise Training, Erectile Dysfunction, and Prostate Cancer awarded by National Institutes of Health 2009 - 2013
- IPA - Jens Dannull awarded by Veterans Administration Medical Center 2007 - 2008
- Prostate Cancer Recovery Enhancement (PROCARE) for African American Men awarded by National Institutes of Health 2007 - 2008
- IPA Agreement - Jens Dannull awarded by Veterans Administration Medical Center 2006 - 2007
- Expression Analysis of Prostate Cancer's Clinical Behavior awarded by National Institutes of Health 2001 - 2006
Publications & Artistic Works
Selected Publications
- Books
  - Merseburger, AS, Kuczyk, MA, and Moul, JW. Urology at a glance. January 1, 2014. Full Text
- Academic Articles
  - Berger, M, Oyeyemi, D, Olurinde, MO, Whitson, HE, Weinhold, KJ, Woldorff, MG, Lipsitz, LA, Moretti, E, Giattino, CM, Roberts, KC, Zhou, J, Bunning, T, Ferrandino, M, Scheri, RP, Cooter, M, Chan, C, Cabeza, R, Browndyke, JN, Murdoch, DM, Devinney, MJ, Shaw, LM, Cohen, HJ, Mathew, JP, and INTUIT Investigators, . "The INTUIT Study: Investigating Neuroinflammation Underlying Postoperative Cognitive Dysfunction." Journal of the American Geriatrics Society 67, no. 4 (April 2019): 794-798. Full Text Open Access Copy
  - Aminsharifi, A, Simon, R, Polascik, TJ, Robertson, CN, Sudan, DL, Collins, BH, and Moul, JW. "Evaluation and active treatment versus active surveillance of localized prostate cancer in renal transplant patients in the era of low and very low risk prostate cancer." The Journal of Urology (March 5, 2019): 101097JU0000000000000207-null. Full Text
  - Alkazemi, MH, Brousell, S, Fantony, J, Tsivian, M, and Moul, JW. "A Case of Fatal Clostridial Necrotizing Fasciitis After Radical Prostatectomy." Urology 122 (December 2018): 28-31. Full Text
  - Crawford, ED, Schellhammer, PF, McLeod, DG, Moul, JW, Higano, CS, Shore, N, Denis, L, Iversen, P, Eisenberger, MA, and Labrie, F. "Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens." The Journal of Urology 200, no. 5 (November 2018): 956-966. (Review) Full Text
  - Crawford, ED, Tombal, B, Keane, T, Boccardo, F, Miller, K, Shore, N, Moul, JW, Damber, J-E, Collette, L, and Persson, B-E. "FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist." Scandinavian Journal of Urology 52, no. 5-6 (October 2018): 349-357. Full Text
  - Moul, Judd W. “Yes or no to local therapy for oligometastatic prostate cancer?.” Nature Reviews. Urology 15, no. 7 (July 2018): 399–400. https://doi.org/10.1038/s41585-018-0028-7.
    Full Text
  - Kowalewski, Karl F., Christian Tapking, Svetlana Hetjens, Felix Nickel, Philipp Mandel, Philipp Nuhn, Manuel Ritter, Judd W. Moul, Joachim W. Thüroff, and Maximilian C. Kriegmair. “Interrupted versus Continuous Suturing for Vesicourethral Anastomosis During Radical Prostatectomy: A Systematic Review and Meta-analysis..” European Urology Focus, June 12, 2018. https://doi.org/10.1016/j.euf.2018.05.009.
    Full Text
  - Wong, Y-N, Manola, J, Hudes, GR, Roth, BJ, Moul, JW, Barsevick, AM, Scher, RM, Volk, MJ, Vaughn, DJ, Williams, SD, Fisch, MJ, Cella, D, Carducci, MA, and Wilding, G. "Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial." Clinical Genitourinary Cancer 16, no. 2 (April 2018): e315-e322. Full Text
  - Gansler, T, Fedewa, S, Qi, R, Lin, CC, Jemal, A, and Moul, JW. "Most Gleason 8 Biopsies are Downgraded at Prostatectomy-Does 4 + 4 = 7?." The Journal of Urology 199, no. 3 (March 2018): 706-712. Full Text
  - Saltzstein, Daniel, Neal D. Shore, Judd W. Moul, Franklin Chu, Raoul Concepcion, Stephan de la Motte, John A. McLane, Stuart Atkinson, Alex Yang, and E David Crawford. “Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects..” Therapeutic Advances in Urology 10, no. 2 (February 2018): 43–50. https://doi.org/10.1177/1756287217738150.
    Full Text
  - Giri, VN, Knudsen, KE, Kelly, WK, Abida, W, Andriole, GL, Bangma, CH, Bekelman, JE, Benson, MC, Blanco, A, Burnett, A, Catalona, WJ, Cooney, KA, Cooperberg, M, Crawford, DE, Den, RB, Dicker, AP, Eggener, S, Fleshner, N, Freedman, ML, Hamdy, FC, Hoffman-Censits, J, Hurwitz, MD, Hyatt, C, Isaacs, WB, Kane, CJ, Kantoff, P, Karnes, RJ, Karsh, LI, Klein, EA, Lin, DW, Loughlin, KR, Lu-Yao, G, Malkowicz, SB, Mann, MJ, Mark, JR, McCue, PA, Miner, MM, Morgan, T, Moul, JW, Myers, RE, Nielsen, SM, Obeid, E, Pavlovich, CP, Peiper, SC, Penson, DF, Petrylak, D, Pettaway, CA, Pilarski, R, Pinto, PA, Poage, W, Raj, GV, Rebbeck, TR, Robson, ME, Rosenberg, MT, Sandler, H, Sartor, O, Schaeffer, E, Schwartz, GF, Shahin, MS, Shore, ND, Shuch, B, Soule, HR, Tomlins, SA, Trabulsi, EJ, Uzzo, R, Vander Griend, DJ, Walsh, PC, Weil, CJ, Wender, R, and Gomella, LG. "Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 36, no. 4 (February 2018): 414-424. Full Text
  - Moul, Judd W. “The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICARE (R) Military Database EDITORIAL COMMENT.” Journal of Urology 198, no. 6 (December 1, 2017): 1301–1301.
    Link to Item
  - Moul, JW. "Editorial Comment." The Journal of Urology 198, no. 6 (December 2017): 1300-null. Full Text
  - Moul, Judd W. “Most Men With Clinically Important Localized Prostate Cancer Deserve First-Line Open or Robotic Radical Prostatectomy.” Oncology New York 31, no. 11 (November 1, 2017): 830-+.
    Link to Item
  - Moul, Judd W. “Counterpoint: Which Treatment Modality for Localized Prostate Cancer Yields Superior Quality of Life: Radiotherapy or Prostatectomy? Most Men With Clinically Important Localized Prostate Cancer Deserve First-Line Open or Robotic Radical Prostatectomy..” Oncology (Williston Park, N.Y.) 31, no. 11 (November 2017): 830–35.
  - Qi, Robert, and Judd Moul. “African American Men With Low-Risk Prostate Cancer Are Candidates for Active Surveillance: The Will-Rogers Effect?.” American Journal of Men’S Health 11, no. 6 (November 2017): 1765–71. https://doi.org/10.1177/1557988317721107.
    Full Text
  - Qi, Robert, Wen-Chi Foo, Michael N. Ferrandino, Leah G. Davis, Sitharthan Sekar, Thomas A. Longo, Ghalib Jibara, Tracy Han, Ilhan Gokhan, and Judd W. Moul. “Over half of contemporary clinical Gleason 8 on prostate biopsy are downgraded at radical prostatectomy..” The Canadian Journal of Urology 24, no. 5 (October 2017): 8982–89.
  - Tay, KJ, Gupta, RT, Holtz, J, Silverman, RK, Tsivian, E, Schulman, A, Moul, JW, and Polascik, TJ. "Does mpMRI improve clinical criteria in selecting men with prostate cancer for active surveillance?." Prostate Cancer and Prostatic Diseases 20, no. 3 (September 2017): 323-327. Full Text
  - Schulman, Ariel A., Christina Sze, Efrat Tsivian, Rajan T. Gupta, Judd W. Moul, and Thomas J. Polascik. “The Contemporary Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Prostate Cancer..” Current Urology Reports 18, no. 7 (July 2017). https://doi.org/10.1007/s11934-017-0699-2.
    Full Text
  - Madden-Fuentes, RJ, Koontz, BF, Harrison, MR, George, DJ, Davidson, B, Gilmore, BF, Moul, JW, Mantyh, C, and Peterson, AC. "How Can We Effectively Address the Medical and Psychological Concerns of Survivors of Pelvic Malignancies?." Oncology (Williston Park) 31, no. 4 (April 15, 2017): 286-294. (Review) Link to Item
  - Madden-Fuentes, RJ, Koontz, BF, Harrison, MR, George, DJ, Davidson, B, Gilmore, BF, Moul, JW, Mantyh, C, and Peterson, AC. "How Can We Effectively Address the Medical and Psychological Concerns of Survivors of Pelvic Malignancies?." Oncology (Williston Park, N.Y.) 31, no. 4 (April 2017): 286-294. (Review)
  - Shore, Neal D., Franklin Chu, Judd Moul, Daniel Saltzstein, Raoul Concepcion, John A. McLane, Stuart Atkinson, Alex Yang, and E David Crawford. “Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer..” Bju International 119, no. 2 (February 2017): 239–44. https://doi.org/10.1111/bju.13482.
    Full Text
  - Moul, JW. "Comparison of DRE and PSA in the Detection of Prostate Cancer." The Journal of Urology 197, no. 2S (February 2017): S208-S209. Full Text
  - Giattino, Charles M., Jacob E. Gardner, Faris M. Sbahi, Kenneth C. Roberts, Mary Cooter, Eugene Moretti, Jeffrey N. Browndyke, et al. “Intraoperative Frontal Alpha-Band Power Correlates with Preoperative Neurocognitive Function in Older Adults..” Frontiers in Systems Neuroscience 11 (January 2017). https://doi.org/10.3389/fnsys.2017.00024.
    Full Text Open Access Copy
  - Heidenreich, Axel, Judd W. Moul, Shahrokh Shariat, and R Jeffrey Karnes. “Role of salvage lymph node dissection in prostate cancer..” Current Opinion in Urology 26, no. 6 (November 2016): 581–89. https://doi.org/10.1097/mou.0000000000000343.
    Full Text
  - Qi, R., and J. W. Moul. “Rising PSA Level in an Anxious Postprostatectomy Patient.” Oncology (Williston Park, N.Y.) 30, no. 9 (September 15, 2016).
  - Qi, R, and Moul, JW. "Rising PSA Level in an Anxious Postprostatectomy Patient." Oncology (Williston Park, N.Y.) 30, no. 9 (September 15, 2016).
  - Moul, Judd W. “Serial Anatomical Prostate Ultrasound during Prostate Cancer Active Surveillance EDITORIAL COMMENTS.” Journal of Urology 196, no. 3 (September 2016): 732–732. https://doi.org/10.1016/j.juro.2016.03.185.
    Full Text Link to Item
  - Qi, Robert, and Judd W. Moul. “Rising PSA Level in an Anxious Postprostatectomy Patient..” Oncology (Williston Park, N.Y.) 30, no. 9 (September 2016): 834–60.
  - Moul, JW. "Castration-resistant prostate cancer: Why should urologists care?." Urologia Colombiana 25, no. 3 (September 1, 2016): 195-197. Full Text
  - Moul, JW. "Castration-resistant prostate cancer: Why should urologists care?." Urologia Colombiana 25, no. 3 (September 1, 2016): 198-200. Full Text
  - Sutton, S Scott, E David Crawford, Judd W. Moul, James W. Hardin, and Eric Kruep. “Determining optimal prostate-specific antigen thresholds to identify an increased 4-year risk of prostate cancer development: an analysis within the Veterans Affairs Health Care System..” World Journal of Urology 34, no. 8 (August 2016): 1107–13. https://doi.org/10.1007/s00345-015-1754-6.
    Full Text
  - Lynch, Henry T., Omofolasade Kosoko-Lasaki, Stephen W. Leslie, Marc Rendell, Trudy Shaw, Carrie Snyder, Anthony V. D’Amico, et al. “Screening for familial and hereditary prostate cancer..” International Journal of Cancer 138, no. 11 (June 2016): 2579–91. https://doi.org/10.1002/ijc.29949.
    Full Text
  - Armstrong, A. J., S. Halabi, P. Healy, W. R. Lee, B. F. Koontz, J. W. Moul, K. Mundy, et al. “A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.” Prostate Cancer and Prostatic Diseases 19, no. 1 (March 2016): 100–106. https://doi.org/10.1038/pcan.2015.59.
    Full Text Link to Item
  - Tay, Kae Jack, Judd W. Moul, and Andrew J. Armstrong. “Management of Prostate Cancer in the Elderly..” Clinics in Geriatric Medicine 32, no. 1 (February 2016): 113–32. https://doi.org/10.1016/j.cger.2015.08.001.
    Full Text
  - McGinley, KF, Tay, KJ, and Moul, JW. "Prostate cancer in men of African origin." Nature Reviews. Urology 13, no. 2 (February 2016): 99-107. (Review) Full Text
  - Tay, KJ, Gupta, RT, Rastinehad, AR, Tsivian, E, Freedland, SJ, Moul, JW, and Polascik, TJ. "Navigating MRI-TRUS fusion biopsy: optimizing the process and avoiding technical pitfalls." Expert Review of Anticancer Therapy 16, no. 3 (January 2016): 303-311. (Review) Full Text
  - Moul, JW. "Hormone naïve prostate cancer: predicting and maximizing response intervals." Asian Journal of Andrology 17, no. 6 (November 2015): 929-933. (Review) Full Text Open Access Copy
  - Moul, Judd W. “Hot topic of cancer survivorship and the 'seven deadly sins'..” Bju International 116, no. 3 (September 2015): 310–11. https://doi.org/10.1111/bju.13115.
    Full Text
  - Davis, K, Wood, S, Dill, E, Fesko, Y, Bitting, RL, Harrison, MR, Armstrong, AJ, Moul, JW, and George, DJ. "Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution." Clin J Oncol Nurs 19, no. 3 (June 2015): 297-303. Full Text Link to Item
  - Moul, Judd W. “High-risk prostate cancer and radical prostatectomy in the setting and context of multidisciplinary care..” Urologic Oncology 33, no. 5 (May 2015): 206–7. https://doi.org/10.1016/j.urolonc.2015.03.004.
    Full Text
  - Tay, Kae Jack, Melissa Mendez, Judd W. Moul, and Thomas J. Polascik. “Active surveillance for prostate cancer: can we modernize contemporary protocols to improve patient selection and outcomes in the focal therapy era?.” Current Opinion in Urology 25, no. 3 (May 2015): 185–90. https://doi.org/10.1097/mou.0000000000000168.
    Full Text
  - Azrad, M., R. T. Vollmer, J. Madden, T. J. Polascik, D. C. Snyder, M. T. Ruffin, J. W. Moul, D. Brenner, X. He, and W. Demark-Wahnefried. “Disparate results between proliferation rates of surgically excised prostate tumors and an in vitro bioassay using sera from a positive randomized controlled trial..” Biotechnic & Histochemistry : Official Publication of the Biological Stain Commission 90, no. 3 (April 2015): 184–89. https://doi.org/10.3109/10520295.2014.976840.
    Full Text
  - Crawford, E David, and Judd W. Moul. “ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury..” Oncology (Williston Park, N.Y.) 29, no. 1 (January 2015): 55–66.
  - Crawford, E. D., and J. W. Moul. “ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury.” Oncology (Williston Park, N.Y.) 29, no. 1 (2015): 55–66.
  - Qi, Robert, and Judd Moul. “High-Risk Prostate Cancer: Role of Radical Prostatectomy and Radiation Therapy..” Oncology Research and Treatment 38, no. 12 (January 2015): 639–44. https://doi.org/10.1159/000441736.
    Full Text
  - Crawford, ED, Moul, JW, Sartor, O, and Shore, ND. "Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl." Expert Opinion on Drug Metabolism & Toxicology 11, no. 9 (January 2015): 1465-1474. (Review) Full Text
  - Moul, Judd W., Mark J. Sarno, Jonathan E. McDermed, Melissa T. Triebell, and Mark A. Reynolds. “NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy..” Urology 84, no. 6 (December 2014): 1427–32. https://doi.org/10.1016/j.urology.2014.07.059.
    Full Text
  - Stewart, Suzanne B., Judd W. Moul, Thomas J. Polascik, Bridget F. Koontz, Cary N. Robertson, Stephen J. Freedland, Daniel J. George, W Robert Lee, Andrew J. Armstrong, and Lionel L. Bañez. “Does the multidisciplinary approach improve oncological outcomes in men undergoing surgical treatment for prostate cancer?.” International Journal of Urology : Official Journal of the Japanese Urological Association 21, no. 12 (December 2014): 1215–19. https://doi.org/10.1111/iju.12561.
    Full Text
  - Moul, J. W., D. Y. T. Chen, E. J. Trabulsi, C. A. Warlick, H. C. Ruckle, J. R. Porter, J. S. Yoshida, et al. “Impact of NADiA ProsVue PSA slope on secondary treatment decisions after radical prostatectomy..” Prostate Cancer and Prostatic Diseases 17, no. 3 (September 2014): 280–85. https://doi.org/10.1038/pcan.2014.25.
    Full Text
  - Reed, Shelby D., Suzanne Biehn Stewart, Charles D. Scales, and Judd W. Moul. “A framework to evaluate the cost-effectiveness of the NADiA ProsVue slope to guide adjuvant radiotherapy among men with high-risk characteristics following prostatectomy for prostate cancer..” Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research 17, no. 5 (July 2014): 545–54. https://doi.org/10.1016/j.jval.2014.04.010.
    Full Text
  - Tripathy, Debu, Brian G. M. Durie, Beatrice Mautner, Krag S. Ferenz, and Judd W. Moul. “Awareness, concern, and communication between physicians and patients on bone health in cancer..” Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer 22, no. 6 (June 2014): 1601–10. https://doi.org/10.1007/s00520-014-2127-1.
    Full Text
  - Crawford, E David, Neal D. Shore, Judd W. Moul, Bertrand Tombal, Fritz H. Schröder, Kurt Miller, Laurent Boccon-Gibod, et al. “Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix..” Urology 83, no. 5 (May 2014): 1122–28. https://doi.org/10.1016/j.urology.2014.01.013.
    Full Text
  - Habib, Ashraf S., Judd W. Moul, Thomas J. Polascik, Cary N. Robertson, Anthony M. Roche, William D. White, Stephen E. Hill, Israel Nosnick, Tong J. Gan, and Tong J. Duke Perioperative Outcome Study Group. “Low central venous pressure versus acute normovolemic hemodilution versus conventional fluid management for reducing blood loss in radical retropubic prostatectomy: a randomized controlled trial..” Current Medical Research and Opinion 30, no. 5 (May 2014): 937–43. https://doi.org/10.1185/03007995.2013.877436.
    Full Text
  - Moul, Judd W. “Utility of LHRH antagonists for advanced prostate cancer..” The Canadian Journal of Urology 21, no. 2 Supp 1 (April 2014): 22–27.
  - Halabi, S, Lin, C-Y, Kelly, WK, Fizazi, KS, Moul, JW, Kaplan, EB, Morris, MJ, and Small, EJ. "Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 32, no. 7 (March 2014): 671-677. Full Text
  - Muller, Berrend G., Jurgen J. Fütterer, Rajan T. Gupta, Aaron Katz, Alexander Kirkham, John Kurhanewicz, Judd W. Moul, et al. “The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel..” Bju International 113, no. 2 (February 2014): 218–27. https://doi.org/10.1111/bju.12243.
    Full Text
  - Canfield, Steven E., Adam S. Kibel, Michael J. Kemeter, Phillip G. Febbo, H Jeffrey Lawrence, and Judd W. Moul. “A guide for clinicians in the evaluation of emerging molecular diagnostics for newly diagnosed prostate cancer..” Reviews in Urology 16, no. 4 (January 2014): 172–80.
  - Jones, L. W., W. E. Hornsby, S. J. Freedland, A. Lane, M. J. West, J. W. Moul, M. N. Ferrandino, et al. “Effects of nonlinear aerobic training on erectile dysfunction and cardiovascular function following radical prostatectomy for clinically localized prostate cancer.” European Urology 65, no. 5 (January 1, 2014): 852–55. https://doi.org/10.1016/j.eururo.2013.11.009.
    Full Text
  - Moul, JW. "Active surveillance for African-American men with prostate cancer: of course! Pro." Oncology (Williston Park, N.Y.) 28, no. 1 (January 1, 2014).
  - O’Shaughnessy, Peter Kevin, Thomas A. Laws, Carol Pinnock, Judd W. Moul, and Adrian Esterman. “Differences in self-reported outcomes of open prostatectomy patients and robotic prostatectomy patients in an international web-based survey..” European Journal of Oncology Nursing : The Official Journal of European Oncology Nursing Society 17, no. 6 (December 2013): 775–80. https://doi.org/10.1016/j.ejon.2013.03.010.
    Full Text
  - Punnen, Sanoj, Matthew R. Cooperberg, Anthony V. D’Amico, Pierre I. Karakiewicz, Judd W. Moul, Howard I. Scher, Thorsten Schlomm, and Stephen J. Freedland. “Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature..” European Urology 64, no. 6 (December 2013): 905–15. https://doi.org/10.1016/j.eururo.2013.05.025.
    Full Text
  - Qi, Peter, Matvey Tsivian, Michael R. Abern, Lionel L. Bañez, Ping Tang, Judd W. Moul, and Thomas J. Polascik. “Long-term oncological outcomes of men undergoing radical prostatectomy with preoperative prostate-specific antigen <2.5 ng/ml and 2.5-4 ng/ml..” Urologic Oncology 31, no. 8 (November 2013): 1527–32. https://doi.org/10.1016/j.urolonc.2012.06.003.
    Full Text
  - Karlin, Jeremy D., Bridget F. Koontz, Stephen J. Freedland, Judd W. Moul, Baruch M. Grob, Wen Wan, Michael P. Hagan, Mitchell S. Anscher, and Drew Moghanaki. “Identifying appropriate patients for early salvage radiotherapy after prostatectomy..” The Journal of Urology 190, no. 4 (October 2013): 1410–15. https://doi.org/10.1016/j.juro.2013.04.078.
    Full Text
  - Koontz, BF, Quaranta, BP, Pura, JA, Lee, WR, Vujaskovic, Z, Gerber, L, Haake, M, Anscher, MS, Robertson, CN, Polascik, TJ, and Moul, JW. "Phase 1 trial of neoadjuvant radiation therapy before prostatectomy for high-risk prostate cancer." International Journal of Radiation Oncology, Biology, Physics 87, no. 1 (September 2013): 88-93. Full Text
  - Miller, K., J. W. Moul, M. Gleave, K. Fizazi, J. B. Nelson, T. Morris, F. E. Nathan, S. McIntosh, K. Pemberton, and C. S. Higano. “Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer..” Prostate Cancer and Prostatic Diseases 16, no. 2 (June 2013): 187–92. https://doi.org/10.1038/pcan.2013.2.
    Full Text
  - Mulhall, JP, Burnett, AL, Wang, R, McVary, KT, Moul, JW, Bowden, CH, DiDonato, K, Shih, W, and Day, WW. "A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy." The Journal of Urology 189, no. 6 (June 2013): 2229-2236. Full Text
  - Fizazi, K, Higano, CS, Nelson, JB, Gleave, M, Miller, K, Morris, T, Nathan, FE, McIntosh, S, Pemberton, K, and Moul, JW. "Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 31, no. 14 (May 2013): 1740-1747. Full Text
  - Azrad, Maria, Robin T. Vollmer, John Madden, Mark Dewhirst, Thomas J. Polascik, Denise C. Snyder, Mack T. Ruffin, Judd W. Moul, Dean E. Brenner, and Wendy Demark-Wahnefried. “Flaxseed-derived enterolactone is inversely associated with tumor cell proliferation in men with localized prostate cancer..” Journal of Medicinal Food 16, no. 4 (April 2013): 357–60. https://doi.org/10.1089/jmf.2012.0159.
    Full Text
  - Abern, M. R., M. R. Bassett, M. Tsivian, L. L. Bañez, T. J. Polascik, M. N. Ferrandino, C. N. Robertson, S. J. Freedland, and J. W. Moul. “Race is associated with discontinuation of active surveillance of low-risk prostate cancer: results from the Duke Prostate Center..” Prostate Cancer and Prostatic Diseases 16, no. 1 (March 2013): 85–90. https://doi.org/10.1038/pcan.2012.38.
    Full Text
  - Fu, Qiang, Judd W. Moul, Lionel Bañez, Leon Sun, Vladimir Mouraviev, Donghua Xie, and Thomas J. Polascik. “Preoperative predictors of pathologic stage T2a and pathologic Gleason score ≤ 6 in men with clinical low-risk prostate cancer treated with radical prostatectomy: reference for active surveillance..” Medical Oncology (Northwood, London, England) 30, no. 1 (March 2013). https://doi.org/10.1007/s12032-012-0326-5.
    Full Text
  - Kimura, M., L. L. Bañez, T. J. Polascik, R. M. Bernal, L. Gerber, C. N. Robertson, C. F. Donatucci, and J. W. Moul. “Sexual bother and function after radical prostatectomy: predictors of sexual bother recovery in men despite persistent post-operative sexual dysfunction..” Andrology 1, no. 2 (March 2013): 256–61. https://doi.org/10.1111/j.2047-2927.2012.00036.x.
    Full Text
  - Tsivian, M., L. L. Bañez, C. J. Keto, M. R. Abern, P. Qi, L. Gerber, J. W. Moul, and T. J. Polascik. “African-American men with low-grade prostate cancer have higher tumor burdens: results from the Duke Prostate Center..” Prostate Cancer and Prostatic Diseases 16, no. 1 (March 2013): 91–94. https://doi.org/10.1038/pcan.2012.39.
    Full Text
  - Banez, L. L., L. Gerber, J. W. Moul, M. S. Anscher, W. R. Lee, and B. F. Koontz. “Image guidance for post-prostatectomy radiotherapy: Are we missing the mark?.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 31, no. 6_suppl (February 2013).
  - Abern, M. R., M. R. Bassett, M. Tsivian, L. L. Bañez, T. J. Polascik, M. N. Ferrandino, C. N. Robertson, S. J. Freedland, and J. W. Moul. “Race is associated with discontinuation of active surveillance of low-risk prostate cancer: Results from the Duke Prostate Center.” Prostate Cancer and Prostatic Diseases 16, no. 1 (2013): 84–89. https://doi.org/10.1038/pcan.2012.38.
    Full Text
  - Fu, Q., J. W. Moul, L. Bañez, L. Sun, V. Mouraviev, D. Xie, and T. J. Polascik. “Preoperative predictors of pathologic stage T2a and pathologic Gleason score ≤ 6 in men with clinical low-risk prostate cancer treated with radical prostatectomy: reference for active surveillance..” Medical Oncology (Northwood, London, England) 30, no. 1 (2013): 326–326.
  - Fu, Qiang, Judd W. Moul, Lionel L. Bañez, Leon Sun, Vladimir Mouraviev, Dongha Xie, and Thomas J. Polascik. “Association between percentage of tumor involvement and Gleason score upgrading in low-risk prostate cancer..” Medical Oncology (Northwood, London, England) 29, no. 5 (December 2012): 3339–44. https://doi.org/10.1007/s12032-012-0270-4.
    Full Text
  - Kimura, Masaki, Jorge R. Caso, Lionel L. Bañez, Bridget F. Koontz, Leah Gerber, Cagri Senocak, Craig F. Donatucci, Zeljko Vujaskovic, Judd W. Moul, and Thomas J. Polascik. “Predicting participation in and successful outcome of a penile rehabilitation programme using a phosphodiesterase type 5 inhibitor with a vacuum erection device after radical prostatectomy..” Bju International 110, no. 11 Pt C (December 2012): E931–38. https://doi.org/10.1111/j.1464-410x.2012.11168.x.
    Full Text
  - Moul, Judd W., Hans Lilja, O John Semmes, Raymond S. Lance, Robert L. Vessella, Martin Fleisher, Clarisse Mazzola, et al. “NADiA ProsVue prostate-specific antigen slope is an independent prognostic marker for identifying men at reduced risk of clinical recurrence of prostate cancer after radical prostatectomy..” Urology 80, no. 6 (December 2012): 1319–25. https://doi.org/10.1016/j.urology.2012.06.080.
    Full Text
  - Stewart, SB, Scales, CD, Moul, JW, and Reed, SD. "Does variation in either age at start of therapy or duration of therapy make chemoprevention with finasteride cost-effective?." Prostate Cancer and Prostatic Diseases 15, no. 4 (December 2012): 380-385. Full Text
  - Nelson, Joel B., Karim Fizazi, Kurt Miller, Celestia Higano, Judd W. Moul, Hideyuki Akaza, Thomas Morris, Stuart McIntosh, Kristine Pemberton, and Martin Gleave. “Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone..” Cancer 118, no. 22 (November 2012): 5709–18. https://doi.org/10.1002/cncr.27674.
    Full Text
  - Westover, Kenneth, Ming-Hui Chen, Judd Moul, Cary Robertson, Thomas Polascik, Daniel Dosoretz, Michael Katin, Sharon Salenius, and Anthony V. D’Amico. “Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer..” Bju International 110, no. 8 (October 2012): 1116–21. https://doi.org/10.1111/j.1464-410x.2012.11012.x.
    Full Text
  - Campbell, Lisa C., Francis J. Keefe, Daphne C. McKee, Sandra J. Waters, and Judd W. Moul. “Masculinity beliefs predict psychosocial functioning in African American prostate cancer survivors..” American Journal of Men’S Health 6, no. 5 (September 2012): 400–408. https://doi.org/10.1177/1557988312450185.
    Full Text
  - Djavan, Bob, James Eastham, Leonard Gomella, Bertrand Tombal, Samir Taneja, Seyed Saeid Dianat, Amir Kazzazi, et al. “Testosterone in prostate cancer: the Bethesda consensus..” Bju International 110, no. 3 (August 2012): 344–52. https://doi.org/10.1111/j.1464-410x.2011.10719.x.
    Full Text
  - Catalona, W. J., A. V. D’Amico, W. F. Fitzgibbons, O. Kosoko-Lasaki, S. W. Leslie, H. T. Lynch, J. W. Moul, M. S. Rendell, and P. C. Walsh. “What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation..” Annals of Internal Medicine 157, no. 2 (July 17, 2012): 137–38.
  - Catalona, William J., Anthony V. D’Amico, William F. Fitzgibbons, Omofolasade Kosoko-Lasaki, Stephen W. Leslie, Henry T. Lynch, Judd W. Moul, Marc S. Rendell, and Patrick C. Walsh. “What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation..” Annals of Internal Medicine 157, no. 2 (July 2012): 137–38. https://doi.org/10.7326/0003-4819-157-2-201207170-00463.
    Full Text
  - Moul, J. W. “Minimally invasive open retropubic prostatectomy: in experienced hands--still the gold standard..” Oncology (Williston Park, N.Y.) 26, no. 7 (July 1, 2012).
  - Moul, Judd W. “Minimally invasive open retropubic prostatectomy: in experienced hands--still the gold standard..” Oncology (Williston Park, N.Y.) 26, no. 7 (July 2012): 610–15.
  - Yu, Evan Y., Kurt Miller, Joel Nelson, Martin Gleave, Karim Fizazi, Judd W. Moul, Faith E. Nathan, and Celestia S. Higano. “Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer..” The Journal of Urology 188, no. 1 (July 2012): 103–9. https://doi.org/10.1016/j.juro.2012.03.008.
    Full Text
  - Kimura, Masaki, Zahid N. Rabbani, Andrew R. Zodda, Hui Yan, Isabel L. Jackson, Thomas J. Polascik, Craig F. Donatucci, Judd W. Moul, Zeljko Vujaskovic, and Bridget F. Koontz. “Role of oxidative stress in a rat model of radiation-induced erectile dysfunction..” The Journal of Sexual Medicine 9, no. 6 (June 2012): 1535–49. https://doi.org/10.1111/j.1743-6109.2012.02716.x.
    Full Text
  - Kimura, Masaki, Lionel L. Bañez, Leah Gerber, Jim Qi, Matvey Tsivian, Stephen J. Freedland, Takefumi Satoh, Thomas J. Polascik, Shiro Baba, and Judd W. Moul. “Association between preoperative erectile dysfunction and prostate cancer features--an analysis from the Duke Prostate Center Database..” The Journal of Sexual Medicine 9, no. 4 (April 2012): 1174–81. https://doi.org/10.1111/j.1743-6109.2011.02547.x.
    Full Text
  - Wattson, Daniel A., Ming-Hui Chen, Brian J. Moran, Daniel E. Dosoretz, Michelle H. Braccioforte, Sharon A. Salenius, and Anthony V. D’Amico. “The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selection..” International Journal of Radiation Oncology, Biology, Physics 82, no. 5 (April 2012): e773–79. https://doi.org/10.1016/j.ijrobp.2011.11.023.
    Full Text
  - Boorjian, SA, Eastham, JA, Graefen, M, Guillonneau, B, Karnes, RJ, Moul, JW, Schaeffer, EM, Stief, C, and Zorn, KC. "A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes." European Urology 61, no. 4 (April 2012): 664-675. (Review) Full Text
  - Stephenson, Andrew J., Michel Bolla, Alberto Briganti, Cesare Cozzarini, Judd W. Moul, Mack Roach, Hein van Poppel, and Anthony Zietman. “Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy..” European Urology 61, no. 3 (March 2012): 443–51. https://doi.org/10.1016/j.eururo.2011.10.010.
    Full Text
  - Schroeck, FR, Krupski, TL, Stewart, SB, Bañez, LL, Gerber, L, Albala, DM, and Moul, JW. "Pretreatment expectations of patients undergoing robotic assisted laparoscopic or open retropubic radical prostatectomy." The Journal of Urology 187, no. 3 (March 2012): 894-898. Full Text
  - George, Daniel, and Judd W. Moul. “Emerging treatment options for patients with castration-resistant prostate cancer..” The Prostate 72, no. 3 (February 2012): 338–49. https://doi.org/10.1002/pros.21435.
    Full Text
  - Moul, J. W., K. S. Ferenz, and B. D. Mautner. “Awareness, concern, and communication between physicians and patients on bone health in nonmetastatic prostate cancer..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 30, no. 5_suppl (February 2012).
  - Moul, J. W., K. S. Ferenz, and B. D. Mautner. “Awareness, concern, and communication between physicians and patients on bone health in nonmetastatic prostate cancer..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 30, no. 5_suppl (February 2012).
  - Singh, A. A., L. L. Banez, L. Gerber, S. J. Freedland, C. N. Robertson, M. Ferrandino, T. Polascik, P. J. Walther, and J. W. Moul. “Perineural versus lymphovascular invasion: Which is a better marker for unfavorable biochemical outcomes following prostatectomy? Results from the Duke Prostate Center Database..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 30, no. 5_suppl (February 2012).
  - Singh, A. A., L. L. Banez, L. Gerber, S. J. Freedland, C. N. Robertson, M. Ferrandino, T. Polascik, P. J. Walther, and J. W. Moul. “Perineural versus lymphovascular invasion: Which is a better marker for unfavorable biochemical outcomes following prostatectomy? Results from the Duke Prostate Center Database..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 30, no. 5_suppl (February 2012).
  - Tang, P, Du, W, Xie, K, Fu, J, Chen, H, Yang, W, and Moul, JW. "Characteristics of baseline PSA and PSA velocity in young men without prostate cancer: Racial differences." The Prostate 72, no. 2 (February 2012): 173-180. Full Text
  - Armstrong, A. J., J. W. Moul, and D. J. George. “What to order from the prostate cancer treatment menu?.” Oncology (Williston Park, N.Y.) 26, no. 1 (January 1, 2012).
  - Azrad, Maria, Kui Zhang, Robin T. Vollmer, John Madden, Thomas J. Polascik, Denise C. Snyder, Mack T. Ruffin, et al. “Prostatic alpha-linolenic acid (ALA) is positively associated with aggressive prostate cancer: a relationship which may depend on genetic variation in ALA metabolism..” Plos One 7, no. 12 (January 2012). https://doi.org/10.1371/journal.pone.0053104.
    Full Text Open Access Copy
  - Fu, Q., J. W. Moul, L. L. Bañez, L. Sun, V. Mouraviev, D. Xie, and T. J. Polascik. “Association between percentage of tumor involvement and Gleason score upgrading in low-risk prostate cancer.” Medical Oncology 29, no. 5 (2012): 3339–44. https://doi.org/10.1007/s12032-012-0270-4.
    Full Text
  - Fu, Qiang, Judd W. Moul, Lionel L. Bañez, Leon Sun, Vladimir Mouraviev, Donghua Xie, and Thomas J. Polascik. “Preoperative predictors of pathologic stage T2a in low-risk prostate cancer: implications for focal therapy..” Urologia Internationalis 89, no. 3 (January 2012): 296–300. https://doi.org/10.1159/000341556.
    Full Text
  - Koontz, Bridget F., Matvey Tsivian, Vladimir Mouraviev, Leon Sun, Zeljko Vujaskovic, Judd Moul, and W Robert Lee. “Impact of primary Gleason grade on risk stratification for Gleason score 7 prostate cancers..” International Journal of Radiation Oncology, Biology, Physics 82, no. 1 (January 2012): 200–203. https://doi.org/10.1016/j.ijrobp.2010.11.023.
    Full Text
  - Loeb, Stacy, H Ballentine Carter, William J. Catalona, Judd W. Moul, and Fritz H. Schroder. “Baseline prostate-specific antigen testing at a young age..” European Urology 61, no. 1 (January 2012): 1–7. https://doi.org/10.1016/j.eururo.2011.07.067.
    Full Text
  - Moul, J. “Comprehensive preoperative evaluation and repair of inguinal hernias at the time of open radical retropubic prostatectomy decreases risk of developing postprostatectomy hernia.” Bju International 110, no. 11 B (2012). https://doi.org/10.1111/j.1464-410X.2012.11335.x.
    Full Text
  - Stewart, Suzanne Biehn, Lionel L. Bañez, Cary N. Robertson, Stephen J. Freedland, Thomas J. Polascik, Donghua Xie, Bridget F. Koontz, et al. “Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center..” The Journal of Urology 187, no. 1 (January 2012): 103–8. https://doi.org/10.1016/j.juro.2011.09.040.
    Full Text
  - Tsivian, Matvey, Daniel M. Moreira, Leon Sun, Vladimir Mouraviev, Masaki Kimura, Judd W. Moul, and Thomas J. Polascik. “Biopsy accuracy in identifying unilateral prostate cancer depends on prostate weight..” Urologic Oncology 30, no. 1 (January 2012): 21–25. https://doi.org/10.1016/j.urolonc.2009.11.001.
    Full Text
  - Moul, JW, and Dawson, N. "Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature." Cancer Investigation 30, no. 1 (January 2012): 1-12. (Review) Full Text
  - Chu, D. I., C. De Nunzio, L. Gerber, J. -. A. Thomas, E. E. Calloway, S. Albisinni, C. Senocak, et al. “Predictive value of digital rectal examination for prostate cancer detection is modified by obesity..” Prostate Cancer and Prostatic Diseases 14, no. 4 (December 2011): 346–53. https://doi.org/10.1038/pcan.2011.31.
    Full Text
  - Crawford, E David, Judd W. Moul, Kyle O. Rove, Curtis A. Pettaway, Lois E. Lamerato, and Alexa Hughes. “Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone..” Bju International 108, no. 11 (December 2011): 1743–49. https://doi.org/10.1111/j.1464-410x.2011.10224.x.
    Full Text
  - Bhaskar, R, Gkoulalas-Divanis, A, Kifer, D, Laxman, S, Singh, L, Wu, X, Clifton, C, Domingo-Ferrer, J, Hay, M, Kalnis, P, Kargupta, H, LeFevre, K, Liu, K, Loukides, G, MacHanavajjhala, A, McSherry, F, Miklau, G, Mokbel, M, Sayal, M, Saygin, Y, Slavkovic, A, Smith, A, Terrovitis, M, Truta, TM, Yu, PS, Vaidya, J, and Li, X. "Preface." Proceedings Ieee International Conference on Data Mining, Icdm (December 1, 2011). Full Text
  - Dreicer, Robert, Dean F. Bajorin, David G. McLeod, Daniel P. Petrylak, and Judd W. Moul. “New data, new paradigms for treating prostate cancer patients--VI: novel hormonal therapy approaches..” Urology 78, no. 5 Suppl (November 2011): S494–98. https://doi.org/10.1016/j.urology.2011.06.058.
    Full Text
  - Dreicer, Robert, Martin Gleave, Adam S. Kibel, J Brantley Thrasher, and Judd W. Moul. “Targeting the androgen receptor--theory and practice..” Urology 78, no. 5 Suppl (November 2011): S482–84. https://doi.org/10.1016/j.urology.2011.05.052.
    Full Text
  - Moul, Judd W., Adam S. Kibel, Mack Roach, and Robert Dreicer. “Indications and practice with androgen deprivation therapy..” Urology 78, no. 5 Suppl (November 2011): S478–81. https://doi.org/10.1016/j.urology.2011.04.025.
    Full Text
  - Moul, Judd W., Christopher P. Evans, Leonard G. Gomella, Mack Roach, and Robert Dreicer. “Traditional approaches to androgen deprivation therapy..” Urology 78, no. 5 Suppl (November 2011): S485–93. https://doi.org/10.1016/j.urology.2011.05.051.
    Full Text
  - Moul, Judd W., and Robert Dreicer. “Focusing on testosterone..” Urology 78, no. 5 Suppl (November 2011): S476–77. https://doi.org/10.1016/j.urology.2011.06.004.
    Full Text
  - Albers, Peter, Ferran Algaba, Gabriella Cohn-Cedermark, Maria DeSantis, Sabine Kliesch, and Judd W. Moul. “Diagnosis, staging, and risk factors: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009..” Urology 78, no. 4 Suppl (October 2011): S427–34. https://doi.org/10.1016/j.urology.2011.03.053.
    Full Text
  - Kimura, Masaki, Lionel L. Bañez, Florian R. Schroeck, Leah Gerber, Jim Qi, Takefumi Satoh, Shiro Baba, et al. “Factors predicting early and late phase decline of sexual health-related quality of life following radical prostatectomy..” The Journal of Sexual Medicine 8, no. 10 (October 2011): 2935–43. https://doi.org/10.1111/j.1743-6109.2011.02387.x.
    Full Text
  - Cotter, Shane E., Ming Hui Chen, Judd W. Moul, W Robert Lee, Bridget F. Koontz, Mitchell S. Anscher, Cary N. Robertson, Philip J. Walther, Thomas J. Polascik, and Anthony V. D’Amico. “Salvage radiation in men after prostate-specific antigen failure and the risk of death..” Cancer 117, no. 17 (September 2011): 3925–32. https://doi.org/10.1002/cncr.25993.
    Full Text
  - Crawford, E David, Bertrand Tombal, Kurt Miller, Laurent Boccon-Gibod, Fritz Schröder, Neal Shore, Judd W. Moul, Jens-Kristian Jensen, Tine Kold Olesen, and Bo-Eric Persson. “A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer..” The Journal of Urology 186, no. 3 (September 2011): 889–97. https://doi.org/10.1016/j.juro.2011.04.083.
    Full Text
  - Arvold, Nils D., Ming-Hui Chen, Judd W. Moul, Brian J. Moran, Daniel E. Dosoretz, Lionel L. Bañez, Michael J. Katin, Michelle H. Braccioforte, and Anthony V. D’Amico. “Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease..” The Journal of Urology 186, no. 1 (July 2011): 91–96. https://doi.org/10.1016/j.juro.2011.03.003.
    Full Text
  - Tang, P, Sun, L, Uhlman, MA, Robertson, CN, Polascik, TJ, and Moul, JW. "Prostate-specific antigen velocity based risk-adapted discontinuation of prostate cancer screening in elderly men." Bju International 108, no. 1 (July 2011): 44-48. Full Text
  - George, D. J., S. Halabi, A. J. Zurita, P. Creel, K. Mundy, J. D. Turnbull, S. E. Yenser Wood, et al. “Investigator-initiated pilot study of sunitinib malate in patients with newly diagnosed prostate cancer prior to prostatectomy: A trial of the DoD/PCF Prostate Cancer Clinical Trials Consortium..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 29, no. 15_suppl (May 2011).
  - Tripathy, D., J. W. Moul, B. G. Durie, and B. D. Mautner. “Assessment of current practices among physicians and awareness and concern among patients for bone health in cancer..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 29, no. 15_suppl (May 2011).
  - Moul, JW. "What matters young low-risk men present conundrum." Oncology Report , no. MAY (May 1, 2011): 12-null.
  - Arvold, N. D., M. Chen, J. W. Moul, B. J. Moran, D. E. Dosoretz, L. L. Banez, M. J. Katin, M. H. Braccioforte, and A. V. D’Amico. “Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low- or intermediate-risk disease..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 29, no. 7_suppl (March 2011).
  - Moul, J. W., O. J. Semmes, R. Vessella, J. E. McDermed, and H. Lilja. “Prognostic impact of post-prostatectomy PSA slope determined with a novel, nucleic acid detection immunoassay (NADiA ProsVue) for total PSA..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 29, no. 7_suppl (March 2011).
  - Moul, Judd W. “Putting Provenge in perspective..” Oncology (Williston Park, N.Y.) 25, no. 3 (March 2011): 255–58.
  - Nelson, J. B., K. Fizazi, K. Miller, C. S. Higano, J. W. Moul, T. Morris, S. McIntosh, K. Pemberton, and M. E. Gleave. “Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC)..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 29, no. 7_suppl (March 2011).
  - Reed, Shelby D., Charles D. Scales, Suzanne B. Stewart, Jielin Sun, Judd W. Moul, Kevin A. Schulman, and Jianfeng Xu. “Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer..” The Journal of Urology 185, no. 3 (March 2011): 841–47. https://doi.org/10.1016/j.juro.2010.10.078.
    Full Text
  - Shore, N. D., J. W. Moul, E. Crawford, E. van der Meulen, T. Olesen, and B. Persson. “Prostate-specific antigen (PSA) progression-free survival (PFS): A comparison of degarelix versus leuprolide in patients with prostate cancer..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 29, no. 7_suppl (March 2011).
  - Arvold, ND, Chen, M, Moul, JW, Moran, BJ, Dosoretz, DE, Banez, LL, Katin, MJ, Braccioforte, MH, and D'Amico, AV. "Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low- or intermediate-risk disease." Journal of Clinical Oncology 29, no. 7_suppl (March 2011): 198-198. Full Text
  - Fu, Qiang, Judd W. Moul, and Leon Sun. “Contemporary radical prostatectomy..” Prostate Cancer 2011 (January 2011). https://doi.org/10.1155/2011/645030.
    Full Text Open Access Copy
  - Caso, Jorge R., Matvey Tsivian, Vladimir Mouraviev, Thomas J. Polascik, and Judd W. Moul. “Pathological T2 sub-divisions as a prognostic factor in the biochemical recurrence of prostate cancer..” Bju International 106, no. 11 (December 2010): 1623–27. https://doi.org/10.1111/j.1464-410x.2010.09439.x.
    Full Text
  - D’Amico, Anthony V., Ming-Hui Chen, Leon Sun, W Robert Lee, Vladimir Mouraviev, Cary N. Robertson, Philip J. Walther, Thomas J. Polascik, David M. Albala, and Judd W. Moul. “Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death..” Bju International 106, no. 11 (December 2010): 1618–22. https://doi.org/10.1111/j.1464-410x.2010.09447.x.
    Full Text
  - Moreira, Daniel M., Joseph C. Presti, William J. Aronson, Martha K. Terris, Christopher J. Kane, Christopher L. Amling, Leon L. Sun, Judd W. Moul, and Stephen J. Freedland. “Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases..” International Journal of Urology : Official Journal of the Japanese Urological Association 17, no. 11 (November 2010): 914–22. https://doi.org/10.1111/j.1442-2042.2010.02631.x.
    Full Text
  - Tang, P, Sun, L, Uhlman, MA, Robertson, CN, Polascik, TJ, Albala, DM, Donatucci, CF, and Moul, JW. "Prostate-specific antigen-based risk-adapted discontinuation of prostate cancer screening in elderly African American and Caucasian American men." Urology 76, no. 5 (November 2010): 1058-1062. Full Text
  - Ali, Amina, Bungo Furusato, Paul O. P. Ts’o, Zhao-Ping Lum, Sally Elsamanoudi, Ahmed Mohamed, Shiv Srivastava, et al. “Assessment of circulating tumor cells (CTCs) in prostate cancer patients with low-volume tumors..” Pathology International 60, no. 10 (October 2010): 667–72. https://doi.org/10.1111/j.1440-1827.2010.02584.x.
    Full Text
  - Caire, Arthur A., Leon Sun, Thomas J. Polascik, David M. Albala, and Judd W. Moul. “Obese African-Americans with prostate cancer (T1c and a prostate-specific antigen, PSA, level of <10 ng/mL) have higher-risk pathological features and a greater risk of PSA recurrence than non-African-Americans..” Bju International 106, no. 8 (October 2010): 1157–60. https://doi.org/10.1111/j.1464-410x.2010.09340.x.
    Full Text
  - Tang, P, Sun, L, Uhlman, MA, Polascik, TJ, Freedland, SJ, and Moul, JW. "Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades: Duke University experience." Cancer 116, no. 20 (October 2010): 4711-4717. Full Text
  - Teeter, Anna E., Leon Sun, Judd W. Moul, and Stephen J. Freedland. “External validation of the SEARCH model for predicting aggressive recurrence after radical prostatectomy: results from the Duke Prostate Center Database..” Bju International 106, no. 6 (September 2010): 796–800. https://doi.org/10.1111/j.1464-410X.2010.09214.x.
    Full Text
  - Caire, AA, Sun, L, Lack, BD, Lum, K, Tang, P, Stackhouse, DA, Robertson, CN, Mouraviev, V, Polascik, TJ, Albala, DM, and Moul, JW. "Predicting non-organ-confined prostate cancer in men diagnosed after 2000." Prostate Cancer and Prostatic Diseases 13, no. 3 (September 2010): 248-251. Full Text
  - Droz, J-P, Balducci, L, Bolla, M, Emberton, M, Fitzpatrick, JM, Joniau, S, Kattan, MW, Monfardini, S, Moul, JW, Naeim, A, van Poppel, H, Saad, F, and Sternberg, CN. "Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology." Bju International 106, no. 4 (August 2010): 462-469. (Review) Full Text Open Access Copy
  - Hammerich, Kai H., Florian R. Schroeck, Dava West, and Judd W. Moul. “Simultaneously detected bilateral testicular cancer of different histopathological origin--a challenging situation for the urologist..” Oncology (Williston Park, N.Y.) 24, no. 8 (July 2010): 757–60.
  - Schröder, Fritz H., Bertrand Tombal, Kurt Miller, Laurent Boccon-Gibod, Neal D. Shore, E David Crawford, Judd Moul, Tine Kold Olesen, and Bo-Eric Persson. “Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study..” Bju International 106, no. 2 (July 2010): 182–87. https://doi.org/10.1111/j.1464-410x.2009.08981.x.
    Full Text
  - Schroeck, Florian R., Michael W. Kattan, Judd W. Moul, William J. Aronson, Joseph C. Presti, Martha K. Terris, Christopher J. Kane, Christopher L. Amling, Leon Sun, and Stephen J. Freedland. “Re-calibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy..” Bju International 105, no. 12 (June 2010): 1654–59. https://doi.org/10.1111/j.1464-410x.2009.09060.x.
    Full Text
  - Caire, Arthur A., Leon Sun, Cary N. Robertson, Thomas J. Polascik, Kelly E. Maloney, Daniel J. George, Marva M. Price, et al. “Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75..” Urology 75, no. 5 (May 2010): 1122–27. https://doi.org/10.1016/j.urology.2009.06.091.
    Full Text
  - Caso, Jorge R., Vladimir Mouraviev, Matvey Tsivian, Thomas J. Polascik, and Judd W. Moul. “Prostate cancer: an evolving paradigm..” Journal of Endourology 24, no. 5 (May 2010): 805–9. https://doi.org/10.1089/end.2009.0539.
    Full Text Open Access Copy
  - Tombal, Bertrand, Kurt Miller, Laurent Boccon-Gibod, Fritz Schröder, Neal Shore, E David Crawford, Judd Moul, Jens-Kristian Jensen, Tine Kold Olesen, and Bo-Eric Persson. “Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics..” European Urology 57, no. 5 (May 2010): 836–42. https://doi.org/10.1016/j.eururo.2009.11.029.
    Full Text
  - Murphy, DG, Bjartell, A, Ficarra, V, Graefen, M, Haese, A, Montironi, R, Montorsi, F, Moul, JW, Novara, G, Sauter, G, Sulser, T, and van der Poel, H. "Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications." European Urology 57, no. 5 (May 2010): 735-746. (Review) Full Text
  - Choueiri, TK, Chen, M-H, D'Amico, AV, Sun, L, Nguyen, PL, Hayes, JH, Robertson, CN, Walther, PJ, Polascik, TJ, Albala, DM, and Moul, JW. "Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death." Cancer 116, no. 8 (April 2010): 1887-1892. Full Text
  - Moreira, D. M., J. C. Presti, W. J. Aronson, M. K. Terris, C. J. Kane, C. L. Amling, L. L. Sun, J. W. Moul, and S. J. Freedland. “The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases..” Prostate Cancer and Prostatic Diseases 13, no. 1 (March 2010): 87–93. https://doi.org/10.1038/pcan.2009.48.
    Full Text
  - Uhlman, Matthew A., Leon Sun, Danielle A. Stackhouse, Thomas J. Polascik, Valdmir Mouraviev, Cary N. Robertson, David M. Albala, and Judd W. Moul. “Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate..” The Journal of Urology 183, no. 3 (March 2010): 997–1001. https://doi.org/10.1016/j.juro.2009.11.046.
    Full Text
  - Tang, P, Sun, L, Uhlman, MA, Robertson, CN, Polascik, TJ, Albala, DM, Donatucci, CF, and Moul, JW. "Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk." The Journal of Urology 183, no. 3 (March 2010): 946-950. Full Text
  - Kawachi, Mark H., Robert R. Bahnson, Michael Barry, J Erik Busby, Peter R. Carroll, H Ballentine Carter, William J. Catalona, et al. “NCCN clinical practice guidelines in oncology: prostate cancer early detection..” Journal of the National Comprehensive Cancer Network : Jnccn 8, no. 2 (February 2010): 240–62. https://doi.org/10.6004/jnccn.2010.0016.
    Full Text
  - Uhlman, Matthew A., Leon Sun, Danielle A. Stackhouse, Arthur A. Caire, Thomas J. Polascik, Cary N. Robertson, John Madden, Robin Vollmer, David M. Albala, and Judd W. Moul. “Tumor volume, tumor percentage involvement, or prostate volume: which is predictive of prostate-specific antigen recurrence?.” Urology 75, no. 2 (February 2010): 460–66. https://doi.org/10.1016/j.urology.2009.06.059.
    Full Text
  - Uhlman, Matthew A., Leon Sun, Danielle A. Stackhouse, Arthur A. Caire, Thomas J. Polascik, Cary N. Robertson, John Madden, Robin Vollmer, David M. Albala, and Judd W. Moul. “Tumor Volume, Tumor Percentage Involvement, or Prostate Volume: Which Is Predictive of Prostate-specific Antigen Recurrence?.” Urology 75, no. 2 (February 2010): 460–66. https://doi.org/10.1016/j.urology.2009.06.059.
    Full Text Link to Item
  - Droz, Jean-Pierre, Lodovico Balducci, Michel Bolla, Mark Emberton, John M. Fitzpatrick, Steven Joniau, Michael W. Kattan, et al. “Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults..” Critical Reviews in Oncology/Hematology 73, no. 1 (January 2010): 68–91. https://doi.org/10.1016/j.critrevonc.2009.09.005.
    Full Text
  - Jayachandran, Jayakrishnan, Florian Schroeck, Leon Sun, Leah Gerber, Daniel M. Moreira, Judd W. Moul, and Stephen J. Freedland. “The Shared Equal Access Regional Cancer Hospital (SEARCH) nomogram for risk stratification in intermediate risk group of men with prostate cancer: validation in the Duke Prostate Center database..” Bju International 105, no. 2 (January 2010): 180–84. https://doi.org/10.1111/j.1464-410x.2009.08728.x.
    Full Text
  - Chino, Junzo, Florian R. Schroeck, Leon Sun, W Robert Lee, David M. Albala, Judd W. Moul, and Bridget F. Koontz. “Robot-assisted laparoscopic prostatectomy is not associated with early postoperative radiation therapy..” Bju International 104, no. 10 (November 2009): 1496–1500. https://doi.org/10.1111/j.1464-410x.2009.08588.x.
    Full Text
  - Sun, Leon, Arthur A. Caire, Cary N. Robertson, Daniel J. George, Thomas J. Polascik, Kelly E. Maloney, Philip J. Walther, et al. “Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras..” The Journal of Urology 182, no. 5 (November 2009): 2242–48. https://doi.org/10.1016/j.juro.2009.07.034.
    Full Text
  - Tsivian, Matvey, Leon Sun, Vladimir Mouraviev, John F. Madden, Janice M. Mayes, Judd W. Moul, and Thomas J. Polascik. “Changes in Gleason score grading and their effect in predicting outcome after radical prostatectomy..” Urology 74, no. 5 (November 2009): 1090–93. https://doi.org/10.1016/j.urology.2009.03.043.
    Full Text
  - Uhlman, MA, Moul, JW, Robertson, CN, and Sun, L. "Prostate-specific antigen screening and prostate cancer mortality: Implications of a randomized European study." Aging Health 5, no. 3 (September 18, 2009): 281-286. Full Text
  - Caire, Arthur A., Leon Sun, Oludotun Ode, Danielle A. Stackhouse, Kelly Maloney, Craig Donatucci, Vladimir Mouraviev, et al. “Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes?.” Urology 74, no. 3 (September 2009): 643–47. https://doi.org/10.1016/j.urology.2009.02.049.
    Full Text
  - Xu, David D., Sandy D. Sun, Flint Wang, Leon Sun, Danielle Stackhouse, Thomas Polascik, David M. Albala, Judd W. Moul, Arthur Caire, and Cary N. Robertson. “Effect of age and pathologic Gleason score on PSA recurrence: analysis of 2911 patients undergoing radical prostatectomy..” Urology 74, no. 3 (September 2009): 654–58. https://doi.org/10.1016/j.urology.2008.12.063.
    Full Text
  - Uhlman, MA, Moul, JW, Tang, P, Stackhouse, DA, and Sun, L. "Risk stratification in the hormonal treatment of patients with prostate cancer." Therapeutic Advances in Medical Oncology 1, no. 2 (September 2009): 79-94. Full Text
  - D’Alonzo, Richard C., Tong J. Gan, Judd W. Moul, David M. Albala, Thomas J. Polascik, Cary N. Robertson, Leon Sun, Philipp Dahm, and Ashraf S. Habib. “A retrospective comparison of anesthetic management of robot-assisted laparoscopic radical prostatectomy versus radical retropubic prostatectomy..” Journal of Clinical Anesthesia 21, no. 5 (August 22, 2009): 322–28. https://doi.org/10.1016/j.jclinane.2008.09.005.
    Full Text
  - Bañez, Lionel L., Gary W. Blake, David G. McLeod, E David Crawford, and Judd W. Moul. “Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up..” Bju International 104, no. 3 (August 2009): 310–14. https://doi.org/10.1111/j.1464-410x.2009.08400.x.
    Full Text
  - Bañez, Lionel L., Leon Sun, Bruce J. Trock, Misop Han, Alan W. Partin, William J. Aronson, Martha K. Terris, et al. “Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy..” The Journal of Urology 182, no. 2 (August 2009): 491–96. https://doi.org/10.1016/j.juro.2009.04.007.
    Full Text
  - Ou, Yangming, Dinggang Shen, Jianchao Zeng, Leon Sun, Judd Moul, and Christos Davatzikos. “Sampling the spatial patterns of cancer: optimized biopsy procedures for estimating prostate cancer volume and Gleason Score..” Medical Image Analysis 13, no. 4 (August 2009): 609–20. https://doi.org/10.1016/j.media.2009.05.002.
    Full Text
  - Stackhouse, Danielle A., Leon Sun, Florian R. Schroeck, Jayakrishnan Jayachandran, Arthur A. Caire, Cyril O. Acholo, Cary N. Robertson, et al. “Factors predicting prostatic biopsy Gleason sum under grading..” The Journal of Urology 182, no. 1 (July 2009): 118–22. https://doi.org/10.1016/j.juro.2009.02.127.
    Full Text
  - Habib, Ashraf S., Thomas J. Polascik, Alon Z. Weizer, William D. White, Judd W. Moul, Magdi A. ElGasim, and Tong J. Gan. “Lidocaine patch for postoperative analgesia after radical retropubic prostatectomy..” Anesthesia and Analgesia 108, no. 6 (June 2009): 1950–53. https://doi.org/10.1213/ane.0b013e3181a21185.
    Full Text
  - Polascik, Thomas J., Janice M. Mayes, Florian R. Schroeck, Leon Sun, John F. Madden, Judd W. Moul, and Vladimir Mouraviev. “Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy..” Cancer 115, no. 10 (May 2009): 2104–10. https://doi.org/10.1002/cncr.24258.
    Full Text
  - Caire, Arthur A., Leon Sun, Thomas J. Polascik, Cary N. Robertson, Kelly E. Maloney, Craig F. Donatucci, Daivd M. Albala, and Judd W. Moul. “PREDICTING NON-ORGAN CONFINED PROSTATE CANCER AFTER THE YEAR 2000.” The Journal of Urology 181, no. 4 (April 2009): 609–609. https://doi.org/10.1016/s0022-5347(09)61710-9.
    Full Text
  - Chen, VH, Mouraviev, V, Mayes, JM, Sun, L, Madden, JF, Moul, JW, and Polascik, TJ. "Utility of a 3-dimensional transrectal ultrasound-guided prostate biopsy system for prostate cancer detection." Technology in Cancer Research & Treatment 8, no. 2 (April 2009): 99-104. Full Text
  - Lack, BD, Sun, L, Caire, AA, Donatucci, CF, Robertson, CN, Mouraviev, V, Polascik, TJ, Albala, DM, Maloney, KE, Walther, PJ, and Moul, JW. "WHO DOES NOT NEED FOLLOW UP TWO YEARS AFTER PROSTATECTOMY? AN ANALYSIS OF 1739 PATIENTS AT DUKE UNIVERSITY MEDICAL CENTER." Journal of Urology 181, no. 4S (April 2009): 759-759. Full Text
  - Lack, BD, Sun, L, Caire, AA, Ode, O, Stackhouse, DA, Maloney, KE, Donatucci, CF, Mouraviev, V, Polascik, TJ, Robertson, CN, Albala, DM, and Moul, JW. "DELAYED PSA RECURRENCE AFTER RADICAL PROSTATECTOMY: HOW TO IDENTIFY PATIENTS AT RISK AND THEIR CLINICAL OUTCOMES?." Journal of Urology 181, no. 4S (April 2009): 457-457. Full Text
  - Moul, JW, Sun, L, Lack, BD, Robertson, CN, Polascik, TJ, Donatucci, CF, Maloney, KE, Price, M, Albala, DM, and Caire, AA. "SAY NO TO THE US PREVENTATIVE TASK FORCE RECOMMENDATION TO NO LONGER OFFER PROSTATE CANCER SCREENING AFTER AGE 75?." Journal of Urology 181, no. 4S (April 2009): 797-797. Full Text
  - Stackhouse, DA, Sun, L, Dahm, P, Kavoussi, LR, Paulson, D, Donatucci, CF, Maloney, KE, Albala, DM, Polascik, TJ, Robertson, CN, and Moul, JW. "PERINEAL RADICAL PROSTATECTOMY: WHAT ARE THE TEN YEAR OUTCOMES?." Journal of Urology 181, no. 4S (April 2009): 210-210. Full Text
  - Moul, Judd W., Vladimir Mouraviev, Leon Sun, Florian R. Schroeck, and Thomas J. Polascik. “Prostate cancer: the new landscape..” Current Opinion in Urology 19, no. 2 (March 2009): 154–60. https://doi.org/10.1097/mou.0b013e328323f5d6.
    Full Text
  - Nguyen, Paul L., Ming-Hui Chen, William J. Catalona, Judd W. Moul, Leon Sun, and Anthony V. D’Amico. “Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors..” International Journal of Radiation Oncology, Biology, Physics 73, no. 3 (March 2009): 659–64. https://doi.org/10.1016/j.ijrobp.2008.05.009.
    Full Text
  - Schroeck, F. R., T. L. Krupski, L. Sun, D. M. Albala, M. M. Price, T. J. Polascik, C. N. Robertson, A. K. Tewari, and J. W. Moul. “Satisfaction and Regret After Open Retropubic or Robot-Assisted Laparoscopic Radical Prostatectomy.” Journal of Urology 181, no. 2 (February 1, 2009): 635–36.
    Link to Item
  - Moul, J. “Prostate Cancer and Prostatic Diseases. Report from Durham..” Prostate Cancer and Prostatic Diseases 12, no. 1 (January 2009). https://doi.org/10.1038/pcan.2009.1.
    Full Text
  - Moul, Judd W. “Post-radical prostatectomy management options for positive surgical margins: argument for observation..” Urologic Oncology 27, no. 1 (January 2009): 92–96. https://doi.org/10.1016/j.urolonc.2008.04.011.
    Full Text
  - Freedland, SJ, Bañez, LL, Sun, LL, Fitzsimons, NJ, and Moul, JW. "Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database." Prostate Cancer and Prostatic Diseases 12, no. 3 (January 2009): 259-263. Full Text
  - Demark-Wahnefried, W, Polascik, TJ, George, SL, Switzer, BR, Madden, JF, Ruffin, MT, Snyder, DC, Owzar, K, Hars, V, Albala, DM, Walther, PJ, Robertson, CN, Moul, JW, Dunn, BK, Brenner, D, Minasian, L, Stella, P, and Vollmer, RT. "Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery." Cancer Epidemiol Biomarkers Prev 17, no. 12 (December 2008): 3577-3587. Full Text Link to Item
  - Schroeck, Florian R., Craig F. Donatucci, Emily C. Smathers, Leon Sun, David M. Albala, Thomas J. Polascik, Judd W. Moul, and Tracey L. Krupski. “Defining potency: a comparison of the International Index of Erectile Function short version and the Expanded Prostate Cancer Index Composite..” Cancer 113, no. 10 (November 2008): 2687–94. https://doi.org/10.1002/cncr.23887.
    Full Text
  - Fitzpatrick, John M., John Anderson, Cora N. Sternberg, Neil Fleshner, Karim Fizazi, Xavier Rébillard, Luigi Dogliotti, et al. “Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach..” Critical Reviews in Oncology/Hematology 68 Suppl 1 (October 2008): S9–22. https://doi.org/10.1016/j.critrevonc.2008.07.019.
    Full Text
  - Isariyawongse, Brandon K., Leon Sun, Lionel L. Bañez, Cary Robertson, Thomas J. Polascik, Kelly Maloney, Craig Donatucci, et al. “Significant discrepancies between diagnostic and pathologic Gleason sums in prostate cancer: the predictive role of age and prostate-specific antigen..” Urology 72, no. 4 (October 2008): 882–86. https://doi.org/10.1016/j.urology.2008.02.021.
    Full Text
  - Schroeck, FR, Krupski, TL, Sun, L, Albala, DM, Price, MM, Polascik, TJ, Robertson, CN, Tewari, AK, and Moul, JW. "Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy." European Urology 54, no. 4 (October 2008): 785-793. Full Text
  - Freedland, Stephen J., Leon Sun, Christopher J. Kane, Joseph C. Presti, Martha K. Terris, Christopher L. Amling, Judd W. Moul, and William J. Aronson. “Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases..” Bju International 102, no. 8 (September 2008): 969–74. https://doi.org/10.1111/j.1464-410x.2008.07934.x.
    Full Text
  - Habib, Ashraf S., William D. White, Magdi A. El Gasim, Gamal Saleh, Thomas J. Polascik, Judd W. Moul, and Tong J. Gan. “Transdermal nicotine for analgesia after radical retropubic prostatectomy..” Anesthesia and Analgesia 107, no. 3 (September 2008): 999–1004. https://doi.org/10.1213/ane.0b013e31816f2616.
    Full Text
  - Polascik, Thomas J., Janice M. Mayes, Leon Sun, John F. Madden, Judd W. Moul, and Vladimir Mouraviev. “Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy..” The Prostate 68, no. 13 (September 2008): 1380–86. https://doi.org/10.1002/pros.20804.
    Full Text
  - Scales, Charles D., Jodi Antonelli, Lesley H. Curtis, Kevin A. Schulman, and Judd W. Moul. “Prostate-specific antigen screening among young men in the United States..” Cancer 113, no. 6 (September 2008): 1315–23. https://doi.org/10.1002/cncr.23667.
    Full Text
  - Rampersaud, Edward N., Leon Sun, Judd W. Moul, John Madden, and Stephen J. Freedland. “Percent tumor involvement and risk of biochemical progression after radical prostatectomy..” The Journal of Urology 180, no. 2 (August 2008): 571–76. https://doi.org/10.1016/j.juro.2008.04.017.
    Full Text
  - Schroeck, Florian R., Leon Sun, Stephen J. Freedland, David M. Albala, Vladimir Mouraviev, Thomas J. Polascik, and Judd W. Moul. “Comparison of prostate-specific antigen recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic or robot-assisted laparoscopic radical prostatectomy..” Bju International 102, no. 1 (July 2008): 28–32. https://doi.org/10.1111/j.1464-410x.2008.07607.x.
    Full Text
  - Weinrich, Sally P., Rachelle E. Seger, Ganesh S. Rao, Evelyn C. Chan, Robert M. Hamm, Paul A. Godley, Judd W. Moul, et al. “A decision aid for teaching limitations of prostate cancer screening..” Journal of National Black Nurses’ Association : Jnbna 19, no. 1 (July 2008): 1–11.
  - Koontz, Bridget F., Vladimir Mouraviev, Jeffrey L. Johnson, Janice Mayes, Stephanie H. Chen, Terence Z. Wong, Mitchell S. Anscher, Leon Sun, Judd Moul, and Thomas J. Polascik. “Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer..” International Journal of Radiation Oncology, Biology, Physics 71, no. 2 (June 2008): 358–61. https://doi.org/10.1016/j.ijrobp.2007.10.020.
    Full Text
  - Mouraviev, Vladimir, Gloria Broadwater, Leon Sun, Janice M. Mayes, Judd W. Moul, and Thomas J. Polascik. “Can prostate-specific antigen and prostate-specific antigen velocity be used for prostate cancer screening in men older than 70 years?.” Urology 71, no. 6 (June 2008): 1020–23. https://doi.org/10.1016/j.urology.2007.11.016.
    Full Text
  - Moul, J. W., D. Wiederkehr, M. Connolly, V. Sendersky, and E. Onel. “The relationship between LHRH-agonist depot formulations and frequency of follow-up with health care providers in patients with prostate cancer..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 26, no. 15_suppl (May 2008).
  - Moul, Judd W., Hongyu Wu, Leon Sun, David G. McLeod, Christopher Amling, Timothy Donahue, Leo Kusuda, et al. “Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy..” The Journal of Urology 179, no. 5 Suppl (May 2008): S53–59. https://doi.org/10.1016/j.juro.2008.03.138.
    Full Text
  - Schroeck, Florian R., Chiquita A Palha de Sousa, Ross A. Kalman, Maitri S. Kalia, Sean A. Pierre, George E. Haleblian, Leon Sun, Judd W. Moul, and David M. Albala. “Trainees do not negatively impact the institutional learning curve for robotic prostatectomy as characterized by operative time, estimated blood loss, and positive surgical margin rate..” Urology 71, no. 4 (April 2008): 597–601. https://doi.org/10.1016/j.urology.2007.12.023.
    Full Text
  - Whittemore, Darren E., Eric J. Hick, Mark R. Carter, Judd W. Moul, Alejandro J. Miranda-Sousa, and Wade J. Sexton. “Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens..” The Journal of Urology 179, no. 2 (February 2008): 516–22. https://doi.org/10.1016/j.juro.2007.09.085.
    Full Text
  - Schroeck, F. R., L. Sun, S. J. Freedland, J. Jayachandran, C. N. Robertson, and J. W. Moul. “Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy..” Prostate Cancer and Prostatic Diseases 11, no. 4 (January 2008): 371–76. https://doi.org/10.1038/pcan.2008.18.
    Full Text
  - Fitzsimons, Nicholas J., Leon L. Sun, Philipp Dahm, Judd W. Moul, John Madden, Tong J. Gan, and Stephen J. Freedland. “A single-institution comparison between radical perineal and radical retropubic prostatectomy on perioperative and pathological outcomes for obese men: an analysis of the Duke Prostate Center database..” Urology 70, no. 6 (December 2007): 1146–51. https://doi.org/10.1016/j.urology.2007.07.065.
    Full Text
  - Mouraviev, Vladimir, Leon Sun, John F. Madden, Janice M. Mayes, Judd W. Moul, and Thomas J. Polascik. “Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy..” Urology 70, no. 6 (December 2007): 1141–45. https://doi.org/10.1016/j.urology.2007.07.066.
    Full Text
  - Scales, Charles D., Judd W. Moul, Lesley H. Curtis, Eric P. Elkin, M. E. Hughes, Peter R. Carroll, and Peter R. CaPSURE Investigators. “Prostate cancer in the Baby Boomer generation: results from CaPSURE..” Urology 70, no. 6 (December 2007): 1162–67. https://doi.org/10.1016/j.urology.2007.08.011.
    Full Text
  - Bañez, Lionel L., Robert J. Hamilton, Alan W. Partin, Robin T. Vollmer, Leon Sun, Carmen Rodriguez, Yiting Wang, et al. “Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer..” Jama 298, no. 19 (November 2007): 2275–80. https://doi.org/10.1001/jama.298.19.2275.
    Full Text
  - Moul, Judd W., Lionel L. Bañez, and Stephen J. Freedland. “Rising PSA in nonmetastatic prostate cancer..” Oncology (Williston Park, N.Y.) 21, no. 12 (November 2007): 1436–54.
  - Nosnik, Israel P., Tong J. Gan, and Judd W. Moul. “Open radical retropubic prostatectomy 2007: the true minimally invasive surgery for localized prostate cancer?.” Expert Review of Anticancer Therapy 7, no. 9 (September 2007): 1309–17. https://doi.org/10.1586/14737140.7.9.1309.
    Full Text
  - Burnett, Arthur L., Gunnar Aus, Edith D. Canby-Hagino, Michael S. Cookson, Anthony V. D’Amico, Roger R. Dmochowski, David T. Eton, et al. “Erectile function outcome reporting after clinically localized prostate cancer treatment..” The Journal of Urology 178, no. 2 (August 2007): 597–601. https://doi.org/10.1016/j.juro.2007.03.140.
    Full Text
  - Kawachi, Mark H., Robert R. Bahnson, Michael Barry, Peter R. Carroll, H Ballentine Carter, William J. Catalona, Jonathan I. Epstein, et al. “Prostate cancer early detection. Clinical practice guidelines in oncology..” Journal of the National Comprehensive Cancer Network : Jnccn 5, no. 7 (August 2007): 714–36. https://doi.org/10.6004/jnccn.2007.0059.
    Full Text
  - Mouraviev, Vladimir, Janice M. Mayes, Leon Sun, John F. Madden, Judd W. Moul, and Thomas J. Polascik. “Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer..” Cancer 110, no. 4 (August 2007): 906–10. https://doi.org/10.1002/cncr.22858.
    Full Text
  - D’Amico, Anthony V., Ming-Hui Chen, William J. Catalona, Leon Sun, Kimberly A. Roehl, and Judd W. Moul. “Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors..” Cancer 110, no. 1 (July 2007): 56–61. https://doi.org/10.1002/cncr.22737.
    Full Text
  - Freedland, Stephen J., and Judd W. Moul. “Prostate specific antigen recurrence after definitive therapy..” The Journal of Urology 177, no. 6 (June 2007): 1985–91. https://doi.org/10.1016/j.juro.2007.01.137.
    Full Text
  - Zhan, Yiqiang, Dinggang Shen, Jianchao Zeng, Leon Sun, Gabor Fichtinger, Judd Moul, and Christos Davatzikos. “Targeted prostate biopsy using statistical image analysis..” Ieee Transactions on Medical Imaging 26, no. 6 (June 2007): 779–88. https://doi.org/10.1109/tmi.2006.891497.
    Full Text
  - Thompson, I, Thrasher, JB, Aus, G, Burnett, AL, Canby-Hagino, ED, Cookson, MS, D'Amico, AV, Dmochowski, RR, Eton, DT, Forman, JD, Goldenberg, SL, Hernandez, J, Higano, CS, Kraus, SR, Moul, JW, Tangen, CM, and AUA Prostate Cancer Clinical Guideline Update Panel, . "Guideline for the management of clinically localized prostate cancer: 2007 update." The Journal of Urology 177, no. 6 (June 2007): 2106-2131. Full Text
  - Moul, Judd W. “Timely diagnosis of testicular cancer..” The Urologic Clinics of North America 34, no. 2 (May 2007): 109–vii. https://doi.org/10.1016/j.ucl.2007.02.003.
    Full Text
  - Robinson, Marnie R., and Judd W. Moul. “Novel techniques for the treatment of localized prostate cancer: evidence of efficacy?.” Current Urology Reports 8, no. 3 (May 2007): 203–10. https://doi.org/10.1007/s11934-007-0007-7.
    Full Text
  - Sun, Leon, Judd W. Moul, James M. Hotaling, Edward Rampersaud, Phillipp Dahm, Cary Robertson, Nicholas Fitzsimons, David Albala, and Thomas J. Polascik. “Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years..” Bju International 99, no. 4 (April 2007): 753–57. https://doi.org/10.1111/j.1464-410x.2006.06682.x.
    Full Text
  - Tseng, Timothy Y., Quinton V. Cancel, Susan F. Fesperman, Hubert R. Kuebler, Leon Sun, Cary N. Robertson, Thomas J. Polascik, et al. “The role of early adopter bias for new technologies in robot assisted laparoscopic prostatectomy..” The Journal of Urology 177, no. 4 (April 2007): 1318–23. https://doi.org/10.1016/j.juro.2006.11.035.
    Full Text
  - Armstrong, A. J., P. G. Febbo, D. J. George, and J. Moul. “Systemic strategies for prostate cancer..” Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology 59, no. 1 (March 2007): 11–25.
  - Fitzsimons, Nicholas J., Leon Sun, and Judd W. Moul. “Medical technologies for the diagnosis of prostate cancer..” Expert Review of Medical Devices 4, no. 2 (March 2007): 227–39. https://doi.org/10.1586/17434440.4.2.227.
    Full Text
  - Moul, Judd W., Leon Sun, James M. Hotaling, Nicholas J. Fitzsimons, Thomas J. Polascik, Cary N. Robertson, Philipp Dahm, et al. “Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening..” The Journal of Urology 177, no. 2 (February 2007): 499–503. https://doi.org/10.1016/j.juro.2006.09.063.
    Full Text
  - Mouraviev, Vladimir, Israel Nosnik, Leon Sun, Cary N. Robertson, Philip Walther, David Albala, Judd W. Moul, and Thomas J. Polascik. “Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience..” Urology 69, no. 2 (February 2007): 311–14. https://doi.org/10.1016/j.urology.2006.10.025.
    Full Text
  - Scales, Charles D., Lesley H. Curtis, Regina D. Norris, Kevin A. Schulman, Philipp Dahm, and Judd W. Moul. “Relationship between body mass index and prostate cancer screening in the United States..” The Journal of Urology 177, no. 2 (February 2007): 493–98. https://doi.org/10.1016/j.juro.2006.09.059.
    Full Text
  - Cookson, MS, Aus, G, Burnett, AL, Canby-Hagino, ED, D'Amico, AV, Dmochowski, RR, Eton, DT, Forman, JD, Goldenberg, SL, Hernandez, J, Higano, CS, Kraus, SR, Moul, JW, Tangen, C, Thrasher, JB, and Thompson, I. "Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes." The Journal of Urology 177, no. 2 (February 2007): 540-545. (Review) Full Text
  - Sun, Mei, Vasantha Srikantan, Lanfeng Ma, Jia Li, Wei Zhang, Gyorgy Petrovics, Mazen Makarem, et al. “Characterization of frequently deleted 6q locus in prostate cancer..” Dna and Cell Biology 25, no. 11 (November 2006): 597–607. https://doi.org/10.1089/dna.2006.25.597.
    Full Text
  - Efstathiou, Jason A., Ming-Hui Chen, William J. Catalona, David G. McLeod, Peter R. Carroll, Judd W. Moul, Kimberly A. Roehl, and Anthony V. D’Amico. “Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality..” Urology 68, no. 2 (August 2006): 342–47. https://doi.org/10.1016/j.urology.2006.02.030.
    Full Text
  - Moul, Judd W., and John F. Ward. “Management of the patient with a rising PSA alone..” Hematology/Oncology Clinics of North America 20, no. 4 (August 2006): 897–908. https://doi.org/10.1016/j.hoc.2006.03.006.
    Full Text
  - Scales, Charles D., Lesley H. Curtis, Regina D. Norris, Kevin A. Schulman, David M. Albala, and Judd W. Moul. “Prostate specific antigen testing in men older than 75 years in the United States..” The Journal of Urology 176, no. 2 (August 2006): 511–14. https://doi.org/10.1016/j.juro.2006.03.060.
    Full Text
  - Merseburger, Axel S., Jörg Hennenlotter, Perikles Simon, Carolin C. Müller, Ursula Kühs, Ruth Knüchel-Clarke, Judd W. Moul, Arnulf Stenzl, and Markus A. Kuczyk. “Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions..” Oncology Reports 16, no. 1 (July 2006): 79–83.
  - Penson, David, Judd Moul, Sanjay Gandhi, and Don Newling. “Use of prostate-specific antigen in the follow-up of patients with localized prostate cancer: results of a nationwide survey of urologists..” Urology 68, no. 1 (July 2006): 80–84. https://doi.org/10.1016/j.urology.2006.01.028.
    Full Text
  - Freedland, Stephen J., Tracey L. Krupski, and Judd W. Moul. “Update on outcomes research databases in prostate cancer 2006..” Current Opinion in Urology 16, no. 3 (May 2006): 168–72. https://doi.org/10.1097/01.mou.0000193394.62221.e9.
    Full Text
  - Anscher, M. S., R. Clough, C. N. Robertson, L. R. Prosnitz, P. Dahm, P. Walther, C. F. Donatucci, et al. “Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate..” Prostate Cancer and Prostatic Diseases 9, no. 3 (January 2006): 254–60. https://doi.org/10.1038/sj.pcan.4500903.
    Full Text
  - Moul, Judd W. “Treatment of PSA only recurrence of prostate cancer after prior local therapy..” Current Pharmaceutical Design 12, no. 7 (January 2006): 785–98. https://doi.org/10.2174/138161206776056092.
    Full Text
  - Tseng, T. Y., D. W. Sevilla, J. W. Moul, and K. E. Maloney. “Prostatic carcinosarcoma 15 years after combined external beam radiation and brachytherapy for prostatic adenocarcinoma: a case report..” Prostate Cancer and Prostatic Diseases 9, no. 2 (January 2006): 195–97. https://doi.org/10.1038/sj.pcan.4500870.
    Full Text
  - Xu, L. L., C. Sun, G. Petrovics, M. Makarem, B. Furusato, W. Zhang, I. A. Sesterhenn, et al. “Quantitative expression profile of PSGR in prostate cancer..” Prostate Cancer and Prostatic Diseases 9, no. 1 (January 2006): 56–61. https://doi.org/10.1038/sj.pcan.4500836.
    Full Text
  - Brassell, Stephen A., Tzu-Cheg Kao, Leon Sun, and Judd W. Moul. “Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer..” Urology 66, no. 6 (December 2005): 1229–33. https://doi.org/10.1016/j.urology.2005.06.106.
    Full Text
  - Cooperberg, Matthew R., Judd W. Moul, and Peter R. Carroll. “The changing face of prostate cancer..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 23, no. 32 (November 2005): 8146–51. https://doi.org/10.1200/jco.2005.02.9751.
    Full Text
  - Moul, Judd W. “Screening for prostate cancer in military populations..” Military Medicine 170, no. 11 (November 2005): 905–14. https://doi.org/10.7205/milmed.170.11.905.
    Full Text
  - Zhou, Ping, Ming-Hui Chen, David McLeod, Peter R. Carroll, Judd W. Moul, and Anthony V. D’Amico. “Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 23, no. 28 (October 2005): 6992–98. https://doi.org/10.1200/jco.2005.01.2906.
    Full Text
  - Stewart, AJ, Scher, HI, Chen, M-H, McLeod, DG, Carroll, PR, Moul, JW, and D'Amico, AV. "Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 23, no. 27 (September 2005): 6556-6560. Full Text
  - Dahm, Philipp, Benjamin K. Yang, Chas R. Salmen, Judd W. Moul, and Tong J. Gan. “Radical perineal prostatectomy for the treatment of localized prostate cancer in morbidly obese patients..” The Journal of Urology 174, no. 1 (July 2005): 131–34. https://doi.org/10.1097/01.ju.0000161593.29525.e2.
    Full Text
  - Moul, Judd W., and Fred Saad. “Low-risk prostate cancer patient: active treatment..” The Canadian Journal of Urology 12 Suppl 2 (June 2005): 25–27.
  - Ward, John F., and Judd W. Moul. “Treating the biochemical recurrence of prostate cancer after definitive primary therapy..” Clinical Prostate Cancer 4, no. 1 (June 2005): 38–44. https://doi.org/10.3816/cgc.2005.n.010.
    Full Text
  - Zhou, P., M. H. Chen, D. McLeod, P. R. Carroll, J. W. Moul, and A. V. D’Amico. “Predictors of prostate cancer-specific mortality following radical prostatectomy or radiation therapy..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 23, no. 16_suppl (June 2005).
  - Bañez, Lionel L., Shiv Srivastava, and Judd W. Moul. “Proteomics in prostate cancer..” Current Opinion in Urology 15, no. 3 (May 2005): 151–56. https://doi.org/10.1097/01.mou.0000165547.48922.12.
    Full Text
  - D’Amico, Anthony V., Judd Moul, Peter R. Carroll, Leon Sun, Deborah Lubeck, and Ming-Hui Chen. “Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer..” The Journal of Urology 173, no. 5 (May 2005): 1572–76. https://doi.org/10.1097/01.ju.0000157569.59229.72.
    Full Text
  - Petrovics, Gyorgy, Aijun Liu, Syed Shaheduzzaman, Bungo Furusato, Chen Sun, Yongmei Chen, Martin Nau, et al. “Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome..” Oncogene 24, no. 23 (May 2005): 3847–52. https://doi.org/10.1038/sj.onc.1208518.
    Full Text
  - Ward, John F., and Judd W. Moul. “Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer..” Current Opinion in Urology 15, no. 3 (May 2005): 187–95. https://doi.org/10.1097/01.mou.0000165553.17534.e3.
    Full Text
  - Ward, JF, and Moul, JW. "Biochemical recurrence after definitive prostate cancer therapy. Part I: defining and localizing biochemical recurrence of prostate cancer." Current Opinion in Urology 15, no. 3 (May 2005): 181-186. (Review) Full Text
  - Ward, John F., and Judd W. Moul. “Rising prostate-specific antigen after primary prostate cancer therapy..” Nature Clinical Practice. Urology 2, no. 4 (April 2005): 174–82. https://doi.org/10.1038/ncpuro0145.
    Full Text
  - Moul, Judd W., and Alexandre R. Zlotta. “Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy..” Bju International 95, no. 3 (February 2005): 285–90. https://doi.org/10.1111/j.1464-410x.2005.05284.x.
    Full Text
  - "Bone complications in prostate cancer: Current and future role of bisphosphonates." Current Oncology 12, no. 3 (January 1, 2005): 71-75. (Review)
  - Gu, Yongpeng, Kee-Hong Kim, Daejin Ko, Shiv Srivastava, Judd W. Moul, David G. McLeod, and Johng S. Rhim. “Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line..” Anticancer Research 25, no. 1A (January 2005): 1–8.
  - Semmes, O John, Ziding Feng, Bao-Ling Adam, Lionel L. Banez, William L. Bigbee, David Campos, Lisa H. Cazares, et al. “Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility..” Clinical Chemistry 51, no. 1 (January 2005): 102–12. https://doi.org/10.1373/clinchem.2004.038950.
    Full Text
  - Woll, Michael M., Matthew T. Hueman, Gayle B. Ryan, Constantin G. Ioannides, Charles G. Henderson, Isabelle A. Sesterhan, Shiv Shrivasta, David G. McLeod, Judd W. Moul, and George E. Peoples. “Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer..” International Journal of Oncology 25, no. 6 (December 2004): 1769–80.
  - D’Amico, Anthony V., Judd Moul, Peter R. Carroll, Leon Sun, Deborah Lubeck, and Ming-Hui Chen. “Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy..” The Journal of Urology 172, no. 5 Pt 2 (November 2004): S42–46. https://doi.org/10.1097/01.ju.0000141845.99899.12.
    Full Text
  - Gu, Yongpeng, Kee-Hong Kim, Daejin Ko, Keiichiro Nakamura, Yutaka Yasunaga, Judd W. Moul, Shiv Srivastava, Paul Arnstein, and Johng S. Rhim. “A telomerase-immortalized primary human prostate cancer clonal cell line with neoplastic phenotypes..” International Journal of Oncology 25, no. 4 (October 2004): 1057–64.
  - Gilligan, Timothy, Judith Manola, Oliver Sartor, Sally P. Weinrich, Judd W. Moul, and Philip W. Kantoff. “Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population..” Clinical Prostate Cancer 3, no. 2 (September 2004): 98–103. https://doi.org/10.3816/cgc.2004.n.019.
    Full Text
  - Moul, J. W., and G. Chodak. “Combination hormonal therapy: a reassessment within advanced prostate cancer..” Prostate Cancer and Prostatic Diseases 7 Suppl 1 (September 2004): S2–7. https://doi.org/10.1038/sj.pcan.4500741.
    Full Text
  - Kirby, RS, and Moul, JW. "Editorial." Prostate Cancer and Prostatic Diseases 7, no. 2 (July 28, 2004): 85-86. Full Text
  - Woll, Michael M., Christine M. Fisher, Gayle B. Ryan, Jennifer M. Gurney, Catherine E. Storrer, Constantin G. Ioannides, Craig D. Shriver, et al. “Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients..” Journal of Clinical Immunology 24, no. 4 (July 2004): 449–61. https://doi.org/10.1023/b:joci.0000029117.10791.98.
    Full Text
  - Penson, David F., Judd W. Moul, Christopher P. Evans, John J. Doyle, Sanjay Gandhi, and Lois Lamerato. “The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data..” The Journal of Urology 171, no. 6 Pt 1 (June 2004): 2250–54. https://doi.org/10.1097/01.ju.0000127732.63726.4c.
    Full Text
  - Shen, Dinggang, Zhiqiang Lao, Jianchao Zeng, Wei Zhang, Isabel A. Sesterhenn, Leon Sun, Judd W. Moul, Edward H. Herskovits, Gabor Fichtinger, and Christos Davatzikos. “Optimized prostate biopsy via a statistical atlas of cancer spatial distribution..” Medical Image Analysis 8, no. 2 (June 2004): 139–50. https://doi.org/10.1016/j.media.2003.11.002.
    Full Text
  - Zeng, J, Sofer, A, Zhang, W, Sun, L, Sesterhenn, I, Moul, J, Mun, SK, and Chouikha, M. "Development and evaluation of optimal prostate biopsy protocols for individual groups of patients." International Congress Series 1268, no. C (June 1, 2004): 803-808. Full Text
  - Moul, JW, and Kirby, RS. "Editorial." Prostate Cancer and Prostatic Diseases 7, no. 1 (April 19, 2004): 1-null. Full Text
  - D'Amico, AV, Moul, JW, Carroll, PR, Cote, K, Sun, L, Lubeck, D, Renshaw, AA, Loffredo, M, and Chen, M-H. "Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure." Journal of the National Cancer Institute 96, no. 7 (April 2004): 509-515. Full Text
  - Moul, Judd W., Hongyu Wu, Leon Sun, David G. McLeod, Christopher Amling, Timothy Donahue, Leo Kusuda, et al. “Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy..” The Journal of Urology 171, no. 3 (March 2004): 1141–47. https://doi.org/10.1097/01.ju.0000113794.34810.d0.
    Full Text
  - Shavers, Vickie L., Martin Brown, Carrie N. Klabunde, Arnold L. Potosky, William Davis, Judd Moul, and Angela Fahey. “Race/ethnicity and the intensity of medical monitoring under 'watchful waiting' for prostate cancer..” Medical Care 42, no. 3 (March 2004): 239–50. https://doi.org/10.1097/01.mlr.0000117361.61444.71.
    Full Text
  - Wu, Hongyan, Leon Sun, Judd W. Moul, Hong Yu Wu, David G. McLeod, Christopher Amling, Raymond Lance, et al. “Watchful waiting and factors predictive of secondary treatment of localized prostate cancer..” The Journal of Urology 171, no. 3 (March 2004): 1111–16. https://doi.org/10.1097/01.ju.0000113300.74132.8b.
    Full Text
  - Amling, Christopher L., Robert H. Riffenburgh, Leon Sun, Judd W. Moul, Raymond S. Lance, Leo Kusuda, Wade J. Sexton, et al. “Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 22, no. 3 (February 2004): 439–45. https://doi.org/10.1200/jco.2004.03.132.
    Full Text
  - Scher, Howard I., Mario Eisenberger, Anthony V. D’Amico, Susan Halabi, Eric J. Small, Michael Morris, Michael W. Kattan, et al. “Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 22, no. 3 (February 2004): 537–56. https://doi.org/10.1200/jco.2004.07.099.
    Full Text
  - Shavers, VL, Brown, ML, Potosky, AL, Klabunde, CN, Davis, WW, Moul, JW, and Fahey, A. "Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer." Journal of General Internal Medicine 19, no. 2 (February 2004): 146-155. Full Text
  - Moul, Judd W. “The evolving definition of advanced prostate cancer..” Reviews in Urology 6 Suppl 8 (January 2004): S10–17.
  - Petroski, R. A., W. B. Warlick, J. Herring, T. F. Donahue, L. Sun, C. V. Smith, R. R. Connelly, D. G. McLeod, and J. W. Moul. “External beam radiation therapy after radical prostatectomy: efficacy and impact on urinary continence..” Prostate Cancer and Prostatic Diseases 7, no. 2 (January 2004): 170–77. https://doi.org/10.1038/sj.pcan.4500718.
    Full Text
  - Petrovics, Gyorgy, Wei Zhang, Mazen Makarem, Jesse P. Street, Roger Connelly, Leon Sun, Isabell A. Sesterhenn, Vasantha Srikantan, Judd W. Moul, and Shiv Srivastava. “Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients..” Oncogene 23, no. 2 (January 2004): 605–11. https://doi.org/10.1038/sj.onc.1207069.
    Full Text
  - Moul, Judd W., and Jackson E. Fowler. “Evolution of therapeutic approaches with luteinizing hormone-releasing hormone agonists in 2003..” Urology 62, no. 6 Suppl 1 (December 2003): 20–28. https://doi.org/10.1016/j.urology.2003.10.014.
    Full Text
  - Barqawi, Al Baha, Judd W. Moul, Ali Ziada, Liann Handel, and E David Crawford. “Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy..” Urology 62, no. 5 (November 2003): 872–76. https://doi.org/10.1016/s0090-4295(03)00667-8.
    Full Text
  - Carter, Corey A., Timothy Donahue, Leon Sun, Hongyu Wu, David G. McLeod, Christopher Amling, Raymond Lance, et al. “Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 21, no. 21 (November 2003): 4001–8. https://doi.org/10.1200/jco.2003.04.092.
    Full Text
  - Moul, Judd W., Leon Sun, Hongyu Wu, David G. McLeod, Christopher Amling, Raymond Lance, John Foley, et al. “Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the Department of Defense (DOD) Center for Prostate Disease Research (CPDR) national database..” Urologic Oncology 21, no. 6 (November 2003): 447–55. https://doi.org/10.1016/s1078-1439(03)00056-5.
    Full Text
  - Moul, Judd W. “Population screening for prostate cancer and emerging concepts for young men..” Clinical Prostate Cancer 2, no. 2 (September 2003): 87–97. https://doi.org/10.3816/cgc.2003.n.015.
    Full Text
  - Moul, Judd W. “Biochemical recurrence of prostate cancer..” Current Problems in Cancer 27, no. 5 (September 2003): 243–72. https://doi.org/10.1016/s0147-0272(03)00032-1.
    Full Text
  - D'Amico, AV, Moul, JW, Carroll, PR, Sun, L, Lubeck, D, and Chen, M-H. "Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy." Journal of the National Cancer Institute 95, no. 18 (September 2003): 1376-1383. Full Text
  - Moul, JW, Anderson, J, Penson, DF, Klotz, LH, Soloway, MS, and Schulman, CC. "Early prostate cancer: prevention, treatment modalities, and quality of life issues." European Urology 44, no. 3 (September 2003): 283-293. (Review) Full Text
  - Bañez, Lionel L., Premkala Prasanna, Leon Sun, Amina Ali, Zhiqiang Zou, Bao-Ling Adam, David G. McLeod, Judd W. Moul, and Shiv Srivastava. “Diagnostic potential of serum proteomic patterns in prostate cancer..” The Journal of Urology 170, no. 2 Pt 1 (August 2003): 442–46. https://doi.org/10.1097/01.ju.0000069431.95404.56.
    Full Text
  - Xu, Linda L., Yinghui Shi, Gyorgy Petrovics, Chen Sun, Mazen Makarem, Wei Zhang, Isabell A. Sesterhenn, et al. “PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression..” Cancer Research 63, no. 15 (August 2003): 4299–4304.
  - Gao, Chun-Ling, Sudhir K. Rawal, Leon Sun, Amina Ali, Roger R. Connelly, Lionel L. Bañez, Isabell A. Sesterhenn, David G. McLeod, Judd W. Moul, and Shiv Srivastava. “Diagnostic potential of prostate-specific antigen expressing epithelial cells in blood of prostate cancer patients..” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 9, no. 7 (July 2003): 2545–50.
  - Moul, Judd W. “Variables in predicting survival based on treating "PSA-only" relapse..” Urologic Oncology 21, no. 4 (July 2003): 292–304. https://doi.org/10.1016/s1078-1439(03)00103-0.
    Full Text
  - D’Amico, Anthony V., Judd Moul, Peter R. Carroll, Leon Sun, Deborah Lubeck, and Ming-Hui Chen. “Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 21, no. 11 (June 2003): 2163–72. https://doi.org/10.1200/jco.2003.01.075.
    Full Text
  - Ko, Daejin, Yongpeng Gu, Yutaka Yasunaga, Keiichiro Nakamura, Shiv Srivastava, Judd W. Moul, Isabell A. Sesterhenn, et al. “A novel neoplastic primary tumor-derived human prostate epithelial cell line..” International Journal of Oncology 22, no. 6 (June 2003): 1311–17.
  - Massengill, Jason C., Leon Sun, Judd W. Moul, Hongyu Wu, David G. McLeod, Christopher Amling, Raymond Lance, et al. “Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy..” The Journal of Urology 169, no. 5 (May 2003): 1670–75. https://doi.org/10.1097/01.ju.0000062674.43964.d0.
    Full Text
  - Rao, Chilukuri N., Takehiko Segawa, Jason R. Navari, Linda Xu, Shiv Srivastava, Judd W. Moul, and Benette Phillips. “Methylation of TFPI-2 gene is not the sole cause of its silencing..” International Journal of Oncology 22, no. 4 (April 2003): 843–48.
  - Gancarczyk, Kevin J., Hongyu Wu, David G. McLeod, Christopher Kane, Leo Kusuda, Raymond Lance, Judy Herring, et al. “Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms..” Urology 61, no. 3 (March 2003): 589–95. https://doi.org/10.1016/s0090-4295(02)02287-2.
    Full Text
  - Johnstone, Peter A. S., Robert H. Riffenburgh, Judd W. Moul, Leon Sun, Hongyu Wu, David G. McLeod, Christopher J. Kane, et al. “Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: a radiation oncology report of the Department of Defense Center for Prostate Disease Research..” International Journal of Radiation Oncology, Biology, Physics 55, no. 4 (March 2003): 964–69. https://doi.org/10.1016/s0360-3016(02)04283-9.
    Full Text
  - Kane, Christopher J., Christopher L. Amling, Peter A. S. Johnstone, Nali Pak, Raymond S. Lance, J Brantley Thrasher, John P. Foley, Robert H. Riffenburgh, and Judd W. Moul. “Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy..” Urology 61, no. 3 (March 2003): 607–11. https://doi.org/10.1016/s0090-4295(02)02411-1.
    Full Text
  - Djavan, Bob, Judd W. Moul, Alexandre Zlotta, Mesut Remzi, and Vincent Ravery. “PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium..” European Urology 43, no. 1 (January 2003): 12–27. https://doi.org/10.1016/s0302-2838(02)00505-5.
    Full Text
  - Elliot, S. J., B. H. Zorn, D. G. McLeod, J. W. Moul, L. Nyberg, L. J. Striker, and G. E. Striker. “Pentosan polysulfate decreases prostate smooth muscle proliferation and extracellular matrix turnover..” Prostate Cancer and Prostatic Diseases 6, no. 2 (January 2003): 138–42. https://doi.org/10.1038/sj.pcan.4500632.
    Full Text
  - Griewe, G. L., R. C. Dean, W. Zhang, D. Young, I. A. Sesterhenn, N. Shanmugam, D. G. McLeod, J. W. Moul, and S. Srivastava. “p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein..” Prostate Cancer and Prostatic Diseases 6, no. 4 (January 2003): 281–85. https://doi.org/10.1038/sj.pcan.4500665.
    Full Text
  - Merseburger, Axel S., Markus A. Kuczyk, Jurgen Serth, Carsten Bokemeyer, Denise Y. Young, Leon Sun, Roger R. Connelly, et al. “Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues..” Oncology Reports 10, no. 1 (January 2003): 223–28.
  - Paquette, Edmond L., Roger R. Connelly, Leon Sun, Laurence R. Paquette, and Judd W. Moul. “Predictors of extracapsular extension and positive margins in African American and white men..” Urologic Oncology 21, no. 1 (January 2003): 33–38. https://doi.org/10.1016/s1078-1439(02)00203-x.
    Full Text
  - Segawa, Takehiko, Martin E. Nau, Linda L. Xu, Rao N. Chilukuri, Mazen Makarem, Wei Zhang, Gyorgy Petrovics, et al. “Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells..” Oncogene 21, no. 57 (December 2002): 8749–58. https://doi.org/10.1038/sj.onc.1205992.
    Full Text
  - Srikantan, Vasantha, Michael Valladares, Johng S. Rhim, Judd W. Moul, and Shiv Srivastava. “HEPSIN inhibits cell growth/invasion in prostate cancer cells..” Cancer Research 62, no. 23 (December 2002): 6812–16.
  - Catalona, William J., Jo Ann V. Antenor, Kimberly A. Roehl, and Judd W. Moul. “Screening for prostate cancer in high risk populations..” The Journal of Urology 168, no. 5 (November 2002): 1980–83. https://doi.org/10.1097/01.ju.0000033320.15267.a6.
    Full Text
  - Davis, Leland D., Wei Zhang, Axel Merseburger, Denise Young, Linda Xu, Johng S. Rhim, Judd W. Moul, Shiv Srivastava, and Isabell A. Sesterhenn. “p63 expression profile in normal and malignant prostate epithelial cells..” Anticancer Research 22, no. 6C (November 2002): 3819–25.
  - Heidenreich, Axel, and Judd W. Moul. “Contralateral testicular biopsy procedure in patients with unilateral testis cancer: is it indicated?.” Seminars in Urologic Oncology 20, no. 4 (November 2002): 234–38. https://doi.org/10.1053/suro.2002.36980.
    Full Text
  - Johnstone, Peter A. S., Christopher J. Kane, Leon Sun, Hongyu Wu, Judd W. Moul, David G. McLeod, Douglas D. Martin, et al. “Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: radiation oncology report of the Department of Defense Center for Prostate Disease Research..” Radiology 225, no. 2 (November 2002): 420–26. https://doi.org/10.1148/radiol.2252011491.
    Full Text
  - Paquette, Edmond L., Leon Sun, Laurence R. Paquette, Roger Connelly, David G. Mcleod, and Judd W. Moul. “Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing..” Urology 60, no. 5 (November 2002): 756–59. https://doi.org/10.1016/s0090-4295(02)01960-x.
    Full Text
  - Nakamura, Keiichiro, Yutaka Yasunaga, Takehiko Segawa, Daejin Ko, Judd W. Moul, Shiv Srivastava, and Johng S. Rhim. “Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines..” International Journal of Oncology 21, no. 4 (October 2002): 825–30.
  - Sun, M, Ma, L, Xu, L, Li, J, Zhang, W, Petrovics, G, Makarem, M, Sesterhenn, I, Zhang, M, Blanchette-Mackie, EJ, Moul, J, Srivastava, S, and Zou, Z. "A human novel gene DERPC on 16q22.1 inhibits prostate tumor cell growth and its expression is decreased in prostate and renal tumors." Molecular Medicine (Cambridge, Mass.) 8, no. 10 (October 2002): 655-663. Full Text
  - Partin, Alan W., Gerald E. Hanks, Eric A. Klein, Judd W. Moul, William G. Nelson, and Howard I. Scher. “Prostate-specific antigen as a marker of disease activity in prostate cancer..” Oncology (Williston Park, N.Y.) 16, no. 9 (September 2002): 1218–24.
  - Moul, Judd W., Hongyu Wu, Leon Sun, David G. McLeod, Christopher Amling, Raymond Lance, Leo Kusuda, et al. “Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database..” Surgery 132, no. 2 (August 2002): 213–19. https://doi.org/10.1067/msy.2002.125315.
    Full Text
  - Partin, Alan W., Gerald E. Hanks, Eric A. Klein, Judd W. Moul, William G. Nelson, and Howard I. Scher. “Prostate-specific antigen as a marker of disease activity in prostate cancer..” Oncology (Williston Park, N.Y.) 16, no. 8 (August 2002): 1024–51.
  - Henderson, CG, Griewe, GL, Siegel, TS, Peppas, DS, Esther, TA, and Moul, JW. "Rapidly progressing adenocarcinoma of the prostate presenting as prostatitis." The Journal of Urology 168, no. 2 (August 2002): 638-639. Full Text
  - Moul, Judd W. “Radical prostatectomy versus radiation therapy for clinically localized prostate carcinoma: the butcher and the baker selling their wares..” Cancer 95, no. 2 (July 2002): 211–14. https://doi.org/10.1002/cncr.10658.
    Full Text
  - Vanasupa, BP, Paquette, EL, Wu, H, Sun, L, McLeod, DG, and Moul, JW. "The role of radical prostatectomy in patients with pretreatment prostate-specific antigen > or = 40 ng/mL." Urologic Oncology 7, no. 4 (July 2002): 167-172. Full Text
  - Donahue, Timothy, and Judd Moul. “Diagnostic accuracy of prostate needle biopsy..” Current Urology Reports 3, no. 3 (June 2002): 215–21. https://doi.org/10.1007/s11934-002-0067-7.
    Full Text
  - Moul, Judd W., Axel S. Merseburger, and Shiv Srivastava. “Molecular markers in prostate cancer: the role in preoperative staging..” Clinical Prostate Cancer 1, no. 1 (June 2002): 42–50. https://doi.org/10.3816/cgc.2002.n.006.
    Full Text
  - Zou, Zhiqiang, Wei Zhang, Denise Young, Martin G. Gleave, Paul Rennie, Theresa Connell, Roger Connelly, Judd Moul, Shiv Srivastava, and Isabell Sesterhenn. “Maspin expression profile in human prostate cancer (CaP) and in vitro induction of Maspin expression by androgen ablation..” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 8, no. 5 (May 2002): 1172–77.
  - Nakamura, Keiichiro, Yutaka Yasunaga, Daejin Ko, Linda L. Xu, Judd W. Moul, Donna M. Peehl, Shiv Srivastava, and Johng S. Rhim. “Cadmium-induced neoplastic transformation of human prostate epithelial cells..” International Journal of Oncology 20, no. 3 (March 2002): 543–47.
  - Desai, A., H. Wu, L. Sun, I. A. Sesterhenn, F. K. Mostofi, D. McLeod, C. Amling, et al. “Complete embedding and close step-sectioning of radical prostatectomy specimens both increase detection of extra-prostatic extension, and correlate with increased disease-free survival by stage of prostate cancer patients..” Prostate Cancer and Prostatic Diseases 5, no. 3 (January 2002): 212–18. https://doi.org/10.1038/sj.pcan.4500600.
    Full Text
  - Johnstone, P. A., R. Booth, R. H. Riffenburgh, C. L. Amling, C. J. Kane, and J. W. Moul. “Initiation of salvage therapy for prostate cancer..” Prostate Cancer and Prostatic Diseases 5, no. 2 (January 2002): 136–43. https://doi.org/10.1038/sj.pcan.4500566.
    Full Text
  - Koff, S. G., R. R. Connelly, J. J. Bauer, D. G. McLeod, and J. W. Moul. “Primary hormonal therapy for prostate cancer: experience with 135 consecutive PSA-ERA patients from a tertiary care military medical center..” Prostate Cancer and Prostatic Diseases 5, no. 2 (January 2002): 152–58. https://doi.org/10.1038/sj.pcan.4500551.
    Full Text
  - Moul, Judd W. “Outcome research: prostate cancer databases..” Urologic Oncology 7, no. 1 (January 2002): 39–42. https://doi.org/10.1016/s1078-1439(01)00134-x.
    Full Text
  - Opell, M. B., J. Zeng, J. J. Bauer, R. R. Connelly, W. Zhang, I. A. Sesterhenn, S. K. Mun, J. W. Moul, and J. H. Lynch. “Investigating the distribution of prostate cancer using three-dimensional computer simulation..” Prostate Cancer and Prostatic Diseases 5, no. 3 (January 2002): 204–8. https://doi.org/10.1038/sj.pcan.4500577.
    Full Text
  - Piper, N. Y., L. Kusada, R. Lance, J. Foley, J. Moul, and T. Seay. “Adenocarcinoma of the prostate: an expensive way to die..” Prostate Cancer and Prostatic Diseases 5, no. 2 (January 2002): 164–66. https://doi.org/10.1038/sj.pcan.4500565.
    Full Text
  - Jani, A. B., F. Vaida, G. Hanks, S. Asbell, O. Sartor, J. W. Moul, M. Roach, et al. “Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era..” International Journal of Cancer 96, no. 6 (December 2001): 363–71. https://doi.org/10.1002/ijc.1035.
    Full Text
  - Moul, J. W., and K. Civitelli. “Managing advanced prostate cancer with Viadur (leuprolide acetate implant)..” Urologic Nursing 21, no. 6 (December 2001): 385–88.
  - Moul, JW. "Prostate-specific antigen-enhanced testing and risk stratification for chemoprevention trials." Urology 57, no. 4 SUPPL. 1 (December 1, 2001): 174-177.
  - Amling, C. L., C. J. Kane, R. H. Riffenburgh, J. F. Ward, J. L. Roberts, R. S. Lance, P. A. Friedrichs, and J. W. Moul. “Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy..” Urology 58, no. 5 (November 2001): 723–28. https://doi.org/10.1016/s0090-4295(01)01373-5.
    Full Text
  - Merseburger, A. S., R. R. Connelly, L. Sun, E. Richter, and J. W. Moul. “Use of serum creatinine to predict pathologic stage and recurrence among radical prostatectomy patients..” Urology 58, no. 5 (November 2001): 729–34. https://doi.org/10.1016/s0090-4295(01)01370-x.
    Full Text
  - Paquette, E. L., R. R. Connelly, I. A. Sesterhenn, W. Zhang, L. Sun, L. R. Paquette, R. Greenspan, D. G. McLeod, and J. W. Moul. “Improvements in pathologic staging for African-American men undergoing radical retropubic prostatectomy during the prostate specific antigen era: implications for screening a high-risk group for prostate carcinoma..” Cancer 92, no. 10 (November 2001): 2673–79. https://doi.org/10.1002/1097-0142(20011115)92:10<2673::aid-cncr1621>3.0.co;2-2.
    Full Text
  - Yasunaga, Y., K. Nakamura, D. Ko, S. Srivastava, J. W. Moul, I. A. Sesterhenn, D. G. McLeod, and J. S. Rhim. “A novel human cancer culture model for the study of prostate cancer..” Oncogene 20, no. 55 (November 2001): 8036–41. https://doi.org/10.1038/sj.onc.1205002.
    Full Text
  - Moul, J. W., R. R. Connelly, D. P. Lubeck, J. J. Bauer, L. Sun, S. C. Flanders, G. D. Grossfeld, and P. R. Carroll. “Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases..” The Journal of Urology 166, no. 4 (October 2001): 1322–27. https://doi.org/10.1016/s0022-5347(05)65761-8.
    Full Text
  - Bissonette, EA, Fulmer, BR, Petroni, GR, Moul, JW, and Theodorescu, D. "Prostate specific antigen kinetics at tumor recurrence after radical prostatectomy do not suggest a worse disease prognosis in black men." The Journal of Urology 166, no. 4 (October 2001): 1328-1331. Full Text
  - Hartzell, JD, Kao, TC, Holland, JC, Holt, SR, and Moul, JW. "Age-specific reference ranges for prostate specific antigen in young men: Retrospective study from the national defense university." Prostate Journal 3, no. 1 (September 27, 2001): 36-41. Full Text
  - Sun, L, Gancarczyk, K, Paquette, EL, McLeod, DG, Kane, C, Kusuda, L, Lance, R, Herring, J, Foley, J, Baldwin, D, Bishoff, JT, Soderdahl, D, Wu, H, Xu, L, and Moul, JW. "Introduction to Department of Defense Center for Prostate Disease Research Multicenter National Prostate Cancer Database, and analysis of changes in the PSA-era." Urologic Oncology 6, no. 5 (September 3, 2001): 203-209. Full Text
  - Moul, J. W., C. J. Kane, and S. B. Malkowicz. “The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy..” The Urologic Clinics of North America 28, no. 3 (August 2001): 459–72. https://doi.org/10.1016/s0094-0143(05)70155-5.
    Full Text
  - Campbell, T., J. Blasko, E. D. Crawford, J. Forman, G. Hanks, D. Kuban, J. Montie, et al. “Clinical staging of prostate cancer: reproducibility and clarification of issues..” International Journal of Cancer 96, no. 3 (June 2001): 198–209. https://doi.org/10.1002/ijc.1017.
    Full Text
  - Xu, L. L., Y. P. Su, R. Labiche, T. Segawa, N. Shanmugam, D. G. McLeod, J. W. Moul, and S. Srivastava. “Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes..” International Journal of Cancer 92, no. 3 (May 2001): 322–28. https://doi.org/10.1002/ijc.1196.
    Full Text
  - Moul, J. W. “Prostate-specific antigen-enhanced testing and risk stratification for chemoprevention trials..” Urology 57, no. 4 Suppl 1 (April 2001): 174–77. https://doi.org/10.1016/s0090-4295(00)00967-5.
    Full Text
  - Siegel, T., J. W. Moul, M. Spevak, W. G. Alvord, and R. A. Costabile. “The development of erectile dysfunction in men treated for prostate cancer..” The Journal of Urology 165, no. 2 (February 2001): 430–35. https://doi.org/10.1097/00005392-200102000-00019.
    Full Text
  - Zeng, J., J. Bauer, W. Zhang, I. Sesterhenn, R. Connelly, J. Lynch, J. Moul, and S. K. Mun. “Prostate biopsy protocols: 3D visualization-based evaluation and clinical correlation..” Computer Aided Surgery : Official Journal of the International Society for Computer Aided Surgery 6, no. 1 (January 2001): 14–21. https://doi.org/10.1002/igs.1006.
    Full Text
  - Kirby, R, Moul, J, and Brawer, M. "Editorial." Prostate Cancer and Prostatic Diseases 4, no. 1 (January 1, 2001): 5-null. Full Text
  - Lance, RS, Freidrichs, PA, Kane, C, Powell, CR, Pulos, E, Moul, JW, McLeod, DG, Cornum, RL, and Brantley Thrasher J, . "A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer within the Uniformed Services Urology Research Group." Bju International 87, no. 1 (January 2001): 61-65. Full Text
  - Moul, J. W. “Targeted screening for prostate cancer in African-American men..” Prostate Cancer and Prostatic Diseases 3, no. 4 (December 2000): 248–55. https://doi.org/10.1038/sj.pcan.4500472.
    Full Text
  - Tarman, G. J., C. J. Kane, J. W. Moul, J. B. Thrasher, J. P. Foley, D. Wilhite, R. H. Riffenburgh, and C. L. Amling. “Impact of socioeconomic status and race on clinical parameters of patients undergoing radical prostatectomy in an equal access health care system..” Urology 56, no. 6 (December 2000): 1016–20. https://doi.org/10.1016/s0090-4295(00)00808-6.
    Full Text
  - Kirby, R, Moul, J, and Brawer, M. "Editorial." Prostate Cancer and Prostatic Diseases 3, no. 4 (December 2000): 217-217. Full Text
  - Smith, CV, Bauer, JJ, Connelly, RR, Seay, T, Kane, C, Foley, J, Thrasher, JB, Kusuda, L, and Moul, JW. "Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database." The Journal of Urology 164, no. 6 (December 2000): 1964-1967. Full Text
  - Xu, LL, Stackhouse, BG, Florence, K, Zhang, W, Shanmugam, N, Sesterhenn, IA, Zou, Z, Srikantan, V, Augustus, M, Roschke, V, Carter, K, McLeod, DG, Moul, JW, Soppett, D, and Srivastava, S. "PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer." Cancer Research 60, no. 23 (December 2000): 6568-6572.
  - Preston, D. M., L. I. Levin, D. J. Jacobson, S. J. Jacobsen, M. Rubertone, E. Holmes, G. P. Murphy, and J. W. Moul. “Prostate-specific antigen levels in young white and black men 20 to 45 years old..” Urology 56, no. 5 (November 2000): 812–16. https://doi.org/10.1016/s0090-4295(00)00764-0.
    Full Text
  - Richter, E., R. R. Connelly, and J. W. Moul. “The role of pretreatment serum albumin to predict pathological stage and recurrence among radical prostatectomy cases..” Prostate Cancer and Prostatic Diseases 3, no. 3 (November 2000): 186–90. https://doi.org/10.1038/sj.pcan.4500418.
    Full Text
  - Heidenreich, B., A. Heidenreich, A. Sesterhenn, S. Srivastava, J. W. Moul, and I. A. Sesterhenn. “Aneuploidy of chromosome 9 and the tumor suppressor genes p16(INK4) and p15(INK4B) detected by in situ hybridization in locally advanced prostate cancer..” European Urology 38, no. 4 (October 2000): 475–82. https://doi.org/10.1159/000020327.
    Full Text
  - Srikantan, V., Z. Zou, G. Petrovics, L. Xu, M. Augustus, L. Davis, J. R. Livezey, et al. “PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer..” Proceedings of the National Academy of Sciences of the United States of America 97, no. 22 (October 2000): 12216–21. https://doi.org/10.1073/pnas.97.22.12216.
    Full Text
  - Gao, C, Zou, Z, Xu, L, Moul, J, Seth, P, and Srivastava, S. "p53-dependent induction of heat shock protein 27 (HSP27) expression." International Journal of Cancer 88, no. 2 (October 2000): 191-194. Full Text
  - Davis, G. C., N. E. Aronson, and J. W. Moul. “Inferior vena cava compression due to massive hydronephrosis from bladder outlet obstruction..” Techniques in Urology 6, no. 3 (September 2000): 226–27.
  - Moul, J. W., T. A. Esther, and J. J. Bauer. “Implementation of a web-based prostate cancer decision site..” Seminars in Urologic Oncology 18, no. 3 (August 2000): 241–44.
  - Bauer, J. J., J. Zeng, W. Zhang, D. G. McLeod, I. A. Sesterhenn, R. R. Connelly, S. K. Mun, and J. W. Moul. “Lateral biopsies added to the traditional sextant prostate biopsy pattern increases the detection rate of prostate cancer..” Prostate Cancer and Prostatic Diseases 3, no. 1 (July 2000): 43–46. https://doi.org/10.1038/sj.pcan.4500397.
    Full Text
  - Moul, J. W. “Prostate specific antigen only progression of prostate cancer..” The Journal of Urology 163, no. 6 (June 2000): 1632–42. https://doi.org/10.1016/s0022-5347(05)67511-8.
    Full Text
  - Xu, L. L., N. Shanmugam, T. Segawa, I. A. Sesterhenn, D. G. McLeod, J. W. Moul, and S. Srivastava. “A novel androgen-regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate..” Genomics 66, no. 3 (June 2000): 257–63. https://doi.org/10.1006/geno.2000.6214.
    Full Text
  - Moul, J. W. “Screening for prostate cancer in African Americans..” Current Urology Reports 1, no. 1 (May 2000): 57–64. https://doi.org/10.1007/s11934-000-0036-y.
    Full Text
  - Kao, TC, Cruess, DF, Garner, D, Foley, J, Seay, T, Friedrichs, P, Thrasher, JB, Mooneyhan, RD, McLeod, DG, and Moul, JW. "Multicenter patient self-reporting questionnaire on impotence, incontinence and stricture after radical prostatectomy." The Journal of Urology 163, no. 3 (March 2000): 858-864. Full Text
  - Xu, LL, Srikantan, V, Sesterhenn, IA, Augustus, M, Dean, R, Moul, JW, Carter, KC, and Srivastava, S. "Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer." The Journal of Urology 163, no. 3 (March 2000): 972-979. Full Text
  - Zou, Z, Gao, C, Nagaich, AK, Connell, T, Saito, S, Moul, JW, Seth, P, Appella, E, and Srivastava, S. "p53 regulates the expression of the tumor suppressor gene maspin." The Journal of Biological Chemistry 275, no. 9 (March 2000): 6051-6054. Full Text
  - Heidenreich, A., S. Srivastava, J. W. Moul, and R. Hofmann. “Molecular genetic parameters in pathogenesis and prognosis of testicular germ cell tumors..” European Urology 37, no. 2 (February 2000): 121–35. https://doi.org/10.1159/000020128.
    Full Text
  - Gao, C., Z. Zou, L. Xu, J. Moul, P. Seth, and S. Srivastava. “p53-Dependent induction of heat shock protein 27 (hsp27) expression.” International Journal of Cancer 88, no. 2 (2000): 191–94. https://doi.org/10.1002/1097-0215(20001015)88:2<191::AID-IJC7>3.0.CO;2-A.
    Full Text
  - Moul, J. W. “Hormonal therapy options for biochemical recurrence of prostate cancer after local therapy..” Molecular Urology 4, no. 3 (January 2000): 267–73.
  - Zhang, W., I. A. Sesterhenn, R. R. Connelly, F. K. Mostofi, and J. W. Moul. “Inflammatory infiltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for racial difference in prostate specific antigen..” The Journal of Urology 163, no. 1 (January 2000): 131–36. https://doi.org/10.1016/s0022-5347(05)67988-8.
    Full Text
  - Bauer, JJ, Zeng, J, Zhang, W, McLeod, DG, Sesterhenn, IA, Connelly, RR, Mun, SK, and Moul, JW. "3-D computer visualization and interactive prostate biopsy simulation leads to an improved systematic technique for the detection of prostate cancer: clinical correlation." Studies in Health Technology and Informatics 70 (January 2000): 20-25.
  - Zeng, J, Bauer, JJ, Yao, X, Zhang, W, McLeod, DG, Sesterhenn, IA, Connelly, RR, Moul, JW, and Mun, SK. "Investigating 3D tumor distribution for optimized diagnosis of prostate cancer." Studies in Health Technology and Informatics 70 (January 2000): 392-398.
  - Stackhouse, G. B., I. A. Sesterhenn, J. J. Bauer, F. K. Mostofi, R. R. Connelly, S. K. Srivastava, and J. W. Moul. “p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy..” The Journal of Urology 162, no. 6 (December 1999): 2040–45. https://doi.org/10.1016/s0022-5347(05)68095-0.
    Full Text
  - Moul, J. W. “Update of clinical and basic science research on prostate cancer from the department of defense center for prostate disease research (DOD-CPDR)..” Prostate Cancer and Prostatic Diseases 2, no. S3 (November 1999). https://doi.org/10.1038/sj.pcan.4500347.
    Full Text
  - Zorn, B, Bauer, JJ, and Moul, JW. "Benign prostatic hyperplasia: New concepts for the millennium." American Journal of Managed Care 5, no. 7 (August 9, 1999): 911-922.
  - Moul, J. W., R. R. Connelly, R. M. Mooneyhan, W. Zhang, I. A. Sesterhenn, F. K. Mostofi, and D. G. McLeod. “Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients..” The Journal of Urology 162, no. 2 (August 1999): 394–97. https://doi.org/10.1016/s0022-5347(05)68568-0.
    Full Text
  - Moul, J. W. “Rising PSA after local therapy failure: immediate vs deferred treatment..” Oncology (Williston Park, N.Y.) 13, no. 7 (July 1999): 985–99.
  - Moul, J. W., and D. R. Lipo. “Prostate cancer in the late 1990s: hormone refractory disease options..” Urologic Nursing 19, no. 2 (June 1999): 125–31.
  - Srikantan, V., I. A. Sesterhenn, L. Davis, G. R. Hankins, F. A. Avallone, J. R. Livezey, R. Connelly, et al. “Allelic loss on chromosome 6Q in primary prostate cancer..” International Journal of Cancer 84, no. 3 (June 1999): 331–35. https://doi.org/10.1002/(sici)1097-0215(19990621)84:3<331::aid-ijc23>3.0.co;2-j.
    Full Text
  - Bauer, J. J., J. Zeng, J. Weir, W. Zhang, I. A. Sesterhenn, R. R. Connelly, S. K. Mun, and J. W. Moul. “Three-dimensional computer-simulated prostate models: lateral prostate biopsies increase the detection rate of prostate cancer..” Urology 53, no. 5 (May 1999): 961–67. https://doi.org/10.1016/s0090-4295(99)00068-0.
    Full Text
  - Gao, C. L., S. Maheshwari, R. C. Dean, L. Tatum, R. Mooneyhan, R. R. Connelly, D. G. McLeod, S. Srivastava, and J. W. Moul. “Blinded evaluation of reverse transcriptase-polymerase chain reaction prostate-specific antigen peripheral blood assay for molecular staging of prostate cancer..” Urology 53, no. 4 (April 1999): 714–21. https://doi.org/10.1016/s0090-4295(98)00608-6.
    Full Text
  - Gao, CL, Dean, RC, Pinto, A, Mooneyhan, R, Connelly, RR, McLeod, DG, Srivastava, S, and Moul, JW. "Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction." The Journal of Urology 161, no. 4 (April 1999): 1070-1076. Full Text
  - Heidenreich, A., I. A. Sesterhenn, F. K. Mostofi, J. W. Moul, and U. H. Engelmann. “[Histopathologic and biological prognostic factors of clinical stage I non-seminomatous germ cell tumors. Implications for risk-adjusted therapy].” Der Urologe. Ausg. A 38, no. 2 (March 1999): 168–78. https://doi.org/10.1007/s001200050262.
    Full Text
  - "Prostate biopsy schemes: 3-d visualization-based evaluation." Studies in Health Technology and Informatics 62 (January 1, 1999): 390-391. Full Text
  - Preston, D. M., J. J. Bauer, R. R. Connelly, T. Sawyer, J. Halligan, E. S. Leifer, D. G. McLeod, and J. W. Moul. “Prostate-specific antigen to predict outcome of external beam radiation for prostate cancer: Walter Reed Army Medical Center experience, 1988-1995..” Urology 53, no. 1 (January 1999): 131–38. https://doi.org/10.1016/s0090-4295(98)00464-6.
    Full Text
  - Sakr, W. A., M. K. Brawer, J. W. Moul, R. Donohue, C. G. Schulman, and Dr Sakr. “Pathology and bio markers of prostate cancer..” Prostate Cancer and Prostatic Diseases 2, no. S1 (January 1999): 7–14. https://doi.org/10.1038/sj.pcan.4500277.
    Full Text
  - Sakr, W. A., M. K. Brawer, J. W. Moul, R. Donohue, and C. G. Schulman. “Pathology and bio markers of prostate cancer.” Prostate Cancer and Prostatic Diseases 2, no. 3331 (1999): 7–14.
  - Moul, JW. "Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy." European Urology 35, no. 5-6 (January 1999): 399-407. (Review) Full Text
  - Moul, J. W. “Pelvic muscle rehabilitation in males following prostatectomy..” Urologic Nursing 18, no. 4 (December 1998): 296–301.
  - Weinrich, M. C., S. J. Jacobsen, S. P. Weinrich, J. W. Moul, J. E. Oesterling, D. Jacobson, and R. Wise. “Reference ranges for serum prostate-specific antigen in black and white men without cancer..” Urology 52, no. 6 (December 1998): 967–73. https://doi.org/10.1016/s0090-4295(98)00448-8.
    Full Text
  - Moul, JW. "Use of prostate-specific antigen in black men: age-adjusted reference ranges for maximal cancer detection." Journal of the National Medical Association 90, no. 11 Suppl (November 1998): S710-S712.
  - Heidenreich, A., I. A. Sesterhenn, F. K. Mostofi, and J. W. Moul. “Immunohistochemical expression of monoclonal antibody 43-9F in testicular germ cell tumours..” International Journal of Andrology 21, no. 5 (October 1998): 283–88. https://doi.org/10.1046/j.1365-2605.1998.00131.x.
    Full Text
  - Bauer, J. J., R. R. Connelly, I. A. Seterhenn, S. Srivastava, D. G. McLeod, and J. W. Moul. “Statistical modeling using preoperative prognostic variables in predicting extracapsular extension and progression after radical prostatectomy for prostate cancer..” Military Medicine 163, no. 9 (September 1998): 615–19. https://doi.org/10.1093/milmed/163.9.615.
    Full Text
  - Moul, J. W., R. M. Mooneyhan, T. -. C. Kao, D. G. McLeod, and D. F. Cruess. “Preoperative and operative factors to predict incontinence, impotence and stricture after radical prostatectomy..” Prostate Cancer and Prostatic Diseases 1, no. 5 (September 1998): 242–49. https://doi.org/10.1038/sj.pcan.4500248.
    Full Text
  - Heidenreich, A, Sesterhenn, IA, Mostofi, FK, and Moul, JW. "Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis." Cancer 83, no. 5 (September 1998): 1002-1011. Full Text
  - Dean, R. C., and J. W. Moul. “New tumor markers of testis cancer..” The Urologic Clinics of North America 25, no. 3 (August 1998): 365–73. https://doi.org/10.1016/s0094-0143(05)70027-6.
    Full Text
  - Moul, J. W. “Best screening tests for prostate cancer..” The Western Journal of Medicine 169, no. 2 (August 1998): 109–10.
  - Bettencourt, MC, Bauer, JJ, Sesterhenn, IA, Connelly, RR, and Moul, JW. "CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy." The Journal of Urology 160, no. 2 (August 1998): 459-465. Full Text
  - Moul, JW. "Treatment options for prostate cancer: Part 2 - Early and late stage and hormone refractory disease." American Journal of Managed Care 4, no. 8 (August 1, 1998): 1171-1182. (Review)
  - Bauer, J. J., S. Srivastava, R. R. Connelly, I. A. Sesterhenn, D. M. Preston, D. G. McLeod, and J. W. Moul. “Significance of familial history of prostate cancer to traditional prognostic variables, genetic biomarkers, and recurrence after radical prostatectomy..” Urology 51, no. 6 (June 1998): 970–76. https://doi.org/10.1016/s0090-4295(98)00103-4.
    Full Text
  - Heidenreich, A, Neubauer, S, and Moul, J. "Ist eine risikoadaptierte Therapie beim nicht-seminomatösen Keimzelltumor im klinischen Stadium I möglich?." Aktuelle Urologie 29, no. 03 (June 1998): 93-102. Full Text
  - Heidenreich, A., J. P. Gaddipati, J. W. Moul, and S. Srivastava. “Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors..” The Journal of Urology 159, no. 5 (May 1998): 1725–30. https://doi.org/10.1097/00005392-199805000-00101.
    Full Text
  - Li, Z., A. Rakkar, Y. Katayose, M. Kim, N. Shanmugam, S. Srivastava, J. W. Moul, D. G. McLeod, K. H. Cowan, and P. Seth. “Efficacy of multiple administrations of a recombinant adenovirus expressing wild-type p53 in an immune-competent mouse tumor model..” Gene Therapy 5, no. 5 (May 1998): 605–13. https://doi.org/10.1038/sj.gt.3300636.
    Full Text
  - Moul, J. W. “Contemporary hormonal management of advanced prostate cancer..” Oncology (Williston Park, N.Y.) 12, no. 4 (April 1998): 499–505.
  - Moul, J. W. “Prostate cancer in African American men..” Prostate Cancer and Prostatic Diseases 1, no. 3 (March 1998): 109–18. https://doi.org/10.1038/sj.pcan.4500222.
    Full Text
  - Bauer, JJ, Connelly, RR, Seterhenn, IA, Deausen, J, Srivastava, S, McLeod, DG, and Moul, JW. "Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer." The Journal of Urology 159, no. 3 (March 1998): 929-933. Full Text
  - Moul, JW, Connelly, RR, Perahia, B, and McLeod, DG. "The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases." The Journal of Urology 159, no. 3 (March 1998): 935-940. Full Text
  - Heidenreich, A, Srivastava, S, Moul, J, and Engelmann, U. "Mutationsanalyse der Tumorsuppressorgene p16INK4und Mxi-1 beim lokalisierten Prostatakarzinom." Aktuelle Urologie 29, no. 01 (February 1998): 24-30. Full Text
  - Heidenreich, A., N. S. Schenkman, I. A. Sesterhenn, K. F. Mostofi, J. W. Moul, S. Srivastava, and U. H. Engelmann. “Immunohistochemical and mutational analysis of the p53 tumour suppressor gene and the bcl-2 oncogene in primary testicular germ cell tumours..” Apmis : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica 106, no. 1 (January 1998): 90–99.
  - Moul, J. W., J. J. Bauer, S. Srivastava, E. Colon, C. K. Ho, I. A. Sesterhenn, and D. G. McLeod. “Perineal seeding of prostate cancer as the only evidence of clinical recurrence 14 years after needle biopsy and radical prostatectomy: molecular correlation..” Urology 51, no. 1 (January 1998): 158–60. https://doi.org/10.1016/s0090-4295(97)00487-1.
    Full Text
  - Moul, JW. "Treatment options for prostate cancer: Part 1 - Stage, grade, PSA, and changes in the 1990s." American Journal of Managed Care 4, no. 7 (January 1, 1998): 1031-1038. (Review)
  - Kenner, J. R., L. C. Sperling, J. Waselenko, N. Dawson, P. Sau, and J. W. Moul. “Suramin keratosis: a unique skin eruption in a patient receiving suramin for metastatic prostate cancer..” The Journal of Urology 158, no. 6 (December 1997): 2245–46. https://doi.org/10.1016/s0022-5347(01)68218-1.
    Full Text
  - Friedrichs, P. A., J. W. Moul, B. Wojcik, C. Donatucci, S. Optenberg, K. Kreder, and I. M. Thompson. “A long-term study of the efficacy of treatment of localized prostate cancer..” Urologic Oncology 3, no. 5–6 (September 1997): 171–76. https://doi.org/10.1016/s1078-1439(98)00021-0.
    Full Text
  - Heidenreich, A., S. Neubauer, F. K. Mostofi, I. A. Sesterhenn, J. W. Moul, and U. H. Engelmann. “[Clinical stage I mature teratoma of the testis--retroperitoneal lymphadenectomy or surveillance?].” Der Urologe. Ausg. A 36, no. 5 (September 1997): 440–44. https://doi.org/10.1007/s001200050123.
    Full Text
  - Heidenreich, A., J. W. Moul, S. Srivastava, and U. H. Engelmann. “Synchronous bilateral testicular tumour: nonseminomatous germ cell tumours and contralateral benign tumours..” Scandinavian Journal of Urology and Nephrology 31, no. 4 (August 1997): 389–92. https://doi.org/10.3109/00365599709030626.
    Full Text
  - Heidenreich, A, Schenkmann, NS, Sesterhenn, IA, Mostofi, FK, McCarthy, WF, Heidenreich, B, and Moul, JW. "Immunohistochemical expression of Ki-67 to predict lymph node involvement in clinical stage I nonseminomatous germ cell tumors." The Journal of Urology 158, no. 2 (August 1997): 620-625. Full Text
  - Douglas, TH, Morgan, TO, McLeod, DG, Moul, JW, Murphy, GP, Barren, R, Sesterhenn, IA, and Mostofi, FK. "Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients." Cancer 80, no. 1 (July 1997): 107-114. Full Text
  - Douglas, T. H., D. G. McLeod, F. K. Mostofi, R. Mooneyhan, R. Connelly, J. W. Moul, and I. A. Sesterhenn. “Prostate-specific antigen-detected prostate cancer (stage T1c): an analysis of whole-mount prostatectomy specimens..” The Prostate 32, no. 1 (June 1997): 59–64. https://doi.org/10.1002/(sici)1097-0045(19970615)32:1<59::aid-pros8>3.0.co;2-7.
    Full Text
  - Augenbraun, M, Go, MF, Moul, JW, and Tan, JS. "Office management of chronic infections." Patient Care 31, no. 9 (May 15, 1997): 78-94.
  - Heidenreich, A., I. A. Sesterhenn, and J. W. Moul. “Prognostic risk factors in low stage testicular germ cell tumors: unanswered questions regarding clinically useful prognosticators for extratesticular disease..” Cancer 79, no. 9 (May 1997): 1641–46. https://doi.org/10.1002/(sici)1097-0142(19970501)79:9<1641::aid-cncr1>3.0.co;2-f.
    Full Text
  - Asgari, K, Sesterhenn, IA, McLeod, DG, Cowan, K, Moul, JW, Seth, P, and Srivastava, S. "Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector." International Journal of Cancer 71, no. 3 (May 1997): 377-382. Full Text
  - Heffernan, JP, Heidenberg, HB, Irby, PB, and Moul, JW. "Gossypiboma (retained surgical sponge) and recurrent bladder neck contracture after radical retropubic prostatectomy and bilateral pelvic lymph node dissection." The Journal of Urology 157, no. 4 (April 1997): 1356-1357. Full Text
  - Bauer, JJ, Connelly, RR, Sesterhenn, IA, Bettencourt, MC, McLeod, DG, Srivastava, S, and Moul, JW. "Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy." Cancer 79, no. 5 (March 1997): 952-962. Full Text
  - Gaddipati, J. P., D. G. McLeod, I. A. Sesterhenn, C. J. Hussussian, Y. A. Tong, P. Seth, N. C. Dracopoli, J. W. Moul, and S. Srivastava. “Mutations of the p16 gene product are rare in prostate cancer..” The Prostate 30, no. 3 (February 1997): 188–94. https://doi.org/10.1002/(sici)1097-0045(19970215)30:3<188::aid-pros7>3.0.co;2-i.
    Full Text
  - Heidenreich, A., J. W. Moul, D. G. McLeod, F. K. Mostofi, and U. H. Engelmann. “The role of retroperitoneal lymphadenectomy in mature teratoma of the testis..” The Journal of Urology 157, no. 1 (January 1997): 160–63. https://doi.org/10.1016/s0022-5347(01)65313-8.
    Full Text
  - Preston, D. M., S. M. Zeidman, M. Spevak, J. W. Moul, and R. A. Costabile. “Intracranial metastatic adenocarcinoma of the prostate presenting as visual disturbance..” Techniques in Urology 3, no. 1 (January 1997): 51–53.
  - Heidenreich, A, Vorreuther, R, Neubauer, S, Westphal, J, Engelmann, UH, and Moul, JW. "The influence of ejaculation on serum levels of prostate specific antigen." The Journal of Urology 157, no. 1 (January 1997): 209-211. Full Text
  - Heidenberg, H. B., J. J. Bauer, D. G. McLeod, J. W. Moul, and S. Srivastava. “The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker?.” Urology 48, no. 6 (December 1996): 971–79. https://doi.org/10.1016/s0090-4295(96)00365-2.
    Full Text
  - Morgan, T. O., D. G. McLeod, E. S. Leifer, G. P. Murphy, and J. W. Moul. “Prospective use of free prostate-specific antigen to avoid repeat prostate biopsies in men with elevated total prostate-specific antigen..” Urology 48, no. 6A Suppl (December 1996): 76–80. https://doi.org/10.1016/s0090-4295(96)00615-2.
    Full Text
  - Glajchen, M, and Moul, JW. "Teleconferencing as a method of educating men about managing advanced prostate cancer and pain." Journal of Psychosocial Oncology 14, no. 2 (December 1, 1996): 73-87. Full Text
  - Bauer, J. J., D. G. Mcleod, and J. W. Moul. “Prostate cancer: diagnosis, treatment, and experience at one tertiary-care military medical center, 1989 and 1994..” Military Medicine 161, no. 11 (November 1996): 646–53. https://doi.org/10.1093/milmed/161.11.646.
    Full Text
  - Bauer, JJ, Sesterhenn, IA, Mostofi, FK, McLeod, DG, Srivastava, S, and Moul, JW. "Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer." The Journal of Urology 156, no. 4 (October 1996): 1511-1516. Full Text
  - Moul, J. W., and A. Heidenreich. “Prognostic factors in low-stage nonseminomatous testicular cancer..” Oncology (Williston Park, N.Y.) 10, no. 9 (September 1996): 1359–68.
  - Bettencourt, MC, Bauer, JJ, Sesterhenn, IA, Mostofi, FK, McLeod, DG, and Moul, JW. "Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy." The Journal of Urology 156, no. 3 (September 1996): 1064-1068. Full Text
  - Morgan, T. O., S. J. Jacobsen, W. F. McCarthy, D. J. Jacobson, D. G. McLeod, and J. W. Moul. “Age-specific reference ranges for serum prostate-specific antigen in black men..” The New England Journal of Medicine 335, no. 5 (August 1996): 304–10. https://doi.org/10.1056/nejm199608013350502.
    Full Text
  - Moul, J. W., M. C. Bettencourt, I. A. Sesterhenn, F. K. Mostofi, D. G. McLeod, S. Srivastava, and J. J. Bauer. “Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer..” Surgery 120, no. 2 (August 1996): 159–66. https://doi.org/10.1016/s0039-6060(96)80283-2.
    Full Text
  - Styler, M. J., P. Crilley, J. Biggs, J. Moul, E. Copelan, D. Topolsky, B. Avalos, et al. “Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis..” Bone Marrow Transplantation 18, no. 1 (July 1996): 171–76.
  - Moul, J. W., T. H. Douglas, W. F. McCarthy, and D. G. McLeod. “Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting..” The Journal of Urology 155, no. 5 (May 1996): 1667–73. https://doi.org/10.1016/s0022-5347(01)66160-3.
    Full Text
  - Moul, JW, Maygarden, SJ, Ware, JL, Mohler, JL, Maher, PD, Schenkman, NS, and Ho, CK. "Cathepsin D and epidermal growth factor receptor immunohistochemistry does not predict recurrence of prostate cancer in patients undergoing radical prostatectomy." The Journal of Urology 155, no. 3 (March 1996): 982-985. Full Text
  - Schwartz, BF, Auman, R, Peretsman, SJ, Moul, JW, Deshon, GE, Hernandez, J, Rozanski, RA, and Thrasher, JB. "Prognostic value of BHCG and local tumor invasion in stage I seminoma of the testis." Journal of Surgical Oncology 61, no. 2 (February 1996): 131-133. Full Text
  - Heidenreich, A., R. Vorreuther, B. Krug, J. W. Moul, and U. H. Engelmann. “Renal milk of calcium: contraindication to extracorporeal shockwave lithotripsy..” Techniques in Urology 2, no. 2 (January 1996): 102–7.
  - Morgan, TO, McLeod, DG, Leifer, ES, Moul, JW, and Murphy, GP. "Prospective use of free PSA to avoid repeat prostate biopsies in men with elevated total PSA." The Prostate. Supplement 7 (January 1996): 58-63.
  - Srivastava, S., D. Katayose, Y. A. Tong, C. R. Craig, D. G. McLeod, J. W. Moul, K. H. Cowan, and P. Seth. “Recombinant adenovirus vector expressing wild-type p53 is a potent inhibitor of prostate cancer cell proliferation..” Urology 46, no. 6 (December 1995): 843–48. https://doi.org/10.1016/s0090-4295(99)80355-0.
    Full Text
  - Bauer, J. J., I. A. Sesterhenn, K. F. Mostofi, D. G. McLeod, S. Srivastava, and J. W. Moul. “p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy..” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 1, no. 11 (November 1995): 1295–1300.
  - Moul, J. W., I. A. Sesterhenn, R. R. Connelly, T. Douglas, S. Srivastava, F. K. Mostofi, and D. G. McLeod. “Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men..” Jama 274, no. 16 (October 1995): 1277–81. https://doi.org/10.1001/jama.274.16.1277.
    Full Text
  - Heidenberg, H. B., I. A. Sesterhenn, J. P. Gaddipati, C. M. Weghorst, G. S. Buzard, J. W. Moul, and S. Srivastava. “Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer..” The Journal of Urology 154, no. 2 Pt 1 (August 1995): 414–21. https://doi.org/10.1097/00005392-199508000-00024.
    Full Text
  - Schenkman, N. S., I. A. Sesterhenn, L. Washington, Y. A. Tong, C. M. Weghorst, G. S. Buzard, S. Srivastava, and J. W. Moul. “Increased p53 protein does not correlate to p53 gene mutations in microdissected human testicular germ cell tumors..” The Journal of Urology 154, no. 2 Pt 1 (August 1995): 617–21. https://doi.org/10.1097/00005392-199508000-00081.
    Full Text
  - Moul, JW, Snow, PB, Fernandez, EB, Maher, PD, and Sesterhenn, IA. "Neural network analysis of quantitative histological factors to predict pathological stage in clinical stage I nonseminomatous testicular cancer." The Journal of Urology 153, no. 5 (May 1995): 1674-1677. Full Text
  - Zhau, H. E., L. S. Zhao, L. W. Chung, B. Q. Chen, P. Troncoso, C. Kao, M. Kojima, et al. “Comparative studies of prostate cancers among United States, Chinese, and Japanese patients: characterization of histopathology, tumor angiogenesis, neuroendocrine factors, and p53 protein accumulations..” Urologic Oncology 1, no. 2 (March 1995): 51–63. https://doi.org/10.1016/1078-1439(95)00009-7.
    Full Text
  - Moul, J. W. “Proper staging techniques in testicular cancer patients..” Techniques in Urology 1, no. 3 (January 1995): 126–32.
  - Maygarden, SJ, Novotny, DB, Moul, JW, Bae, VL, and Ware, JL. "Evaluation of cathepsin D and epidermal growth factor receptor in prostate carcinoma." Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc 7, no. 9 (December 1994): 930-936.
  - Moul, J. W., E. B. Fernandez, M. G. Bryan, P. Steuart, C. K. Ho, and D. G. McLeod. “Thymic hyperplasia in newly diagnosed testicular germ cell tumors..” The Journal of Urology 152, no. 5 Pt 1 (November 1994): 1480–83.
  - Fernandez, E. B., I. A. Sesterhenn, W. F. McCarthy, F. K. Mostofi, and J. W. Moul. “Proliferating cell nuclear antigen expression to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors..” The Journal of Urology 152, no. 4 (October 1994): 1133–38. https://doi.org/10.1016/s0022-5347(17)32522-3.
    Full Text
  - Fernandez, E. B., J. W. Moul, J. P. Foley, E. Colon, and D. G. McLeod. “Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumors..” Urology 44, no. 4 (October 1994): 548–52. https://doi.org/10.1016/s0090-4295(94)80056-1.
    Full Text
  - Heidenberg, H. B., J. W. Moul, F. K. Mostofi, and D. G. McLeod. “Clinically detected carcinoma of the prostate treated by radical prostatectomy in a 29-year-old man..” The Journal of Urology 152, no. 3 (September 1994): 966–67. https://doi.org/10.1016/s0022-5347(17)32626-5.
    Full Text
  - Fernandez, E. B., E. Colon, D. G. McLeod, and J. W. Moul. “Efficacy of radiographic chest imaging in patients with testicular cancer..” Urology 44, no. 2 (August 1994): 243–48. https://doi.org/10.1016/s0090-4295(94)80139-8.
    Full Text
  - Lewis, D. J., I. A. Sesterhenn, W. F. McCarthy, and J. W. Moul. “Immunohistochemical expression of P53 tumor suppressor gene protein in adult germ cell testis tumors: clinical correlation in stage I disease..” J Urol 152, no. 2 Pt 1 (August 1994): 418–23.
    Link to Item
  - Gaddipati, J. P., D. G. McLeod, H. B. Heidenberg, I. A. Sesterhenn, M. J. Finger, J. W. Moul, and S. Srivastava. “Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers..” Cancer Research 54, no. 11 (June 1994): 2861–64.
  - Moul, J. W. “For incontinence after prostatectomy, tap a diversity of treatments..” Contemporary Urology 6, no. 4 (April 1994): 78–88.
  - Moul, J. W. “An important goal of prostatectomy: minimizing incontinence..” Contemporary Urology 6, no. 3 (March 1994): 15–28.
  - Lewis, D. J., J. W. Moul, S. C. Williams, I. A. Sesterhenn, and E. Colon. “Perirenal liposarcoma containing extramedullary hematopoiesis associated with renal cell carcinoma..” Urology 43, no. 1 (January 1994): 106–9. https://doi.org/10.1016/s0090-4295(94)80279-3.
    Full Text
  - Moul, J. W., D. J. Lewis, A. A. Ross, D. G. Kahn, C. K. Ho, and D. G. McLeod. “Immunohistologic detection of prostate cancer pelvic lymph node micrometastases: correlation to preoperative serum prostate-specific antigen..” Urology 43, no. 1 (January 1994): 68–73. https://doi.org/10.1016/s0090-4295(94)80267-x.
    Full Text
  - Moul, JW, Schanne, FJ, Thompson, IM, Frazier, HA, Peretsman, SA, Wettlaufer, JN, Rozanski, TA, Stack, RS, Kreder, KJ, and Hoffman, KJ. "Testicular cancer in blacks. A multicenter experience." Cancer 73, no. 2 (January 1994): 388-393. Full Text
  - Moul, J. W. “Benign prostatic hyperplasia. New concepts in the 1990s..” Postgraduate Medicine 94, no. 6 (November 1993): 141–52.
  - Schenkman, N. S., J. W. Moul, E. R. Nicely, M. I. Maggio, and C. K. Ho. “Synchronous bilateral testis tumor: mixed germ cell and theca cell tumors..” Urology 42, no. 5 (November 1993): 593–95. https://doi.org/10.1016/0090-4295(93)90286-j.
    Full Text
  - Kuhn, EJ, Kurnot, RA, Sesterhenn, IA, Chang, EH, and Moul, JW. "Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma." The Journal of Urology 150, no. 5 Pt 1 (November 1993): 1427-1433. (Review)
  - Moul, J. W. “Prostatitis. Sorting out the different causes..” Postgraduate Medicine 94, no. 5 (October 1993): 191–94.
  - Moul, J. W., G. G. Wind, and C. R. Wright. “Tortuous and aberrant external iliac artery precluding radical retropubic prostatectomy for prostate cancer..” Urology 42, no. 4 (October 1993): 450–52. https://doi.org/10.1016/0090-4295(93)90384-m.
    Full Text
  - Moul, J. W., J. P. Foley, C. L. Hitchcock, W. F. McCarthy, I. A. Sesterhenn, R. L. Becker, and J. L. Griffin. “Flow cytometric and quantitative histological parameters to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors..” The Journal of Urology 150, no. 3 (September 1993): 879–83. https://doi.org/10.1016/s0022-5347(17)35638-0.
    Full Text
  - Moul, J. W., J. T. Bishoff, S. M. Theune, and E. H. Chang. “Absent ras gene mutations in human adrenal cortical neoplasms and pheochromocytomas..” The Journal of Urology 149, no. 6 (June 1993): 1389–94. https://doi.org/10.1016/s0022-5347(17)36397-8.
    Full Text
  - Moul, J. W. “1992 New York-Tidewater chapters History of Military Medicine Essay Award recipient. James Claude Kimbrough: the father of modern U.S. Army urology..” Military Medicine 158, no. 4 (April 1993): 213–22. https://doi.org/10.1093/milmed/158.4.213.
    Full Text
  - Moul, J. W., S. M. Theune, and E. H. Chang. “Detection of RAS mutations in archival testicular germ cell tumors by polymerase chain reaction and oligonucleotide hybridization..” Genes, Chromosomes & Cancer 5, no. 2 (September 1992): 109–18. https://doi.org/10.1002/gcc.2870050204.
    Full Text
  - Moul, J. W., and J. R. Moellman. “Unnecessary mastectomy for gynecomastia in testicular cancer patient..” Military Medicine 157, no. 8 (August 1992): 433–34. https://doi.org/10.1093/milmed/157.8.433.
    Full Text
  - Bishop, J. R., J. W. Moul, S. A. Sihelnik, D. S. Peppas, T. S. Gormley, and D. G. McLeod. “Use of glycosylated hemoglobin to identify diabetics at high risk for penile periprosthetic infections..” The Journal of Urology 147, no. 2 (February 1992): 386–88. https://doi.org/10.1016/s0022-5347(17)37244-0.
    Full Text
  - Moul, J. W., M. I. Maggio, M. R. Hardy, and D. S. Hartman. “Retroaortic left renal vein in testicular cancer patient: potential staging and treatment pitfall..” The Journal of Urology 147, no. 2 (February 1992): 454–56. https://doi.org/10.1016/s0022-5347(17)37269-5.
    Full Text
  - Moul, J. W. “Retroperitoneal fibrosis following radiotherapy for stage I testicular seminoma..” The Journal of Urology 147, no. 1 (January 1992): 124–26. https://doi.org/10.1016/s0022-5347(17)37155-0.
    Full Text
  - Moul, J. W., C. K. Ho, and D. G. McLeod. “Primary malignant melanoma of the scrotum..” International Urology and Nephrology 24, no. 6 (January 1992): 641–43. https://doi.org/10.1007/bf02551300.
    Full Text
  - Moul, J. W., P. A. Friedrichs, R. S. Lance, S. M. Theune, and E. H. Chang. “Infrequent RAS oncogene mutations in human prostate cancer..” The Prostate 20, no. 4 (January 1992): 327–38. https://doi.org/10.1002/pros.2990200407.
    Full Text
  - Nicely, E. R., R. A. Costabile, and J. W. Moul. “Rupture of the deep dorsal vein of the penis during sexual intercourse..” The Journal of Urology 147, no. 1 (January 1992): 150–52. https://doi.org/10.1016/s0022-5347(17)37168-9.
    Full Text
  - Moul, J. W., J. P. Foley, G. G. Wind, S. Rubin, J. A. Coffey, and D. G. McLeod. “Celiac axis and superior mesenteric artery injury associated with left radical nephrectomy for locally advanced renal cell carcinoma..” The Journal of Urology 146, no. 4 (October 1991): 1104–7. https://doi.org/10.1016/s0022-5347(17)38013-8.
    Full Text
  - Moul, JW, and Paulson, DF. "The role of radical surgery in the management of radiation recurrent and large volume prostate cancer." Cancer 68, no. 6 (September 1991): 1265-1271. Full Text
  - Moul, J. W., M. R. Hardy, and D. G. McLeod. “Adrenal cortical carcinoma with vena cava tumor thrombus requiring cardiopulmonary bypass for resection..” Urology 38, no. 2 (August 1991): 179–83. https://doi.org/10.1016/s0090-4295(05)80083-4.
    Full Text
  - Moul, J, Dodge, R, Robertson, J, Paulson, D, and Walther, P. "The impact of the ?cisplatin era? of treatment on survival in testicular cancer." World Journal of Urology 9, no. 1 (March 1991). Full Text
  - Paulson, D. F., J. W. Moul, and P. J. Walther. “Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results..” The Journal of Urology 144, no. 5 (November 1990): 1180–84. https://doi.org/10.1016/s0022-5347(17)39686-6.
    Full Text
  - Bishop, J. R., J. W. Moul, L. Maldonado, and D. G. McLeod. “Transitional cell carcinomatous meningitis after M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) chemotherapy..” Urology 36, no. 4 (October 1990): 373–77. https://doi.org/10.1016/0090-4295(90)80253-j.
    Full Text
  - Paulson, D. F., J. W. Moul, J. E. Robertson, and P. J. Walther. “Postoperative radiotherapy of the prostate for patients undergoing radical prostatectomy with positive margins, seminal vesicle involvement and/or penetration through the capsule..” The Journal of Urology 143, no. 6 (June 1990): 1178–82. https://doi.org/10.1016/s0022-5347(17)40219-9.
    Full Text
  - Moul, J. W., D. F. Paulson, R. K. Dodge, and P. J. Walther. “Delay in diagnosis and survival in testicular cancer: impact of effective therapy and changes during 18 years..” The Journal of Urology 143, no. 3 (March 1990): 520–23. https://doi.org/10.1016/s0022-5347(17)40007-3.
    Full Text
  - Moul, JW, Paulson, DF, and Walther, PJ. "Refusal of cancer therapy in testicular cancer: Recognizing and preventing a significant problem." World Journal of Urology 8, no. 1 (March 1, 1990): 58-62. Full Text
  - Moul, JW. "The problem of postprostatectomy incontinence." Problems in Urology 4, no. 1 (January 1, 1990): 108-123.
  - Moul, J. W., J. E. Robertson, S. L. George, D. F. Paulson, and P. J. Walther. “Complications of therapy for testicular cancer..” The Journal of Urology 142, no. 6 (December 1989): 1491–96. https://doi.org/10.1016/s0022-5347(17)39135-8.
    Full Text
  - Moul, J. W., D. F. Paulson, G. Fuller, M. R. Gottfried, and W. L. Floyd. “Prostate cancer with solitary parotid metastasis correctly diagnosed with immunohistochemical stains..” The Journal of Urology 142, no. 5 (November 1989): 1328–29. https://doi.org/10.1016/s0022-5347(17)39078-x.
    Full Text
  - Moul, J. W., and D. G. McLeod. “Negative pressure devices in the explanted penile prosthesis population..” The Journal of Urology 142, no. 3 (September 1989): 729–31. https://doi.org/10.1016/s0022-5347(17)38869-9.
    Full Text
  - Moul, J. W., B. J. Miles, S. J. Skoog, and D. G. McLeod. “Risk factors for perineal seeding of prostate cancer after needle biopsy..” The Journal of Urology 142, no. 1 (July 1989): 86–88. https://doi.org/10.1016/s0022-5347(17)38668-8.
    Full Text
  - Moul, J. W., R. Davis, J. A. Vaccaro, S. A. Sihelnik, W. D. Belville, and D. G. McLeod. “Acute urinary retention associated with prostatic carcinoma..” The Journal of Urology 141, no. 6 (June 1989): 1375–77. https://doi.org/10.1016/s0022-5347(17)41312-7.
    Full Text
  - Dejter, S. W., R. E. Cunningham, P. D. Noguchi, R. V. Jones, J. W. Moul, D. G. McLeod, and J. H. Lynch. “Prognostic significance of DNA ploidy in carcinoma of prostate..” Urology 33, no. 5 (May 1989): 361–66. https://doi.org/10.1016/0090-4295(89)90026-5.
    Full Text
  - Peppas, D. S., J. W. Moul, and D. G. McLeod. “Candida albicans corpora abscess following penile prosthesis placement..” The Journal of Urology 140, no. 6 (December 1988): 1541–42. https://doi.org/10.1016/s0022-5347(17)42101-x.
    Full Text
  - Moul, J. W., and A. B. Belman. “A review of surgical treatment of undescended testes with emphasis on anatomical position..” The Journal of Urology 140, no. 1 (July 1988): 125–28. https://doi.org/10.1016/s0022-5347(17)41504-7.
    Full Text
  - Moul, J. W., and D. G. McLeod. “Bilateral organ-limited amyloidosis of the distal ureter associated with osseous metaplasia and radiographic calcification..” The Journal of Urology 139, no. 4 (April 1988): 807–9. https://doi.org/10.1016/s0022-5347(17)42647-4.
    Full Text
  - Moul, J. W., and D. G. McLeod. “Experience with the AMS 600 malleable penile prosthesis..” The Journal of Urology 135, no. 5 (May 1986): 929–31. https://doi.org/10.1016/s0022-5347(17)45926-x.
    Full Text
- Book Sections
  - Moul, JW. "Population Screening for Prostate Cancer and Early Detection." In Prostate Cancer: Science and Clinical Practice: Second Edition, 3-12. December 3, 2015. Full Text
  - Abern, MR, Tsivian, M, and Moul, JW. "Prostate cancer." In Urology at a Glance, 201-205. January 1, 2014. Full Text
  - Bañez, LL, Srivastava, S, and Moul, JW. "Rationale for molecular markers of prostate cancer." In Prostate Cancer: Principles and Practice, 259-268. January 1, 2005.
  - Moul, JW. "Population Screening for Prostate Cancer and Early Detection in High-risk African American Men." In Prostate Cancer: Science and Clinical Practice, 3-10. January 1, 2003. Full Text
  - Griewe, G. L., R. Dean, W. Zhang, I. A. Sesterhenn, S. Srivastava, and J. W. Moul. “Laser-capture microdissection.,” 53:165–73, 2001. https://doi.org/10.1385/1-59259-144-2:165.
    Full Text
  - Douglas, TH, and Moul, JW. "Artificial neural networks in urologic oncology." In Artificial Neural Networks in Cancer Diagnosis, Prognosis, and Patient Management, 93-102. January 1, 2001.
  - Srivastava, S, and Moul, JW. "Chapter 8 Molecular progression of prostate cancer." , 155-187. December 1, 1999. Full Text
  - Douglas, T. H., and J. W. Moul. “Applications of neural networks in urologic oncology.,” 16:35–39, 1998.
  - Moul, J. W., S. Srivastava, and D. G. McLeod. “Molecular implications of the antiandrogen withdrawal syndrome.,” 13:157–63, 1995.
  - McLeod, DG, and Moul, JW. "Controversies in the treatment of prostate cancer with maximal androgen deprivation." , 345-359. April 1995. Full Text
  - Moul, J. W. “Molecular biology of testicular cancer,” 8:1–11, 1994.
  - Moul, JW. "Early and accurate diagnosis of testicular cancer." , 58-66. January 1, 1994.
  - Moul, JW. "Early complications and toxicities of testicular cancer therapy." , 141-153. January 1, 1994.
  - Moul, J. W. “Renal cell carcinoma,” 4:255–72, 1990.
  - Moul, JW. "Renal adenoma." , 203-206. January 1, 1990.
  - Moul, JW. "Renal oncocytoma." , 207-221. January 1, 1990.
- Other Articles
  - Moul, Judd W. “Editorial Comment..” Urology, January 2017. https://doi.org/10.1016/j.urology.2016.09.047.
    Full Text
  - Moul, Judd W. “Editorial Comment..” The Journal of Urology, September 2016. https://doi.org/10.1016/j.juro.2016.03.185.
    Full Text
  - Ostermann, J, and Onural, L. "Editorial." 3dtv Conference 2016-August (August 22, 2016). Full Text
  - Moul, Judd W., and James H. Semans. “Editorial Comment..” Urology, July 2016. https://doi.org/10.1016/j.urology.2015.11.067.
    Full Text
  - Moul, JW. "Editorial Commentary." Urology Practice 3, no. 3 (May 1, 2016): 217-null. Full Text
  - Dunlap, C. “Preface,” 2016.
  - Moul, Judd W. “Editorial comment..” Urology, January 2016. https://doi.org/10.1016/j.urology.2015.08.027.
    Full Text
  - Polascik, Thomas J., Kae Jack Tay, and Judd W. Moul. “Keeping an Open Mind About Novel Concepts for Management of Prostate Cancer..” European Urology, December 2015. https://doi.org/10.1016/j.eururo.2015.02.024.
    Full Text
  - Moul, Judd W. “Editorial Comment..” Urology, October 2015. https://doi.org/10.1016/j.urology.2015.05.035.
    Full Text
  - Peterson, Andrew C. “Editorial comment..” Urology, May 2015. https://doi.org/10.1016/j.urology.2014.12.048.
    Full Text
  - Leong, Kam W. “Editorial..” Biomaterials, January 2015. https://doi.org/10.1016/j.biomaterials.2014.10.047.
    Full Text
  - Moul, J. W. “Editorial Comment.” Urology, 2015. https://doi.org/10.1016/j.urology.2015.05.035.
    Full Text
  - Moul, J. W., and J. H. Semans. “Editorial comment.” Urology, January 1, 2015. https://doi.org/10.1016/j.urology.2014.07.073.
    Full Text
  - Moul, Judd W., and James H. Semans. “Editorial comment..” Urology, January 2015. https://doi.org/10.1016/j.urology.2014.07.073.
    Full Text
  - Wiener, J., E. Balleisen, L. Bennear, and K. Krawiec. “Conclusion,” 2015.
  - Moul, Judd. “Reply: To PMID 25432832..” Urology, December 2014. https://doi.org/10.1016/j.urology.2014.07.063.
    Full Text
  - Moul, Judd. “Editorial comment..” Urology, November 2014. https://doi.org/10.1016/j.urology.2014.05.075.
    Full Text
  - Moul, Judd W. “The urology perspective on expanding androgen-targeted treatments for men with castration-resistant prostate cancer..” Oncology (Williston Park, N.Y.), August 2014.
  - Routh, Jonathan C. “Editorial comment..” Urology, July 2014. https://doi.org/10.1016/j.urology.2014.02.031.
    Full Text
  - Biehn Stewart, Suzanne, Shelby D. Reed, and Judd W. Moul. “Will the future of health care lead to the end of the robotic golden years?.” European Urology, February 2014. https://doi.org/10.1016/j.eururo.2012.10.019.
    Full Text
  - Moul, Judd W. “Active surveillance for African-American men with prostate cancer: of course! Pro..” Oncology (Williston Park, N.Y.), January 2014.
  - Moul, Judd W., Patrick C. Walsh, Marc S. Rendell, Henry T. Lynch, Stephen W. Leslie, Omofolasade Kosoko-Lasaki, William P. Fitzgibbons, Isaac Powell, Anthony V. D’Amico, and William J. Catalona. “Re: Early detection of prostate cancer: AUA guideline: H. B. Carter, P. C. Albertsen, M. J. Barry, R. Etzioni, S. J. Freedland, K. L. Greene, L. Holmberg, P. Kantoff, B. R. Konety, M. H. Murad, D. F. Penson and A. L. Zietman J Urol 2013; 190: 419-426..” The Journal of Urology, September 2013. https://doi.org/10.1016/j.juro.2013.07.002.
    Full Text
  - Moul, Judd W. “Prostate cancer: active surveillance in African American men..” Nature Reviews. Urology, June 2013. https://doi.org/10.1038/nrurol.2013.97.
    Full Text
  - Moul, Judd. “Comprehensive preoperative evaluation and repair of inguinal hernias at the time of open radical retropubic prostatectomy decreases risk of developing postprostatectomy hernia..” Bju International, December 2012. https://doi.org/10.1111/j.1464-410x.2012.11335.x.
    Full Text
  - Moul, JW, and McDermed, JE. "Reply." Urology 80, no. 6 (December 1, 2012): 1326-1327. Full Text
  - Moul, Judd W. “When should we pull the trigger for post-radical prostatectomy radiotherapy?.” European Urology, September 2012. https://doi.org/10.1016/j.eururo.2012.05.066.
    Full Text
  - Moul, JW. "Radiotherapy comparison favors IMRT for prostate cancer: Commentary." Oncology Report , no. MAY (May 1, 2012): 11-null.
  - Moul, JW. "Men avoid therapy for sexual side effects of prostatectomy: Commentary." Oncology Report , no. MAY (May 1, 2012): 14-null.
  - Moul, JW. "In the pipeline: Galeterone lowers PSA in CRPC study: Commentary." Oncology Report , no. MAY (May 1, 2012): 12-null.
  - Moul, Judd W. “Prostate cancer: making the switch from LHRH antagonist to LHRH agonist..” Nature Reviews. Urology, March 2012. https://doi.org/10.1038/nrurol.2012.5.
    Full Text
  - Armstrong, Andrew J., Judd W. Moul, and Daniel J. George. “What to order from the prostate cancer treatment menu?.” Oncology (Williston Park, N.Y.), January 2012.
  - Loeb, S, Carter, HB, Catalona, WJ, Moul, J, and Schroder, FH. "Reply from Authors re: Seth A. Strope, Gerald L. Andriole. Prostate-Specific Antigen-Based Risk Assessment in Younger Men. Eur Urol 2012;61:8-9." European Urology 61, no. 1 (January 1, 2012): 9-10. (Review) Full Text
  - Moul, Judd W., and Robert Dreicer. “New data, new paradigms for treating patients with prostate cancer: introduction..” Urology, November 2011. https://doi.org/10.1016/j.urology.2011.03.061.
    Full Text
  - Dreicer, R, and Moul, JW. "Conclusion." Urology 78, no. 5 SUPPL. (November 1, 2011). Full Text
  - Tang, P, Sun, L, Uhlman, MA, Robertson, CN, Polascik, TJ, and Moul, JW. "Re: Prostate-specific antigen velocity based risk-adapted discontinuation of prostate cancer screening in elderly men." Journal of Urology 186, no. 5 (November 1, 2011): 1880-1881. Full Text
  - Walsh, PC. "Re: Salvage Radiation in Men After Prostate-Specific Antigen Failure and the Risk of Death." Journal of Urology 186, no. 5 (November 2011): 1876-1876. Full Text
  - Fitzpatrick, John M., Joaquim Bellmunt, Robert Dreicer, Neil E. Fleshner, Christopher J. Logothetis, Judd W. Moul, Bertrand Tombal, and Alexandre Zlotta. “Maximizing outcomes in genitourinary cancers across the treatment continuum..” Bju International, April 2011. https://doi.org/10.1111/j.1464-410x.2010.10035.x.
    Full Text
  - Moul, Judd W. “Putting Provenge in perspective..” Oncology (Williston Park), March 2011.
    Link to Item
  - Moul, JW. "Editorial comment. Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--Implications for a risk-adapted follow-up strategy." Urology 76, no. 5 (November 2010): 1205-null. Full Text
  - Moul, Judd W. “Editorial comment..” Urology, September 2010. https://doi.org/10.1016/j.urology.2010.04.006.
    Full Text
  - Moul, J. W. “Low-risk men can delay prostatectomy until biopsy upgrade: Comment.” Oncology Report, July 1, 2010.
  - Moul, J. W. “Radiation plus ADT improves overall, disease-free survival: Comment.” Oncology Report, July 1, 2010.
  - Moul, J. W. “Reliance on PSA triggers may lead to overtreatment: Commentary.” Oncology Report, May 20, 2010.
  - Moul, Judd W. “Radiotherapy: Secondary malignancies after prostate cancer treatment..” Nature Reviews. Clinical Oncology, May 2010. https://doi.org/10.1038/nrclinonc.2010.59.
    Full Text
  - Moul, JW. "Reply." Urology 75, no. 5 (May 2010): 1130-1130. Full Text
  - Moul, J. W. “Report from Durham..” Prostate Cancer and Prostatic Diseases, March 2010. https://doi.org/10.1038/pcan.2009.65.
    Full Text
  - Moul, JW, Tang, P, and Sun, L. "Editorial comment on: Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts." European Urology 57, no. 3 (March 2010): 452-null. Full Text
  - Moul, Judd W. “Editorial comment..” Urology, February 2010. https://doi.org/10.1016/j.urology.2009.07.1249.
    Full Text
  - Moul, JW. "Editorial comment." Urology 76, no. 5 (January 1, 2010): 1205-null. Full Text
  - Moul, JW. "Reply." Urology 75, no. 5 (January 1, 2010): 1128-1129. Full Text
  - Moul, JW. "Editorial: Report from Durham." Prostate Cancer and Prostatic Diseases 13, no. 1 (January 1, 2010): 1-null. Full Text
  - Stewart, Suzanne Biehn, Charles D. Scales, and Judd W. Moul. “Health policy: Health-care implications of resident duty-hour restrictions..” Nature Reviews. Urology, December 2009. https://doi.org/10.1038/nrurol.2009.230.
    Full Text
  - Moul, JW. "Hormone therapy for prostate cancer raises heart disease risk: Commentary." Oncology Report , no. WINT (December 1, 2009): 26-null.
  - Moul, Judd W. “Innovations in urology from military medicine..” Urologic Oncology, September 2009. https://doi.org/10.1016/j.urolonc.2009.01.022.
    Full Text
  - Moul, JW. "Four clinical risk factors predict survival surrogate: Commentary." Oncology Report , no. FALL (September 1, 2009): 25-null.
  - Moul, JW. "Adjuvant radiotherapy remains rare in prostate cancer care: Commentary." Oncology Report , no. FALL (September 1, 2009): 26-null.
  - Moul, Judd W. “Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer..” Cancer, August 2009. https://doi.org/10.1002/cncr.24393.
    Full Text
  - Moul, Judd W. “Will the global economic downturn affect prostate cancer care? Pelvic lymphadenectomy as an example..” European Urology, June 2009. https://doi.org/10.1016/j.eururo.2009.03.062.
    Full Text
  - "Report from Durham." Prostate Cancer and Prostatic Diseases 12, no. 1 (February 23, 2009): 1-null. Full Text
  - Moul, J. W. “Report from Durham..” Prostate Cancer and Prostatic Diseases, January 2009. https://doi.org/10.1038/pcan.2009.34.
    Full Text
  - Moul, Judd W. “Twenty-five year evolution of medical hormonal therapy for prostate cancer..” Bju International, January 2009. https://doi.org/10.1111/j.1464-410x.2008.08271.x.
    Full Text
  - Moul, J. "Report from Durham." Prostate Cancer and Prostatic Diseases 12, no. 1 (2009): 1--null. Full Text
  - Moul, Judd W. “Are we overtreating prostate cancer?.” The Journal of Urology, December 2008. https://doi.org/10.1016/j.juro.2008.09.067.
    Full Text
  - Moul, JW, and Mouraviev, V. "Should elderly men be screened for prostate cancer?." Aging Health 4, no. 5 (October 10, 2008): 443-446. Full Text
  - Moul, Judd W. “Point: radical prostatectomy is the treatment of choice for high-risk prostate cancer patients..” Brachytherapy, October 2008. https://doi.org/10.1016/j.brachy.2008.08.003.
    Full Text
  - Moul, JW. "Rebuttal to Dr. Stock." Brachytherapy 7, no. 4 (October 1, 2008): 283-null. Full Text
  - "Sunitinib combination reduces PSA levels in metastatic HRPC: Commentary." Oncology Report , no. FALL (September 1, 2008): 39-null.
  - "More leukemia diagnosed years after EBRT for prostate cancer: Commentary." Oncology Report , no. FALL (September 1, 2008): 108-null.
  - Moul, J. W. “Primary androgen blockade is no better than watchful waiting: Commentary.” Oncology Report, September 1, 2008.
  - Moul, J. W. “Carboplatin matches radiation in stage I seminoma: Commentary.” Oncology Report, September 1, 2008.
  - Moul, JW. "Androgen deprivation ups diabetes risk, but not AMIs: Commentary." Oncology Report , no. FALL (September 1, 2008): 42-null.
  - Moul, Judd W. “Words of wisdom. Re: obesity-related plasma hemodilution and PSA concentration among men with prostate cancer..” European Urology, July 2008. https://doi.org/10.1016/j.eururo.2008.03.062.
    Full Text
  - Koontz, BF, and Moul, J. "Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer." Cancer 112, no. 11 (June 1, 2008): 2518-2519. (Letter) Full Text
  - Moul, J. W. “Report from Durham..” Prostate Cancer and Prostatic Diseases, January 2008. https://doi.org/10.1038/pcan.2008.43.
    Full Text
  - Moul, J. W. “Report from Durham..” Prostate Cancer and Prostatic Diseases, January 2008. https://doi.org/10.1038/pcan.2008.8.
    Full Text
  - Petrovics, G, Liu, A, Shaheduzzaman, S, Furusato, B, Sun, C, Chen, Y, Nau, M, Ravindranath, L, Dobi, A, Srikantan, V, Sesterhenn, IA, McLeod, DG, Vahey, M, Moul, JW, and Srivastava, S. "Erratum: Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome (Oncogene (2005) 24 (3847-3852) DOI:10.1038/sj.onc.1208518)." Oncogene 26, no. 46 (October 11, 2007): 6684-null. Full Text
  - "Choice of consultation specialist sways treatment decisions: Commentary." Oncology Report , no. FALL (September 1, 2007): 55-null.
  - "Stress management eases fear, aids postsurgical function: Commentary." Oncology Report , no. FALL (September 1, 2007): 53-null.
  - "Circulating tumor cells may be better surrogate than PSA: Commentary." Oncology Report , no. FALL (September 1, 2007): 51-null.
  - "Better QOL with adjuvant chemotherapy than radiation: Commentary." Oncology Report , no. FALL (September 1, 2007): 62-null.
  - "Flaxseed slows prostate cancer growth in randomized study: Commentary." Oncology Report , no. FALL (September 1, 2007): 52-null.
  - "PSA decline of 30% may be surrogate marker for overall survival: Commentary." Oncology Report , no. FALL (September 1, 2007): 52-53.
  - "Postsurgical prognostic tools give inaccurate predictions: Commentary." Oncology Report , no. FALL (September 1, 2007): 50-null.
  - "Bevacizumab plus interferon-α improves survival: Commentary." Oncology Report , no. FALL (September 1, 2007): 57-null.
  - "Satraplatin boosts progression-free survival in SPARC: Commentary." Oncology Report , no. FALL (September 1, 2007): 49-null.
  - "Adjuvant radiotherapy linked to better cause-specific survival: Commentary." Oncology Report , no. FALL (September 1, 2007): 62-null.
  - "Follow-up after EBRT falls short of guideline: Commentary." Oncology Report , no. FALL (September 1, 2007): 56-null.
  - "Adjuvant radiotherapy averts biochemical progression." Oncology Report , no. FALL (September 1, 2007): 51-null.
  - "Intermittent androgen suppression is safe alternative: Commentary." Oncology Report , no. FALL (September 1, 2007): 50-null.
  - Freedland, S. J., and J. W. Moul. “Sunitinib active in bevacizumab-resistant kidney cancer: Commentary.” Oncology Report, September 1, 2007.
  - Freedland, SJ, and Moul, JW. "More positive needle biopsies in African American men: Commentary." Oncology Report , no. FALL (September 1, 2007): 54-null.
  - Moul, JW. "Report from Durham." Prostate Cancer and Prostatic Diseases 10, no. 3 (September 1, 2007): 211-null. Full Text
  - Moul, JW. "Report from Durham." Prostate Cancer and Prostatic Diseases 10, no. 1 (March 1, 2007): 1-null. Full Text
  - Freedland, S. J., J. W. Moul, and J. F. Ward. “PSA recurrence of prostate cancer: Update 2006.” Consultant, December 1, 2006.
  - Moul, J. W. “The Eisenberger/Sinibaldi article reviewed.” Oncology, December 1, 2006.
  - Lee, W Robert, and Judd W. Moul. “Can prostate-specific antigen nadir predict prostate cancer outcomes following radiotherapy?.” Nature Clinical Practice. Oncology, October 2006. https://doi.org/10.1038/ncponc0612.
    Full Text
  - Freedland, S. J., D. J. George, and J. W. Moul. “Zoledronic acid maintains BMD in GnRH agonist-treated men with prostate cancer: Comment.” Oncology Report, September 1, 2006.
  - Freedland, S. J., and J. W. Moul. “Bicalutamide added to standard care reduces risk of bone metastasis: Comment.” Oncology Report, September 1, 2006.
  - Freedland, SJ, and Moul, JW. "Intermittent maximum androgen blockade is a worthwhile option for metastatic disease: Comment." Oncology Report , no. FALL (September 1, 2006): 50-null.
  - Freedland, SJ, and Moul, JW. "Absolute PSA value is powerful predictor of survival after androgen deprivation: Comment." Oncology Report , no. FALL (September 1, 2006): 48-49.
  - George, DJ, and Moul, JW. "Sunitinib and temsirolimus: New standards of care for metastatic RCC? Comment." Oncology Report , no. FALL (September 1, 2006).
  - George, DJ, and Moul, JW. "Perioperative chemotherapy surprisingly underused for transitional cell carcinoma: Comment." Oncology Report , no. FALL (September 1, 2006): 58-59.
  - George, DJ, and Moul, JW. "Salvage chemotherapy yields high cure rate in recurrent germ cell tumors: Comment." Oncology Report , no. FALL (September 1, 2006): 58-null.
  - Moul, JW, Freedland, SJ, and George, DJ. "Peripheral androgen blockage produces durable PSA responses in prostate cancer: Comment." Oncology Report , no. FALL (September 1, 2006): 47-null.
  - Moul, JW. "PSA doubling time key to reducing prostate cancer mortality: Comment." Oncology Report , no. FALL (September 1, 2006): 47-48.
  - Moul, JW. "Lower risk of recurrence with chemo than with lymph node dissection in stage I NSGCT: Comment." Oncology Report , no. FALL (September 1, 2006): 57-null.
  - Moul, JW. "Report from Durham." Prostate Cancer and Prostatic Diseases 9, no. 3 (September 1, 2006): 199-null. Full Text
  - Moul, Judd W. “The role of cytotoxic chemotherapy in prostate cancer - A critical reevaluation 20 years later - The Eisenberger/Sinibaldi article reviewed.” Oncology New York. P R R INC, July 1, 2006.
    Link to Item
  - Moul, JW. "Prostate cancer." Current Opinion in Urology 16, no. 3 (May 1, 2006): 121-122. Full Text
  - Moul, JW. "Editorial introduction." Current Opinion in Urology 16, no. 3 (May 1, 2006). Full Text
  - Moul, J. W. “Treating the troops a model for battling health-care disparities.” Oncology New York. P R R INC, March 1, 2006.
    Link to Item
  - Moul, JW. "Report from Durham." Prostate Cancer and Prostatic Diseases 9, no. 1 (March 1, 2006): 1-null. Full Text
  - Moul, JW. "Editorial comment." Journal of Urology 175, no. 1 (January 2006): 129-129. Full Text
  - Dahm, P, and Moul, JW. "Immunization with TG4010 appears biologically active in prostate cancer. Comment." Oncology Report , no. FALL (September 1, 2005): 56-null.
  - Moul, JW, and Dahm, P. "TICE chemotherapy achieves good response in germ cell tumors. Comment." Oncology Report , no. FALL (September 1, 2005): 60-61.
  - Moul, JW. "Adjuvant RT reduces biochemical progression after radical prostatectomy. Comment." Oncology Report , no. FALL (September 1, 2005): 55-null.
  - Moul, JW. "Report from Durham." Prostate Cancer and Prostatic Diseases 8, no. 3 (September 2005): 201-201. Full Text
  - Moul, JW. "High probability of metastases or death in untreated prostate cancer. Comment." Oncology Report , no. FALL (September 1, 2005): 58-59.
  - Moul, JW. "Favorable trends with DN-101 and docetaxel in androgen-independent prostate cancer. Comment." Oncology Report , no. FALL (September 1, 2005): 54-null.
  - Moul, JW. "RT-PCR for PSA predicts time to disease progression in HR prostate cancer. Comment." Oncology Report , no. FALL (September 1, 2005): 57-null.
  - &NA, and, . "Editorial introduction." Current Opinion in Urology 15, no. 3 (May 2005): i-i. Full Text
  - Moul, J. W. “Untitled.” Current Opinion in Urology. LIPPINCOTT WILLIAMS & WILKINS, May 1, 2005.
    Link to Item
  - Moul, JW. "Treating invasive bladder cancer with TUR/chemotherapy feasible for selected patients." Oncology Report , no. SPRING (March 1, 2005): 58-59.
  - Moul, JW. "Radiation dose escalation for early-stage prostate cancer found safe and effective." Oncology Report , no. SPRING (March 1, 2005): 52-53.
  - Vieweg, J, and Moul, JW. "Promising phase II results for lenalidomide in metastatic renal cell cancer." Oncology Report , no. SPRING (March 1, 2005): 57-58.
  - Moul, JW. "In Reply:." Journal of Clinical Oncology 23, no. 6 (February 20, 2005): 1322-1323. Full Text
  - Moul, J. “Report from Durham..” Prostate Cancer and Prostatic Diseases, January 2005. https://doi.org/10.1038/sj.pcan.4500795.
    Full Text
  - Moul, JW. "Prostate cancer." Current Opinion in Urology 15, no. 3 (January 1, 2005): 149-150. Full Text
  - Pitts, W Reid. “Re: the economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data..” The Journal of Urology, December 2004. https://doi.org/10.1097/01.ju.0000145135.83351.cb.
    Full Text
  - Moul, J. W. “The Cooperberg/Park/Carroll article reviewed.” Oncology, September 1, 2004.
  - Moul, JW. "Editorial." Prostate Cancer and Prostatic Diseases 7, no. 3 (September 1, 2004): 179-null. Full Text
  - Kirby, R., and J. W. Moul. “Is the PSA test useless?.” Prostate Cancer and Prostatic Diseases, January 2004. https://doi.org/10.1038/sj.pcan.4500777.
    Full Text
  - Kirby, RS, and Moul, JW. "Editorial." Prostate Cancer and Prostatic Diseases 6, no. 4 (December 1, 2003): 267-null. Full Text
  - Moul, JW, and Kirby, R. "PCPD editorial." Prostate Cancer and Prostatic Diseases 6, no. 3 (October 9, 2003): 199-null. Full Text
  - Kirby, RS, and Moul, JW. "PCPD editorial." Prostate Cancer and Prostatic Diseases 6, no. 2 (July 15, 2003): 107-null. Full Text
  - "EDITORIAL COMMENT." Journal of Urology 170, no. 1 (July 2003): 76-77. Full Text
  - Kirby, R, Brawer, M, and Moul, J. "Editorial." Prostate Cancer and Prostatic Diseases 6, no. 1 (January 1, 2003): 1-null. Full Text
  - Moul, JW, and Vaughn, DJ. "Leuprolide acetate: Viewpoints." American Journal of Cancer 2, no. 1 (January 1, 2003): 65-null. Full Text
  - Kirby, RS, Moul, JW, and Brawer, MK. "Editorial." Prostate Cancer and Prostatic Diseases 5, no. 4 (December 1, 2002): 247-null. Full Text
  - Moul, Judd W. “Prostate biopsy quantitative histology as a staging and prognostic factor..” The Journal of Urology, February 2002. https://doi.org/10.1097/00005392-200202000-00017.
    Full Text
  - Kirby, R, Brawer, M, and Moul, J. "Editorial." Prostate Cancer and Prostatic Diseases 5, no. 2 (January 1, 2002): 83-null. Full Text
  - Kirby, R, Moul, J, and Brawer, M. "Editorial." Prostate Cancer and Prostatic Diseases 5, no. 3 (January 1, 2002): 167-null. Full Text
  - Kirby, R, Moul, J, and Brawer, M. "Editorial." Prostate Cancer and Prostatic Diseases 5, no. 1 (January 1, 2002): 1-null. Full Text
  - Moul, JW. "The D'Amico article reviewed: The CPDR/CaPSURE recurrence equation." Oncology 15, no. 8 (December 1, 2001): 1060-1062.
  - Kirby, R, Moul, J, and Brawer, M. "Editorial." Prostate Cancer and Prostatic Diseases 4, no. 3 (October 14, 2001): 137-null. Full Text
  - Anscher, M. S. “Re: The development of erectile dysfunction in men treated for prostate cancer..” J Urol, September 2001.
    Link to Item
  - Kirby, R, Moul, J, and Brawer, M. "Editorial." Prostate Cancer and Prostatic Diseases 4, no. 2 (June 2001): 71-71. Full Text
  - Feleppa, EJ, Ketterling, JA, Kalisz, A, Urban, S, Porter, CR, Gillespie, J, Schiff, PB, Ennis, RD, Wuu, CS, Moul, JW, Sesterhenn, IA, and Scardino, PT. "Prostate imaging based on RF spectrum analysis and non-linear classifiers for guiding biopsies and targeting radiotherapy." Proceedings of Spie the International Society for Optical Engineering 4325 (January 1, 2001): 371-379. Full Text
  - Kirby, R, Brawer, M, and Moul, J. "Editorial." Prostate Cancer and Prostatic Diseases 4, no. 4 (January 1, 2001): 195-null. Full Text
  - Zeng, J, Sofer, A, Bauer, JJ, Zhang, W, Sesterhenn, IA, Moul, JW, and Mun, SK. "Probability of cancer detection with optimized prostate biopsy protocols." Proceedings of Spie the International Society for Optical Engineering 4319 (January 1, 2001): 623-633. Full Text
  - "Prostate and prostatic diseases: Editorial." Prostate Cancer and Prostatic Diseases 3, no. 3 (December 27, 2000): 135-null.
  - Xu, LL, Shanmugam, N, Segawa, T, Sesterhenn, IA, McLeod, DG, Moul, JW, and Srivastava, S. "Erratum: A novel androgen-regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate (Genomics (2000) 66:3 (257-263))." Genomics 70, no. 3 (December 15, 2000): 407-null. Full Text
  - Moul, J. W., T. Segawa, L. L. Xu, L. Sun, I. A. Sesterhenn, and S. Srivastava. “cDNA microarray gene chip for prostate cancer and translational study in a prospective tissue bank and clinical longitudinal database..” Prostate Cancer and Prostatic Diseases, December 2000. https://doi.org/10.1038/sj.pcan.4500455.
    Full Text
  - "Prostate cancer and prostatic diseases: Editorial." Prostate Cancer and Prostatic Diseases 3, no. 2 (September 12, 2000): 61-null.
  - Bauer, JJ, Zeng, J, Zhang, W, Sesterhenn, IA, Dean, R, Moul, JW, and Mun, SK. "Simulated prostate biopsy: prostate cancer distribution and clinical correlation." Medical Imaging 2000: Image Display and Visualization (April 18, 2000). Full Text
  - Zeng, J, Bauer, JJ, Yao, X, Zhang, W, Sesterhenn, IA, Connelly, RR, Moul, JW, and Mun, SK. "Building an accurate 3D map of prostate cancer using computerized models of 280 whole-mounted radical prostatectomy specimens." Proceedings of Spie the International Society for Optical Engineering 3976 (January 1, 2000): 466-477.
  - Heidenreich, A, Sesterhenn, IA, Mostofi, FK, Moul, JW, and Hennequin, C. "Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis." Progres En Urologie 9, no. 2 (April 1, 1999): 396-397.
  - Bauer, JJ, Zeng, J, Weir, J, Zhang, W, Sesterhenn, IA, Connelly, RR, Moul, JW, and Mun, SK. "Optimization of prostate biopsy." Proceedings of Spie the International Society for Optical Engineering 3658 (January 1, 1999): 300-307.
  - Yu, P, McClain, M, Xuan, J, Wang, Y, Sesterhenn, IA, Moul, JW, Zhang, W, and Mun, SK. "Model supported virtual environment for prostate cancer pattern analysis." Proceedings of Spie the International Society for Optical Engineering 3658 (January 1, 1999): 78-88.
  - Moul, J. W., J. J. Bauer, I. A. Sesterhenn, G. B. Stackhouse, and S. Srivastava. “Re: p53 protein and gene alterations in pathological stage C prostate carcinoma..” The Journal of Urology, May 1998. https://doi.org/10.1097/00005392-199805000-00077.
    Full Text
  - Herr, H. W. “Prognostic risk factors in low stage testicular germ cell tumors: unanswered questions regarding clinically useful prognosticators for extratesticular disease..” Cancer, January 1998. https://doi.org/10.1002/(sici)1097-0142(19980101)82:1<231::aid-cncr33>3.0.co;2-1.
    Full Text
  - Heidenreich, A., I. A. Sesterhenn, K. F. Mostofi, and W. Judd. “Prognostic risk factors in low stage nonseminumatous testicular germ cell tumors (NTGCT).” British Journal of Urology, December 1, 1997.
  - Mostofi, F. K., I. A. Sesterhenn, C. J. Davis, D. G. McLeod, T. Douglas, and J. W. Moul. “Frequency and location of benign prostatic glands in the surgical margin of 147 radical retropubic prostatectomies for carcinoma.” British Journal of Urology, December 1, 1997.
  - Moul, J. W. “The Powell Article Reviewed.” Oncology, December 1, 1997.
  - Bauer, JJ, Mostofi, FK, McLeod, DG, Srivastava, S, and Moul, JW. "Apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer patients." British Journal of Urology 80, no. SUPPL. 2 (December 1, 1997): 232-null.
  - Hayes, WS, Sesterhenn, IA, Xuan, J, Wang, Y, Becker, RL, Lynch, JH, Moul, JW, McLeod, DG, Losee, J, Mun, SK, and Mostofi, FK. "Interactive three dimensional modeling of localized prostate cancer: Computer simulation of needle biopsy technique." British Journal of Urology 80, no. SUPPL. 2 (December 1, 1997): 267-null.
  - Moul, J. W. “Prostate cancer 1997--practicing what we preach..” The Journal of Urology, November 1997. https://doi.org/10.1016/s0022-5347(01)64146-6.
    Full Text
  - Moul, J. W. “PSA thresholds for prostate cancer detection..” Jama, September 1997. https://doi.org/10.1001/jama.278.9.699b.
    Full Text
  - Moul, J. W. “Epidemiology and screening for prostate cancer..” The American Journal of Managed Care, August 1997.
  - Sawyer, R., J. J. Berman, and G. W. Moore. “Prostate-specific antigen in black men..” The New England Journal of Medicine, January 1997. https://doi.org/10.1056/nejm199701093360212.
    Full Text
  - Moul, JW. "Radical prostatectomy and cryotherapy--some answers, more questions." The Journal of Urology 157, no. 1 (January 1997): 256-257. Full Text
  - Douglas, T. H., W. F. McCarthy, D. G. McLeod, and J. W. Moul. “Patient selection for experimental adjuvant therapy after radical prostatectomy..” Urology, February 1996. https://doi.org/10.1016/s0090-4295(99)80436-1.
    Full Text
  - Moul, J. W. “DNA ploidy in nonseminomatous germ cell testicular tumor..” Urology, July 1994. https://doi.org/10.1016/s0090-4295(94)80037-5.
    Full Text
  - Moul, J. W., W. F. McCarthy, E. B. Fernandez, and I. A. Sesterhenn. “Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I nonseminomatous testicular cancer..” Cancer Research, January 1994.
  - Stewart, D. A., D. J. Stewart, and K. T. Mai. “Active chemotherapy for metastatic stromal cell tumor of the testis..” Urology, December 1993. https://doi.org/10.1016/0090-4295(93)90547-n.
    Full Text
  - Bejany, D. E., P. E. Perito, M. Lustgarten, and R. K. Rhamy. “Gangrene of the penis after implantation of penile prosthesis: case reports, treatment recommendations and review of the literature..” The Journal of Urology, July 1993. https://doi.org/10.1016/s0022-5347(17)35433-2.
    Full Text
  - Cookson, M. S., and P. W. Nadig. “Long-term results with vacuum constriction device..” The Journal of Urology, February 1993. https://doi.org/10.1016/s0022-5347(17)36059-7.
    Full Text
  - Moul, JW. "Retroperitoneal lymphadenectomy." Canadian Journal of Surgery. Journal Canadien De Chirurgie 36, no. 1 (February 1993): 16-17. (Letter)
  - Moul, J. W. “Testicular tumour..” British Journal of Hospital Medicine, October 1992.
  - Moul, J. W. “Refusal in testicular cancer patients: implications for surveillance..” British Journal of Cancer, May 1992. https://doi.org/10.1038/bjc.1992.168.
    Full Text Open Access Copy
  - Moul, JW, and McLeod, DG. "Melanomas that defy clinical recognition." Jama 267, no. 19 (May 1992): 2605-null. (Letter) Full Text
  - Moul, J. W. “Inappropriate surgery for testicular cancer..” British Journal of Hospital Medicine, January 1992.
  - Moul, J. W. “Gynaecomastia and extragonadal symptoms leading to diagnosis delay of germ cell tumours in young men..” Postgraduate Medical Journal, December 1991. https://doi.org/10.1136/pgmj.67.794.1082-a.
    Full Text
  - Moul, JW, Paulson, DF, and Walther, PJ. "Refusal of cancer treatment in testicular cancer patients." Journal of the National Cancer Institute 81, no. 20 (October 1989): 1587-1588. (Letter) Full Text
- Conference Papers
  - Freedland, SJ, Allen, J, Armstrong, AJ, Moul, JW, Sandler, HM, Levin, D, Howard, LE, and Lin, P-H. "Interim analysis of a prospective randomized trial of dietary carbohydrate restriction for men with a rising PSA after failed primary treatment: Carbohydrate and Prostate Study 2 (CAPS2)." : American Society of Clinical Oncology (ASCO), February 20, 2018. Full Text
  - Stone, S, Cooperberg, MR, Flake, DD, Davis, JW, Moul, JW, Tward, JD, and Brawer, MK. "Evaluation of microarrays for measuring cell cycle progression (CCP) gene expression." : American Society of Clinical Oncology (ASCO), May 20, 2017. Full Text
  - Moul, JW, McLane, JA, Atkinson, S, and Concepcion, RS. "Head-to-head pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprorelin acetate formulations in male patients." : American Society of Clinical Oncology (ASCO), February 20, 2017. Full Text
  - Armstrong, AJ, Halabi, S, Healy, P, Lee, WR, Koontz, BF, Moul, JW, Mundy, K, Creel, P, Wood, S, Davis, K, Carducci, MA, Stein, M, Hobbs, C, Reimer, B, Nguyen, M, Anand, M, Bratt, L, Kim, S, Tran, PT, George, DJ, and Department of Defense Prostate Cancer Clinical Trials Consortium, . "A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy." March 2016. Full Text
  - Scardino, Peter T., Jack M. Cuzick, Steve Stone, Brent Evans, Matthew R. Jorgensen, James Andrew Eastham, Thomas E. Keane, et al. “Application of active surveillance threshold to series of samples submitted for commercial testing..” In Journal of Clinical Oncology, 34:84–84. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.2_suppl.84.
    Full Text
  - Saltzstein, DR, Moul, JW, de la Motte, S, McLane, JA, Osborne, DW, Yang, A, and Concepcion, RS. "Randomized head-to-head prospective study of pharmacokinetic and pharmacodynamic properties of leuprolide acetate formulations: 7.5 mg single depot subcutaneous vs 7.5 mg intramuscular microsphere." : American Society of Clinical Oncology (ASCO), May 20, 2015. Full Text
  - Reed, SD, Biehn Stewart, S, Scales, CD, and Moul, JW. "Use of PSA Slope to Guide Adjuvant Radiotherapy in Post-Prostatectomy Prostate Cancer has Potential to be Cost Effective." : Elsevier BV, May 2014. Full Text
  - Reynolds, MA, Moul, JW, and McDermed, J. "NADIA® Psa Slope Impacts Urologists’ Recommendations for Adjuvant Radiotherapy for Prostate Cancer Patients with High-Risk Pathology Following Radical Prostatectomy." : Elsevier BV, May 2014. Full Text
  - Koontz, BF, Kalman, NS, Bañez, LL, Livengood, KP, Anscher, MS, Moul, JW, and Lee, WR. "Image Guidance Affects Biochemical Outcome for Postprostatectomy Radiation Therapy." : Elsevier BV, October 2013. Full Text
  - Halabi, S., C. Y. Lin, W. K. Kelly, K. Fizazi, J. W. Moul, E. Kaplan, M. J. Morris, and E. J. Small. “A validated prognostic model for predicting overall survival in patients with metastatic chemotherapy naive castrate-resistant prostate cancer.” In European Journal of Cancer, 49:S679–S679. ELSEVIER SCI LTD, 2013.
    Link to Item
  - Kalman, Noah S., Lionel L. Banez, Leah Gerber, Judd W. Moul, Mitchell Steven Anscher, W Robert Lee, and Bridget F. Koontz. “Image guidance for post-prostatectomy radiotherapy: Are we missing the mark?.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013. https://doi.org/10.1200/jco.2013.31.6_suppl.56.
    Full Text Link to Item
  - Moul, JW, Lilja, H, Lance, R, Vessella, R, McDermed, JE, Sarno, MJ, and Adams, TH. "Value of NADiA ProsVue on the CAPRA-S nomogram for predicting postprostatectomy clinical recurrence." : American Society of Clinical Oncology (ASCO), February 20, 2013. Full Text
  - "Oncologist roundtable: Is the Zaltrap pricing reversal a 'watershed moment'?." January 1, 2013.
  - Bassett, Mitchell, Michael Abern, Lionel Lloyds Banez, Michael Ferrandino, Cary N. Robertson, Brant Allen Inman, Thomas Polascik, Stephen J. Freedland, Philip John Walther, and Judd W. Moul. “African American race to predict for earlier failure of active surveillance: Results from the Duke Prostate Center.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - Moul, Judd W., Hans Lilja, Oliver John Semmes, Robert Vessella, Jonathan E. McDermed, Mark J. Sarno, and Robert E. Klem. “Post-prostatectomy PSA slope (ProsVue) in Gleason score >= 7 disease.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - Moul, Judd W., Krag S. Ferenz, and Beatrice Delhey Mautner. “Awareness, concern, and communication between physicians and patients on bone health in nonmetastatic prostate cancer.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012. https://doi.org/10.1200/jco.2012.30.5_suppl.246.
    Full Text Link to Item
  - Singh, Abhay A., Lionel Lloyds Banez, Leah Gerber, Stephen J. Freedland, Cary N. Robertson, Michael Ferrandino, Thomas Polascik, Philip John Walther, and Judd W. Moul. “Perineural versus lymphovascular invasion: Which is a better marker for unfavorable biochemical outcomes following prostatectomy? Results from the Duke Prostate Center Database.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012. https://doi.org/10.1200/jco.2012.30.5_suppl.34.
    Full Text Link to Item
  - Koontz, B. F., L. Gerber, L. L. Bañez, I. T. Degirmenci, Z. Vujaskovic, M. S. Anscher, C. N. Robertson, T. J. Polascik, J. W. Moul, and W. R. Lee. “3D Conformal and Intensity Modulated Radiotherapy to the Prostate Bed have Similar Biochemical Outcomes.” In International Journal of Radiation Oncology*Biology*Physics, 81:S406–7. Elsevier BV, 2011. https://doi.org/10.1016/j.ijrobp.2011.06.659.
    Full Text
  - Koontz, B. F., W. R. Lee, Z. Vujaskovic, M. Carroll, B. P. Quaranta, M. S. Anscher, C. N. Robertson, T. J. Polascik, and J. W. Moul. “Neoadjuvant Radiotherapy plus Prostatectomy for High Risk Prostate Cancer.” In International Journal of Radiation Oncology*Biology*Physics, 81:S397–S397. Elsevier BV, 2011. https://doi.org/10.1016/j.ijrobp.2011.06.640.
    Full Text
  - Wattson, DA, Chen, M, Moul, JW, Moran, BJ, Dosoretz, DE, Robertson, CN, Polascik, TJ, Braccioforte, MH, Salenius, SA, and D'Amico, AV. "The Number of High-Risk Factors and the Risk of Prostate Cancer-Specific Mortality Following Radical Prostatectomy or Brachytherapy." : Elsevier BV, October 2011. Full Text
  - George, D. J., S. Halabi, A. J. Zurita, P. Creel, K. Mundy, J. D. Turnbull, S. E. Yenser Wood, et al. “Investigator-initiated pilot study of sunitinib malate in patients with newly diagnosed prostate cancer prior to prostatectomy: A trial of the DoD/PCF Prostate Cancer Clinical Trials Consortium..” In Journal of Clinical Oncology, 29:4664–4664. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.4664.
    Full Text
  - Tripathy, D., J. W. Moul, B. G. Durie, and B. D. Mautner. “Assessment of current practices among physicians and awareness and concern among patients for bone health in cancer..” In Journal of Clinical Oncology, 29:e19617–e19617. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.e19617.
    Full Text
  - Calloway, EE, Chu, DI, Gerber, L, Thomas, J-A, Robertson, CN, Polascik, TJ, Moul, JW, and Bañez, LL. "1204 HEIGHT AND THE RISK FOR AGGRESSIVE PROSTATE CANCER AT THE TIME OF BIOPSY–RESULTS FROM THE DUKE PROSTATE CENTER DATABASE." : Ovid Technologies (Wolters Kluwer Health), April 2011. Full Text
  - Chu, DI, De Nunzio, C, Gerber, L, Thomas, J-A, Calloway, E, Albisinni, S, McKeever, MG, Moreira, DM, Senocak, C, Tubaro, A, Moul, JW, Freedland, SJ, and Bañez, LL. "2029 SHOULD A DIGITAL RECTAL EXAMINATION BE OPTIONAL FOR EARLY DETECTION OF PROSTATE CANCER IN OBESE MEN?." : Ovid Technologies (Wolters Kluwer Health), April 2011. Full Text
  - Gerber, L, Bãnez, LL, Freedland, SJ, Xie, D, Qi, JJ, Polascik, TJ, Robertson, CN, and Moul, JW. "335 DIABETES MELLITUS AND THE RISK OF HIGH-GRADE PROSTATE CANCER: RESULTS FROM THE DUKE PROSTATE CENTER." : Ovid Technologies (Wolters Kluwer Health), April 2011. Full Text
  - Moul, J. W., O. J. Semmes, R. Vessella, J. E. McDermed, and H. Lilja. “Prognostic impact of post-prostatectomy PSA slope determined with a novel, nucleic acid detection immunoassay (NADiA ProsVue) for total PSA..” In Journal of Clinical Oncology, 29:47–47. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.7_suppl.47.
    Full Text
  - Nelson, J. B., K. Fizazi, K. Miller, C. S. Higano, J. W. Moul, T. Morris, S. McIntosh, K. Pemberton, and M. E. Gleave. “Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC).” In Journal of Clinical Oncology, Vol. 29. AMER SOC CLINICAL ONCOLOGY, 2011.
    Link to Item
  - Shore, N. D., J. W. Moul, E. Crawford, E. van der Meulen, T. Olesen, and B. Persson. “Prostate-specific antigen (PSA) progression-free survival (PFS): A comparison of degarelix versus leuprolide in patients with prostate cancer..” In Journal of Clinical Oncology, 29:12–12. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.7_suppl.12.
    Full Text
  - Cotter, SE, Chen, M, Moul, JW, Lee, WR, Koontz, BF, Anscher, MS, and D'Amico, AV. "Salvage Radiation in Men with PSA Failure following Radical Prostatectomy and the Risk of Death." : Elsevier BV, November 2010. Full Text
  - Crawford, E., S. S. Sutton, J. W. Moul, C. A. Pettaway, J. W. Hardin, S. A. Poston, and E. J. Kruep. “Using prostate-specific antigen threshold to identify increased 4-year risk of prostate cancer..” In Journal of Clinical Oncology, 28:4565–4565. American Society of Clinical Oncology (ASCO), 2010. https://doi.org/10.1200/jco.2010.28.15_suppl.4565.
    Full Text
  - Shore, N. D., J. W. Moul, E. Crawford, T. Olesen, and B. Persson. “Long-term prostate-specific antigen (PSA) control in prostate cancer (PCa) patients switched from leuprolide to degarelix or receiving continuous degarelix treatment..” In Journal of Clinical Oncology, 28:4673–4673. American Society of Clinical Oncology (ASCO), 2010. https://doi.org/10.1200/jco.2010.28.15_suppl.4673.
    Full Text
  - Bañez, Lionel L., Leon Sun, Bruce J. Trock, Misop Han, Alan W. Partin, William J. Aronson, Martha K. Terris, et al. “BODY MASS INDEX AND PROSTATE-SPECIFIC ANTIGEN AS A PREDICTOR OF ADVERSE PATHOLOGY AND BIOCHEMICAL RECURRENCE FOLLOWING RADICAL PROSTATECTOMY.” In The Journal of Urology, 181:574–574. Ovid Technologies (Wolters Kluwer Health), 2009. https://doi.org/10.1016/s0022-5347(09)61619-0.
    Full Text
  - Koontz, Bridget F., Brian P. Quaranta, Madelaine Carroll, Zeljko Vujaskovic, W Robert Lee, Cary N. Robertson, Thomas J. Polascik, Mitchell S. Anscher, and Judd W. Moul. “PHASE I TRIAL OF PROSTATECTOMY AFTER PLANNED PRE-OPERATIVE RADIOTHERAPY FOR HIGH RISK LOCALIZED PROSTATE CANCER: PRELIMINARY RESULTS.” In The Journal of Urology, 181:713–713. Ovid Technologies (Wolters Kluwer Health), 2009. https://doi.org/10.1016/s0022-5347(09)61992-3.
    Full Text
  - Schroeck, FR, Kattan, MW, Moul, JW, Aronson, WJ, Presti, JC, Terris, MK, Kane, CJ, Amling, CL, Sun, L, and Freedland, SJ. "RECALIBRATION AND EXTERNAL VALIDATION OF AN EXISTING NOMOGRAM TO PREDICT AGGRESSIVE RECURRENCES AFTER RADICAL PROSTATECTOMY (RP)." : Ovid Technologies (Wolters Kluwer Health), April 2009. Full Text
  - Thomas, JA, Jayachandran, J, Bañez, LL, Sun, L, Madden, JC, Vollmer, RT, Lark, AL, Gerber, L, Moul, JW, and Freedland, SJ. "DOES PATHOLOGICAL GLEASON SCORE RE-REVIEW BY A MODERN PATHOLOGIST IMPROVE RISK STRATIFICATION RELATIVE TO HISTORICAL GLEASON SCORE?." : Ovid Technologies (Wolters Kluwer Health), April 2009. Full Text
  - Chino, JP, Schroeck, FR, Sun, L, Lee, W, Albala, DM, Moul, JW, and Koontz, BF. "Does Robotic Prostatectomy Increase the Need for Adjuvant Radiation Therapy? The Impact of Choice of Surgery and Pretreatment Disease Characteristics on Adjuvant Indications." : Elsevier BV, September 2008. Full Text
  - Koontz, BF, Chino, J, Schroeck, FR, Sun, L, Lee, WR, and Moul, JW. "What Factors Influence Referral for Postoperative Radiation Therapy for Prostate Cancer?." : Elsevier BV, September 2008. Full Text
  - Moul, J. W., D. Wiederkehr, M. Connolly, V. Sendersky, and E. Onel. “The relationship between LHRH-agonist depot formulations and frequency of follow-up with health care providers in patients with prostate cancer.” In Journal of Clinical Oncology, 26:16002–16002. American Society of Clinical Oncology (ASCO), 2008. https://doi.org/10.1200/jco.2008.26.15_suppl.16002.
    Full Text
  - Banez, LL, Sun, L, Aronson, WJ, Terris, MK, Presti, JC, Amling, CL, Kane, CJ, Moul, JW, and Freedland, SJ. "IS PSA A POOR PREDICTOR OF ADVERSE PATHOLOGY AND BIOCHEMICAL FAILURE FOLLOWING RADICAL PROSTATECTOMY IN OBESE MEN?." : Ovid Technologies (Wolters Kluwer Health), April 2008. Full Text
  - Fitzsimons, NJ, Sun, L, Moul, JW, Madden, JF, and Freedland, SJ. "OBESE MEN HAVE LARGER AND HIGHER-GRADE TUMORS: AN ANALYSIS OF THE DUKE PROSTATE CENTER DATABASE." : Ovid Technologies (Wolters Kluwer Health), April 2008. Full Text
  - Freedland, SJ, Moul, JW, Sun, L, Neville, TB, Kaminski, DA, Falvello, VB, Terris, MK, Aronson, WJ, Presti, JC, Amling, CL, and Kane, CJ. "DYNAMIC SCREENING DETECTS PROSTATE CANCER (PC) EARLIER AND WOULD LEAD TO IMRPROVED CANCER CONTROL: RESULTS FROM THE DUKE PROSTATE CENTER AND THE SEARCH DATABASE." : Ovid Technologies (Wolters Kluwer Health), April 2008. Full Text
  - Freedland, SJ, Sun, L, Neville, TB, Kaminski, DA, Falvello, VB, and Moul, JW. "DYNAMIC SCREENING FOR PROSTATE CANCER IMPROVES AUCs RELATIVE TO STATIC SCREENING USING A SINGLE PSA THRESHOLD – RESULTS FROM THE DUKE PROSTATE CENTER." : Ovid Technologies (Wolters Kluwer Health), April 2008. Full Text
  - Freedland, SJ, Sun, L, and Moul, JW. "SMALL PROSTATE SIZE PREDICTS BIOCHEMICAL PROGRESSION AFTER RADICAL PROSTATECTOMY." : Ovid Technologies (Wolters Kluwer Health), April 2008. Full Text
  - Jayachandran, J, Banez, LL, Aronson, WJ, Terris, MK, Presti, JC, Amling, CL, Kane, CJ, Sun, L, Moul, JW, and Freedland, SJ. "OBESITY AS A PREDICTOR OF ADVERSE OUTCOME ACROSS BLACK AND WHITE RACE: RESULTS FROM THE SEARCH AND DUKE PROSTATE CENTER DATABASES." : Ovid Technologies (Wolters Kluwer Health), April 2008. Full Text
  - Moul, JW, Sun, L, Robertson, CN, Donatucci, CF, Albala, DM, Walther, PJ, Mouraviev, V, Schroeck, FR, and Polascik, TJ. "OLDER MEN ASSOCIATED WITH ADVANCED DISEASE AND POOR OUTCOME: AN ANALYSIS OF 14601 PROSTATE CANCER MEN IN DUKE PROSTATE CENTER." : Ovid Technologies (Wolters Kluwer Health), April 2008. Full Text
  - Schroeck, FR, Sun, L, Levy, DE, Bryan, K-AN, Freedland, SJ, Jayachandran, J, Price, M, Williams, R, and Moul, JW. "RACE AND PROSTATE WEIGHT AS INDEPENDENT PREDICTORS FOR BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY." : Ovid Technologies (Wolters Kluwer Health), April 2008. Full Text
  - Sun, L, Zorn, KC, Albala, DM, Shikanov, SA, Zagaja, GP, Shalhav, AL, Robertson, CN, Donatucci, CF, Walther, PJ, Mouraviev, V, Schroeck, FR, Polascik, TJ, and Moul, JW. "PRE-TREATMENT FACTORS PREDICTIVE OF POSITIVE SURGICAL MARGIN IN CONTEMPORARY RADICAL PROSTATECTOMIES." : Ovid Technologies (Wolters Kluwer Health), April 2008. Full Text
  - Joniau, S, Balducci, L, Bolla, M, Emberton, M, Fitzpatrick, J, Kattan, M, Monfardini, S, Moul, JW, Naeim, A, Van Poppel, H, Saad, F, Sternberg, C, and Droz, JP. "SIOG (INTERNATIONAL SOCIETY OF GERIATRIC ONCOLOGY) LOCALISED PROSTATE CANCER GUIDELINES PROPOSALS IN SENIOR ADULT MEN." : Elsevier BV, March 2008. Full Text
  - Mouraviev, Vladimir, Leon Sun, John F. Madden, Janice M. Mayes, Judd W. Moul, Daniel J. George, Philip G. Febbo, and Thomas J. Polascik. “Tumor laterality does not predict biochemical prostate cancer recurrence after radical prostatectomy.” In Journal of Endourology, 21:A216–A216. MARY ANN LIEBERT INC, 2007.
    Link to Item
  - Bañez, LL, Hamilton, RJ, Vollmer, RT, Moul, JW, Amling, CL, Kane, CJ, Aronson, WJ, Terris, MK, Presti, JC, and Freedland, SJ. "1418: Can Hemodilution Explain the Lower PSA Concentrations Among Obese Men?." : Ovid Technologies (Wolters Kluwer Health), April 2007. Full Text
  - Isariyawongse, BK, Sun, L, Banez, LL, Madden, J, Mouraviev, V, and Maul, JW. "1884: Up to 53.8% Discrepancy between Diagnostic and Pathological Gleason Scores in 2963 Prostate Cancer Patients: The Predictive Value of Age and Prostate Size." : Ovid Technologies (Wolters Kluwer Health), April 2007. Full Text
  - Rampersaud, EN, Sun, L, and Moul, JW. "1027: Tumor Percentage of Prostatectomy Specimens is an Independent Risk Factor for Biochemical Recurrence and Negative Clinicopathological Variables." : Ovid Technologies (Wolters Kluwer Health), April 2007. Full Text
  - Sun, L, Rampersaud, EN, and Moul, JW. "455: Racial Disparities Remain in Prostate Cancer - An Analysis on 10530 Men Diagnosed During PSA Era." : Ovid Technologies (Wolters Kluwer Health), April 2007. Full Text
  - Furusato, R., D. Osborn, I. Rosner, J. Cullen, C. Davis, J. W. Moul, S. Srivastava, D. McLeod, I. Sesterhenn, and A. Allen. “Clinico-pathologic aspects of follow-up on small tumor volume prostate cancer after the radical prostatectomy at Walter reed army medical center.” In Modern Pathology, 20:147A-147A. NATURE PUBLISHING GROUP, 2007.
    Link to Item
  - Furusato, R., D. Osborn, I. Rosner, J. Cullen, C. Davis, J. W. Moul, S. Srivastava, D. McLeod, I. Sesterhenn, and A. Allen. “Clinico-pathologic aspects of follow-up on small tumor volume prostate cancer after the radical prostatectomy at Walter reed army medical center.” In Modern Pathology, 20:147A-147A, 2007.
    Link to Item
  - Proia, A. D., L. L. Sun, K. R. Perkinson, T. J. Polascik, V. Mouraviev, C. F. Donatucci, C. N. Robertson, et al. “Ki-67: A potential prognostic biomarker for PSA recurrence?.” In Journal of Urology, 175:87–87. LIPPINCOTT WILLIAMS & WILKINS, 2006.
    Link to Item
  - Furusato, B., L. L. Banez, P. Prasan, Y. Chen, A. Ali, J. W. Moul, D. G. McLeod, S. Srivastava, and I. A. Sesterhenn. “Evaluation of serum SELDI-TOF proteomic information and tumor volume in prostate cancer patients.” In Laboratory Investigation, 86:137A-137A. NATURE PUBLISHING GROUP, 2006.
    Link to Item
  - Furusato, B., L. L. Banez, P. Prasan, Y. Chen, A. Ali, J. W. Moul, D. G. McLeod, S. Srivastava, and I. A. Sesterhenn. “Evaluation of serum SELDI-TOF proteomic information and tumor volume in prostate cancer patients.” In Modern Pathology, 19:137A-137A. NATURE PUBLISHING GROUP, 2006.
    Link to Item
  - Zhou, P., M. H. Chen, D. McLeod, P. R. Carroll, J. W. Moul, and A. V. D’Amico. “Predictors of prostate cancer-specific mortality following radical prostatectomy or radiation therapy..” In Journal of Clinical Oncology, 23:389S-389S. AMER SOC CLINICAL ONCOLOGY, 2005.
    Link to Item
  - Banez, L. L., B. Furusato, P. Prasanna, Y. M. Chen, A. Ali, J. W. Moul, D. G. McLeod, I. A. Sesterhenn, and S. Srivastava. “Evaluation of serum SELDI-TOF proteomic information and tumor volume in prostate cancer patients.” In Journal of Urology, 173:64–65. LIPPINCOTT WILLIAMS & WILKINS, 2005.
    Link to Item
  - Yang, B. K., C. R. Salmen, T. J. Gan, J. W. Moul, and P. Dahm. “Radical perineal prostatectomy for the treatment of localized prostate cancer in obese and non-obese patients: A matched control study.” In Journal of Urology, 173:53–53, 2005.
    Link to Item
  - Banez, L. L., P. Prasanna, L. Sun, A. Ali, B. L. Adam, D. G. McLeod, J. W. Moul, and S. Srivastava. “Serum proteomic profiling using SELDI-TOF for prostate cancer diagnosis.” In Journal of Urology, 171:440–41. LIPPINCOTT WILLIAMS & WILKINS, 2004.
    Link to Item
  - Banez, L. L., P. Prasanna, L. Sun, A. Ali, Z. Q. Zou, D. G. McLeod, J. W. Moul, and S. Srivastava. “Diagnostic potential of serum proteomic patterns in prostate cancer.” In Journal of Urology, 169:54–55. LIPPINCOTT WILLIAMS & WILKINS, 2003.
    Link to Item
  - Zeng, J., J. J. Bauer, A. Sofer, X. Yao, B. Opell, W. Zhang, I. A. Sesterhenn, J. W. Moul, J. Lynch, and S. K. Mun. “Distribution of prostate cancer for optimized biopsy protocols.” In Lecture Notes in Computer Science (Including Subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics), 1935:287–96, 2000.
  - Bauer, JJ, Zeng, J, Sesterhenn, KA, Moul, JW, and Mun, SK. "Comparison of prostate biopsy protocols using 3D computer simulation." January 1, 1998. Full Text
  - Wang, Y, Ding, H, Xuan, J, Sesterhenn, IA, Moul, JW, and Mun, SK. "3D model supported virtual environment for prostate disease interpretation and biopsy design." January 1, 1998. Full Text
  - Xuan, J, Wang, Y, Sesterhenn, IA, Moul, JW, and Mun, SK. "3-D model supported prostate biopsy simulation and evaluation." January 1, 1998.
Teaching & Mentoring
Advising & Mentoring
- I serve as a mentor for the Duke Medical School 3rd year research year. I also serve as a mentor for the Duke CAPE program for undergraduates interested in a career in medicine. I also serve as a mentor for Duke urology residents including the Duke Urology Residents who are part of the Duke- US Army urology training agreement
Available to mentor:
- Fellow
- Professional
- Resident
- Undergraduate

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Duke Appointment History

Awards & Honors

Global Scholarship

Teaching

Selected Grants

Selected Publications

Books

Academic Articles

Book Sections

Other Articles

Conference Papers

Advising & Mentoring

Available to mentor: